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DNA repair is required for the maintenance of genome stability. In the last years DNA 
repair pathways have emerged as important targets for cancer therapy. Since standard 
anticancer agents are mainly DNA-damaging drugs, its combination with DNA repair 
inhibitors may contribute to improve treatment outcomes. Among the multiple effectors 
involved in DNA repair, the multifunctional base excision repair (BER) protein 
apurinic/apyrimidinic endonuclease 1 (APE1) is one of the most attractive druggable 
targets in this field. 
APE1 is the major endonuclease in BER participating in the repair of different DNA 
lesions including toxic abasic sites. In addition to the DNA repair activity, APE1 also 
acts independently as a reduction/oxidation signalling protein modulating the activation 
and DNA binding ability of several transcription factors implicated in cell survival and 
tumour promotion and progression. In this context, this thesis is focused on the 
combination of APE1 pharmacological inhibitors with conventional anticancer agents in 
the highly aggressive human breast cancer MDA-MB-231 cell line. 
Endonuclease activity has been the most studied function of APE1 in cancer therapy. 
Methoxyamine (MX), a commercially available indirect inhibitor of APE1 DNA repair 
function, was evaluated in combination with doxorubicin (Dox) in MDA-MB-231 cells. 
The chemotherapeutic drug Dox is widely used in the treatment of advanced breast 
cancer and may act, in part, by inducing oxidative DNA damage. MX had little effects in 
viability and colony formation of MDA-MB-231 cells. However, a significant increase in 
the frequency of micronucleated cells and an alteration in the pattern of micronuclei 
distribution were observed suggesting an increase in Dox genotoxicity. The differential 
results obtained in terms of cytotoxicity and genotoxicity showed that a therapeutic 
strategy based on APE1 inhibition is likely to have no relevance for the improvement of 
outcomes of Dox treatment. 
Although several putative inhibitors of APE1 endonuclease activity have been reported 
they still lack potential to be translated to the clinical setting. Therefore, in this thesis a 
structure-based virtual screening (SBVS) study based on molecular docking analysis of 
National Cancer Institute (NCI) database of compounds was performed to identify 
novel small-molecule inhibitors of APE1. The evaluation of SBVS study most promising 
compounds in a fluorescence-based APE1 endonuclease activity assay revealed three 
APE1 inhibitors. Compound 22 was a potent APE1 inhibitor showing inhibitory effects 
at nanomolar concentrations, while compounds 37 and 41 inhibited the enzyme in the 
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micromolar range. These novel scaffolds for the design of more potent APE1 inhibitors 
did not affect the viability of non-tumourigenic human breast epithelial MCF10A cell line 
highlighting their promising features. 
The importance of APE1 modulation is beyond its functions in DNA repair. Therefore, 
E3330, a commercially available inhibitor of APE1 redox function, was also evaluated 
as single agent and in combination with the taxane drug docetaxel (DTX) in MDA-MB-
231 cells. DTX has anti-migratory and anti-angiogenic effects and is frequently used in 
advanced breast cancer refractory to anthracycline-based regimens. Consequently, 
relevant endpoints of cell migration and invasion were studied in addition to cell 
viability, proliferation and cell cycle profile assessment. Minor effects were observed in 
cell proliferation. However, E3330 alone significantly reduced the collective cell 
migration evaluated by the wound-healing assay without affecting chemotaxis and 
chemoinvasion. The combination of E3330 with DTX significantly decreased invasion 
of MDA-MB-231 cells suggesting a potential therapeutic role in metastatic breast 
cancer. 
The results described in this work emphasise the importance of preclinical studies of 
APE1 functions in cancer therapy and highlight the potential of novel drug 
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As células de mamífero desenvolveram um conjunto de mecanismos que atuam de 
forma regulada e coordenada para proteger a integridade do genoma. Estes 
mecanismos incluem as vias de reparação de DNA responsáveis pela reparação de 
lesões resultantes da exposição constante do material genético a agentes químicos e 
físicos exógenos, assim como a produtos endógenos resultantes dos processos 
celulares como é o caso das espécies reativas de oxigénio (ROS). As várias vias de 
reparação de DNA podem atuar de forma coordenada ou independente de acordo com 
a complexidade das lesões. 
Nos últimos anos, as proteínas das vias de reparação de DNA têm sido consideradas 
importantes alvos terapêuticos no tratamento do cancro. A atual terapêutica do cancro 
baseia-se na utilização de agentes indutores de lesões de DNA com o objetivo de 
induzir a acumulação de lesões citotóxicas que ultrapassem a capacidade de 
reparação das células tumorais culminando na morte celular. Para além disso, as 
células tumorais apresentam frequentemente mutações em genes que codificam 
proteínas envolvidas na reparação. Desta forma, a inibição de uma via de reparação, 
responsável por compensar a incapacidade de reparação do DNA da via que 
apresenta as mutações, poderá ser uma estratégia terapêutica que aumente a eficácia 
e diminua a toxicidade dos agentes antitumorais. Por outro lado, existe uma 
redundância de funções nos mecanismos de reparação de DNA que pode contribuir 
para a resistência aos fármacos antitumorais. Neste contexto, a modulação das vias 
de reparação de DNA constitui uma importante estratégia terapêutica no tratamento do 
cancro. 
A via de reparação por excisão de bases (BER) é a principal responsável pela 
remoção e reparação de pequenas lesões induzidas por oxidação, alquilação e 
desaminação de bases do DNA. A BER também reconhece e remove o uracilo 
presente no DNA e está envolvida na reparação de locais abásicos citotóxicos 
espontaneamente induzidos durante o metabolismo celular ou formados como 
produtos intermédios durante a reparação de bases lesadas. A BER participa ainda na 
reparação de quebras de cadeias simples (SSBs). 
De acordo com o tipo de lesão e o tamanho do fragmento de nucleótidos a remover 
após a excisão da base por DNA glicosilases, a reparação pode ocorrer através de 
duas sub-vias da BER designadas por short-patch (SP-BER) e long-patch (LP-BER). 
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A enzima endonuclease apurínica/apirimidínica 1 (APE1) é a principal endonuclease 
nas células de mamíferos responsável pela incisão do local abásico resultante da 
remoção das lesões não volumosas do DNA. Esta enzima multifuncional participa nas 
duas sub-vias da BER, apresentando-se como um importante alvo terapêutico para 
aumentar a sensibilidade a diferentes agentes antitumorais como demonstrado por 
vários estudos pré-clínicos e clínicos. Para além disso, alterações de expressão e da 
distribuição intracelular da APE1 têm sido correlacionadas com o prognóstico de 
diversos tipos de cancro, nomeadamente o cancro da mama. 
Apesar de ser uma importante enzima de reparação, a APE1 também tem um papel 
independente como proteína de redução/oxidação em vias de sinalização celular, 
modulando a ativação e a capacidade de ligação ao DNA de vários fatores de 
transcrição envolvidos na sobrevivência celular e na progressão tumoral. A modulação 
da função redox da APE1 constitui também uma estratégia terapêutica relevante uma 
vez que está envolvida na regulação simultânea de vários processos necessários à 
metastização. 
Neste âmbito, a presente tese visa a avaliação de uma estratégia terapêutica que 
combina inibidores da atividade endonucleásica e/ou da função redox da APE1, 
comercialmente disponíveis, com fármacos antitumorais atualmente utilizados na 
terapêutica do cancro da mama. Para além disso, perante a relevância da função de 
reparação de DNA da APE1 e a inexistência de inibidores da APE1 com potencial para 
serem utilizados na clínica, este trabalho pretende também identificar novos inibidores 
da atividade endonucleásica desta enzima. 
Os tumores da mama constituem o tipo de cancro mais comum nas mulheres. A 
elevada mortalidade do cancro da mama deve-se, principalmente, ao desenvolvimento 
de metástases. Uma vez que a APE1 tem sido associada a prognósticos menos 
favoráveis no cancro da mama, a linha celular MDA-MB-231, representativa de 
adenocarcinoma da mama agressivo, com capacidades invasivas in vitro e 
tumorigénicas in vivo foi selecionada como modelo de cancro da mama em estadio 
avançado neste trabalho. 
A antraciclina doxorrubicina (Dox) é um dos fármacos antitumorais mais utilizados no 
tratamento do cancro da mama em estadio avançado. Apesar da complexidade dos 
mecanismos de ação da Dox não se encontrar completamente elucidada, este 
fármaco pode induzir a formação de ROS que por sua vez podem provocar a oxidação 
de bases de DNA. A Dox também é um fármaco com propriedades genotóxicas 
reconhecidas, nomeadamente com características aneugénicas e clastogénicas, que 
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também pode induzir SSBs. Ambos os tipos de lesões podem ser alvos de reparação 
pela BER. Desta forma, a metoxiamina (MX), um inibidor indireto da função da APE1 
comercialmente disponível e em estudos clínicos de fase I, foi estudada em 
combinação com a Dox em células MDA-MB-231. Várias concentrações dos 
compostos e diferentes protocolos de exposição foram adotados para mimetizar a 
administração dos fármacos na clínica. Diferentes métodos foram também utilizados 
para avaliar os efeitos da combinação do fármaco citotóxico Dox com a MX em termos 
de viabilidade celular (ensaio do MTT e do violeta de cristal), proliferação celular 
(ensaio de formação de colónias) e genotoxicidade. Enquanto que a utilização da MX 
apresentou um ligeiro efeito sensibilizador da viabilidade e proliferação das células 
tratadas com Dox, um efeito significativo foi observado na genotoxicidade. O ensaio do 
micronúcleo em células com a citocinese bloqueada (ensaio CBMN) revelou um 
aumento pronunciado na frequência das células micronucleadas e uma alteração no 
padrão de distribuição dos micronúcleos sugerindo um aumento da genotoxicidade da 
Dox na presença da MX. Contudo, estes resultados mostram que as células MDA-MB-
231 têm uma capacidade para tolerar os efeitos genotóxicos da combinação do 
inibidor da APE1 com a Dox evidenciando uma ausência de relevância desta 
estratégia terapêutica para melhorar os resultados do tratamento do cancro da mama 
com Dox. Estes resultados podem estar associados aos diferentes mecanismos de 
ação descritos para a Dox e à redundância das vias de reparação. 
Apesar de, atualmente, vários possíveis inibidores da actividade endonucleásica da 
APE1 se encontrarem descritos na literatura, estes não têm evidenciado potencial para 
a sua utilização na clínica. Desta forma, neste trabalho também foi proposta a 
identificação de novos inibidores diretos da APE1. Um estudo computacional de 
screening virtual baseado na estrutura (SBVS) e em análises de docking molecular foi 
realizado com os compostos químicos depositados no repositório do National Cancer 
Institute (NCI). Os compostos mais promissores identificados no estudo computacional 
foram avaliados num ensaio bioquímico de atividade endonucleásica da APE1 
baseado na fluorescência para identificar potenciais inibidores desta enzima. Os 
compostos 22, 37 e 41 mostraram a capacidade para inibir a APE1. De facto, o 
composto 22 demonstrou ser um dos mais potentes inibidores da APE1 identificados 
até à data, inibindo a enzima quando utilizado em concentrações na ordem dos 
nanomolar. Por sua vez, concentrações na ordem dos micromolar dos compostos 37 e 
41 inibiram a APE1. A inibição da APE1 foi também avaliada num ensaio 
mecanisticamente diferente para confirmar o carácter inibidor destes compostos. É de 
notar que os compostos 22, 37 e 41 não apresentaram efeitos na viabilidade celular 
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das células de mama não tumorais MCF10A. Para além disso, a presença de grupos 
sulfonato e isotiocianato no composto 22 evidencia a relevância destes grupos 
funcionais para o desenvolvimento de novos inibidores potentes da APE1. 
A importância da modulação da APE1 não se deve apenas à sua função na reparação 
do DNA mas também à sua atividade como factor de sinalização redox. Neste 
contexto, devido ao papel emergente das espécies reativas e da regulação redox no 
desenvolvimento de agentes antitumorais, o inibidor redox comercialmente disponível 
da APE1, o E3330 foi estudado individualmente e em combinação com o taxano 
docetaxel (DTX) em células MDA-MB-231. O DTX é um fármaco antitumoral 
frequentemente utilizado no cancro da mama avançado refratário ao tratamento com 
antraciclinas. O seu mecanismo de ação baseia-se na indução de uma 
hiperestabilização dos microtúbulos. Para além disso, o DTX apresenta propriedades 
antimigratórias e antiangiogénicas. Consequentemente, para além dos efeitos na 
viabilidade, proliferação e ciclo celular, também foram avaliados os efeitos na 
migração e invasão celular. Enquanto que os efeitos observados na proliferação 
celular foram ligeiros, o E3330 diminuiu significativamente a migração celular coletiva 
sem afetar a quimiotaxia e a quimioinvasão. Por sua vez, a combinação do E3330 com 
o DTX reduziu significativamente a invasão das células MDA-MB-231 sugerindo um 
potencial terapêutico no cancro da mama metastático. É de notar, que até à data, este 
parece ser o primeiro estudo focado na avaliação da combinação terapêutica destes 
dois compostos. 
De um modo geral, os resultados descritos nesta tese realçam a importância de se 
efetuarem estudos pré-clínicos sobre as diferentes funções da APE1 na terapêutica do 
cancro e evidenciam o potencial de novas combinações de fármacos e do 
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1.1. DNA REPAIR PATHWAYS AND CANCER THERAPY – A BRIEF OVERVIEW 
DNA is continuously exposed to numerous sources of damage which include 
exogenous chemical and physical agents and endogenous genotoxic insults related to 
physiological and cellular processes namely the reactive species generated by 
metabolism and the replication errors [1,2]. Cells have evolved a set of tightly 
regulated, coordinated and redundant surveillance mechanisms to protect the genome 
stability. These complex molecular pathways are collectively named DNA damage 
response (DDR) and they detect, signal, control cell cycle progression, promote the 
DNA repair and activate cell death machineries to counteract the thousands of lesions 
that threat the genome integrity (Fig. 1.1) [1–6]. 
In general, a DNA lesion is recognized by several sensor proteins of DDR. These DNA 
damage sensors initiate signalling pathways that can slow down or transiently arrest 
the cell cycle progression increasing the available time for DNA repair [2,4]. Cells have 
multiple DNA repair pathways to prevent the accumulation of a wide diversity of DNA 
lesions. These DNA repair mechanisms target different types of DNA damage and they 
can act independently or interact according to the complexity of DNA lesions [1,2]. 
The major DNA repair pathways include the a) direct reversal repair, b) mismatch 
repair (MMR) c) base excision repair (BER), d) nucleotide excision repair (NER), e) 
translesion synthesis (TLS), f) homologous recombination (HR), g) non-homologous 
end-joining (NHEJ) and h) the Fanconi anemia (FA) pathways [1,2]. The present work 
is focused on human apurinic/apyrimidinic endonuclease 1 (APE1), a key BER enzyme 
considered a promising target for cancer therapy, including breast cancer. In this 
context, a detailed description of the other mentioned DNA repair pathways is beyond 
the scope of this thesis. Several comprehensive reviews on this topic have been 
published in the last years [1,2,7–13]. 
Although the majority of the DNA repair systems require the coordinated action of 
several proteins, a small group of DNA lesions can be directly repaired by a single 
protein mechanism without the incision of the DNA backbone or the base excision. The 
direct reversal repair is a simple and error-free DNA repair process with high substrate 
specificity [14,15]. In addition, the BER pathway identifies and excises bases damaged 
by alkylation, oxidation, deamination, depurination/depyrimidination, removes the uracil 
from DNA and also repairs DNA single-strand breaks (SSBs) [2,16]. While BER repairs 
small adducts, NER ensures the removal of bulky helix-distorting base lesions which 





segment containing the damaged base, usually with 24–32 oligonucleotides of length, 
has to be excised and replaced to complete the repair. NER may proceed through two 
sub-pathways depending on the substrate: the global-genome NER (GG-NER) targets 
lesions in the entire genome and the transcription-coupled NER (TC-NER) is involved 
in the removal of transcription-blocking damage to allow an accurate gene expression 
[13,16,17]. The MMR eliminates mispaired bases and small insertion-deletion loops 
generated during DNA replication [2,16,18]. Moreover, mammalian cells use the TLS to 
 
Figure 1.1 Sources of DNA damage and general overview of DNA repair pathways and biological 
responses to DNA lesions [2,3,6]. Abbreviations: ROS - reactive oxygen species; RNS - reactive 
nitrogen species; DR - direct reversal repair; MMR - mismatch repair; BER - base excision repair; NER - 
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bypass the lesions that could be incompletely repaired and often remain in the DNA 
during replication jeopardizing the progress and the fidelity of replicative polymerases 
[8,19]. 
For DNA double-strand breaks (DSBs), two major DNA repair pathways are available: 
the NHEJ and the HR. NHEJ repairs the DSBs by promoting the direct ligation of 
broken DNA ends. Conversely, HR requires an homologous undamaged DNA template 
to carry out the repair of DSBs, interstrand cross-links (ICLs) and to restart stalled 
replication forks. Thus, NHEJ is considered an error-prone mechanism which can be 
activated in all phases of the cell cycle whereas HR is generally classified as an error-
free repair strategy primarily restricted to late S and G2 phase. In fact, HR is more 
prominent after the DNA replication because an intact sister chromatid can be used as 
template for repair [2,16,20,21]. For ICLs repair, which cannot be completely removed 
by MMR and/or NER, HR cooperates with the FA pathway. In general, the repair of 
these lesions can occur only in the S-phase during the DNA replication [2,22]. 
The outcomes of DNA lesions are unpredictable despite cell efforts for the genome 
maintenance. They depend not only on the nature of the damage but also on the 
number and location of DNA lesions, cell type, cell cycle phase and differentiation 
stage [6]. An inaccurate repair and/or the overwhelming of the DNA repair mechanisms 
yield the accumulation of DNA lesions (Fig. 1.1). The blockage of transcription or 
replication is a common consequence inducing senescence or cell death, particularly in 
non-proliferating cells, and contributing for ageing [6,23]. On the other hand, in 
proliferating cells permanent mutations appear during the replication cycles of 
damaged DNA. Similarly, structural chromosomal aberrations may be generated during 
the DSBs repair and dysregulate gene expression. The transmission of these 
alterations to descendant cells can also result in mutations. The inactivation of certain 
tumour suppressor genes, the activation of oncogenes and an enhanced genomic 
instability are potential effects of these harmful mutations. Consequently, if these 
alterations constitute a selective advantage for cells they may contribute to an 
uncontrolled and sustained cellular proliferation leading to the development of 
precancerous lesions and ultimately to cancer progression [2,6,23,24]. Mutations can 
also affect genes required for DNA repair such as breast cancer 1/2, early onset genes 
(BRCA1 and BRCA2). Both are tumour suppressor genes which encode proteins 
involved in DDR and HR and inherited germline mutations in BRCA1 and BRCA2 have 
been correlated with a higher susceptibility to develop hereditary breast and ovarian 
cancer among others [25–27]. The epigenetic alterations which involve the chromatin 





carcinogenic role through the inactivation of the DDR and DNA repair effectors and 
enabling the malignant transformation of cells and tumour development [2,6,23,24]. 
Another important aspect regarding DNA repair and cancer is the resistance to 
anticancer agents. Cancer therapy is challenging and generally it involves the use of 
different strategies to target specific molecular and cellular features of cancer cells in 
order to cure, or at least hamper the tumour progression. 
The most fundamental hallmark of cancer cells is their ability to proliferate at higher 
rates than non-tumour cells which renders the cell cycle an attractive target in cancer 
therapy [28]. In addition to the inhibitors of the mitotic spindle and the targeting of 
growth signalling pathways, cell cycle is frequently disrupted by the DNA-damaging 
agents. Actually, many chemotherapeutic regimens are based on DNA-damaging 
drugs often used in complementary combinations [2,8]. Their effectiveness depends on 
their ability to directly or indirectly damage DNA with the generation of cytotoxic lesions 
that overwhelm the DNA repair capacity and ultimately induce cell death of rapid 
proliferating cancer cells (Table 1.1). In view of this, the rationale for their use in cancer 
therapy is, as abovementioned, the genomic instability and replicative stress of tumour 
cells as well as the presence of mutator phenotypes in DNA repair genes which can 
impair or even inactivate DNA repair pathways increasing the cell death induced by 
DNA-damaging drugs [2,8,29].  
However, the efficacy of DNA-damaging drugs is frequently precluded by toxicity 
issues and cancer resistance to therapy. Although non-tumour cells have a lower 
replication rate and are usually proficient in the DDR being less susceptible to the 
effects of ionising radiation (IR) and chemotherapeutic drugs, their DNA can also be 
damaged with the subsequent development of side effects [8]. In respect to the 
resistance to DNA-damage agents, there is a redundancy of DNA repair mechanisms 
that may lead to the activation of another DNA repair pathway upon failure of the first 
attempt to repair the lesions. Moreover, cancer cells may also present an increased 
activity of the DNA-damage signalling and DNA repair pathways preventing the 








Table 1.1 Anticancer agents and DNA repair pathways involved in the repair of DNA damage-
induced by cancer treatment. The major DNA repair pathways contributing to the repair of lesions are 
represented in bold. Adapted from [2,8,29,32]. 
In this context, the modulation of DNA repair is a targeted therapeutic approach to 
improve the outcomes of cancer treatments (Fig. 1.2). DNA repair inhibitors may not 
only overcome the resistance to anticancer agents but also increase their sensitivity 
and specificity decreasing the toxic side effects. This is particularly important in 
tumours with somatic mutations that lead to the inactivation of a certain DNA repair 
pathway. In these circumstances cancer cells will be more dependent on the remaining 
Anticancer agents Types of DNA lesions 
DNA repair 
pathways 
Radiotherapy and radiomimetics   




Monofunctional alkylators   
Alkylsulphonates (e.g. busulfan);  Nitrosoureas 
(e.g. BCNU); Temozolomide (TMZ) 
Base damage; Replication 




NER; TLS; FA 
Bifunctional alkylators   
Nitrogen mustards (e.g. cyclophosphamide); 
Mytomicin C; Cisplatin 
DSBs; DNA crosslinks; 
Replication lesions; Bulky 
DNA adducts 
NER; HR; FA; 
TLS; MMR 
Antimetabolites   
5-Fluorouracil (5-FU); Thiopurines (e.g. 6-
mercaptopurine); Folate analogues (e.g. 
methotrexate); Gemcitabine/Troxacitabine 




Topoisomerase inhibitors   
Camptothecin (Topo I); Etoposide (Topo II); 
Anthracyclines (Topo II) 
DSBs; SSBs; Replication 




Taxanes   
Docetaxel; Paclitaxel Taxanes-induced ROS 
[32,33] -oxidative base 
damage (?) 
BER (?) 
Replication inhibitors   






DNA repair pathways which could be targeted with DNA repair inhibitors to induce a 
hypersensitivity to anticancer drugs and decrease the toxic side effects [2,8,16]. The 
concept of synthetic lethality has also emerged as a therapeutic approach in tumours 
carrying genetic defects [8,29,33]. The underlying principle of synthetic lethality is the 
cells ability to tolerate and maintain viability upon inactivation of only one pathway due 
to mutations of genes that code relevant proteins [8,29,33]. The use of chemical 
inhibitors to abrogate a second and redundant DNA repair pathway promotes the 
accumulation of DNA damage and induces cell death [8,29,33]. Synthetic lethality has 
been notably relevant in tumour cells harbouring mutations in proteins associated with 
defects in HR which have shown to be sensitive to inhibitors of proteins involved in 
BER, namely poly(ADP-ribose)polymerase 1 (PARP1) [29,34,35]. These are clinical 
opportunities to personalised therapy since it requires the knowledge of tumour genetic 
alterations to improve the specificity of the treatment, the overall survival and to the use 
of DNA repair inhibitors in monotherapy limiting the number of drugs administered and 
consequently the toxicity of therapeutic agents. 
 
Figure 1.2 Rationale for the use of DNA repair inhibitors in cancer therapy. A jeopardised DNA repair 
increases the sensitivity to anticancer drugs and decreases the toxic side effects. An increased DNA repair 
activity is related with the resistance to anticancer agents. Targeting DNA repair is an opportunity to 
improve the cancer therapy outcomes [2,8,32]. 
1.2. THE BASE EXCISION REPAIR (BER) PATHWAY 
The basic steps of the base excision repair pathway were first described in the 70s 
decade by Tomas Lindahl1 after the identification of the Escherichia coli uracil-DNA 
glycosylase [9,36,37]. BER is known to play a critical role in the removal and 
replacement of several small non-bulky DNA lesions generated by oxidation, alkylation 
or deamination and the uracil from DNA. It is also the major DNA repair pathway 
responsible for repairing the apurinic/apyrimidinic (AP) sites spontaneously produced 
during the cellular metabolism or as intermediates of this pathway during the repair of 
                                            
1 Awarded with the Nobel Prize in Chemistry 2015 along with Paul Modrich and Aziz Sancar for 





base modifications inflicted by endogenous or exogenous genotoxicants (Fig. 1.3). The 
SSBs can occur directly by the attack of ROS to the deoxyribose or indirectly upon 
repair being also a substrate of BER [9,10,38]. In this context, it is essential to highlight 
the pivotal role of the human APE1, a topic that will be thoroughly described in this and 
in the next sections of the present thesis. 
 
Figure 1.3 Chemical structures of some base lesions and apurinic/apyrimidinic (AP) sites 
commonly recognized and repaired by base excision repair pathway. Adapted from [9]. Abbreviation: 
FapyG - 2,6-diamino-4-hydroxy-5-formamidopyrimidine. 
In general, BER comprises five coordinated enzymatic steps (Fig. 1.4) which include 
the recognition and excision of the damaged base by a DNA glycosylase, the incision 
of the AP site by APE1 or the AP lyase function of a bifunctional DNA glycosylase, the 
removal of the 5’- or 3’- terminal blocking groups, the DNA synthesis by a DNA 
polymerase for filling the resulting gap and, finally, the nick sealing carried out by a 
DNA ligase [9,10,39,40]. 
Firstly, a lesion-specific DNA glycosylase recognizes and removes the damaged or 
inappropriate base. The hydrolytic cleavage of the N-glycosidic bond linking the 
incorrect base and the DNA sugar-phosphate backbone carried out by DNA 
glycosylases produces an AP site [41,42]. The intact AP sites generated by the 
monofunctional DNA glycosylases (UNG, TDG, SMUG1, MUTYH, MBD4 and 





phosphodiester backbone 5’ to the AP site producing a SSB with a deoxyribose 
phosphate (dRP) group at the 5’ end and a 3’-OH termini. In the case of bifunctional 
DNA glycosylases (such as OGG1, NTHL1, NEIL1, NEIL2 and NEIL3) which also have 
an intrinsic AP lyase activity, the AP site incision is performed by the DNA glycosylase 
itself 3’ to the AP site. The resulting SSB presents a 3’-non-ligatable group which 
should be removed to provide the proper substrate to be channeled to the following 
step of BER [10,39–41]. NTH1 and OGG1, primarily responsible for the excision of the 
oxidative lesions 8-oxo-7,8-dihydroguanine (8-oxoG) and 2,6-diamino-4-hydroxy-5-
formamidopyrimidine (FapyG), have a weak lyase activity. They catalyse the AP site 
processing via a β-elimination reaction which creates an intermediate with a 5’-
phosphate (5’-P) and a 3’-phospho-α,β-unsaturated aldehyde (3’-PUA) moiety. The 3’-
blocking group is removed by APE1 intrinsic 3’-phosphodiesterase activity [10,39,40]. 
Regarding the NEIL glycosylase family responsible for the removal of oxidised 
pyrimidines, formamidopyrimidines, 5’-hydroxyuracil and urea from the DNA, the AP 
site incision is accomplished through a β, δ-elimination reaction with the formation of a 
SSB carrying a 3’-phospate (3’-P) group. Since the 3’-P moiety is not a suitable 
substrate for APE1, it can be removed by the phosphatase activity of polynucleotide 
kinase/phosphatase (PNKP) in an APE1-independent BER pathway [10,39,40,43,44]. 
However, the APE1-independent repair of AP sites is inefficient in the APE1 
replacement during repair of the most commonly generated AP lesions.  
The next steps of BER can proceed through two sub-pathways: the short-patch BER 
(SP-BER) or the long-patch BER (LP-BER) [10,39,40]. The aforementioned base 
excision and the cleaning of the terminal blocking groups are common to both sub-
pathways. However, they diverge in the length of the DNA fragment to be replaced and 
in the subsets of enzymes involved in the DNA synthesis and nick sealing. The SP-
BER seems to be the predominant BER sub-pathway and only one nucleotide is 
displaced to continue the repair. Then the DNA polymerase β (Polβ) lyase activity 
removes the 5’-dRP moiety and promotes the DNA synthesis from the 3’-OH group 
through its DNA polymerase activity to fill the existing gap. To complete the repair, the 
nick sealing is mediated by the integrated action of DNA ligase IIIα and the scaffold 
protein X-ray cross-complementing factor 1 (XRCC1) [10,39,40]. When 5’ end cleaning 
lyase activity of Polβ is incapable to remove the 5’-blocking groups present in oxidised 
AP sites BER occurs through LP-BER [10,39,40]. For example, the C1’-oxidised 2’-
deoxyribonolactone is repaired by LP-BER to avoid the formation of a DNA-protein 
cross-link with the Polβ [39,45]. LP-BER requires the strand displacement synthesis of 





the replicative DNA polymerases δ and ε (Polδ/ε) although Polβ may also participate in 
the initiation of LP-BER [46,47]. The replication factor C (RFC) and the proliferating cell 
nuclear antigen (PCNA) support the Polδ/ε and the flap endonuclease 1 (FEN1).
 
Figure 1.4 Overview of base excision repair (BER) sub-pathways: short-patch BER and long-patch 
BER. Both sub-pathways require the recognition and excision of the damaged base by a DNA glycosylase. 
After the strand incision at the abasic sites, 5’- and 3’- ends are processed by different enzymes according 
to the blocking groups. The repair may proceed through SP-BER or LP-BER to accomplish the DNA 
synthesis and ligation. Adapted from [40]. 
During the synthesis of the displaced oligonucleotide containing the 5’-sugar 
phosphate, PCNA functions as an accessory sliding clamp for Polδ/ε that is loaded into 





structure-specific FEN1 [10,39,49]. Consequently, the substrate for DNA ligase I is 
created and double-stranded DNA is restored by nick sealing [10,39,40]. 
The selection of SP-BER or LP-BER remains to be fully clarified. The nature of the 
DNA damage, the intracellular levels of ATP, the protein-protein interactions, the cell 
cycle phase and the differentiation stage of cells have been reported to influence the 
sub-pathway choice. 
The type of the DNA lesion determines the BER initiating DNA glycosylase and the 5’- 
and 3’-blocking moieties, which will define the DNA polymerase to be recruited and 
thus the BER sub-pathway [10,47,50–52]. Moreover, nick sealing reactions depend on 
the intracellular ATP availability to generate a covalent phosphodiester bond linking the 
5’- and 3’-DNA strand ends. In the presence of high ATP levels the catalytic activity of 
the complex DNA ligase IIIα/XRCC1 is favored being the SP-BER the predominant 
mechanism. Under conditions of ATP depletion the DNA repair is shifted from SP-BER 
to LP-BER due to the promotion of strand displacement DNA synthesis by Polβ and 
allowing the DNA ligation by DNA ligase I [53,54]. 
In BER the intermediates are transferred to the next enzyme in a sequential and tightly 
orchestrated stepwise process to prevent the exposure of the cellular components to 
potentially harmful molecules [52]. Among the protein-protein interactions regulating 
the switch between SP-BER and LP-BER, XRCC1 and SSBs sensor proteins PARPs 
have a critical role in BER coordination [39,52]. XRCC1 is regarded as a scaffold 
protein interacting with several BER proteins to stimulate their recruitment for the 
SSBs, to promote their stabilisation and modulating their activities. In addition to DNA 
ligase IIIα [55], XRCC1 has been described to interact with proteins implied in different 
stages of both sub-pathways [56] such as the PCNA [57], APE1 [58], PNK [59,60], Polβ 
[61–63], NEILs [43,44,64], PARP1 and 2 [63,65,66]. The enrollment of PARP enzymes, 
especially PARP1, to the DNA-strand break is an early event of BER and probably 
occurs after the strand incision carried out by APE1 or a bifunctional DNA glycosylase. 
The activated proteins catalyse a nicotinamide adenine dinucleotide (NAD+)-dependent 
synthesis of poly(ADP-ribose) chains which are a signal to the recruitment of multiple 
enzymes of BER for the damaged DNA site. PARPs functionally and physically interact 
with APE1, XRCC1, Polβ, PCNA and DNA ligase IIIα to boost the DNA repair. In the 
presence of an overwhelming DNA damage, PARPs can be overactivated leading to 






The cell cycle stage may also govern the SP-BER or LP-BER selection. The LP-BER 
shares proteins with the replicative machinery (e.g. FEN1, Polβ/δ/ε, DNA ligase I) 
suggesting its involvement in the repair of replication-associated DNA lesions. This 
hypothesis is supported by the detection at replication foci of protein complexes 
containing the aforementioned proteins. Thus the LP-BER can be more dominant at 
S/G2 cell cycle phases while a faster BER pathway such as SP-BER will be required in 
G1 phase (reviewed in [52]). 
1.3. OVERVIEW OF HUMAN APURINIC/APYRIMIDINIC ENDONUCLEASE 1 
(APE1) FUNCTIONS 
APE1 is undoubtedly a key DNA repair enzyme that plays a crucial role in genome 
integrity as the major endonuclease in BER. Among the several physiological functions 
of APE1, its endonuclease activity and consequently its role as an upstream key player 
in SP-BER and LP-BER are of utmost importance as it was mentioned in the previous 
section. However, the therapeutic opportunities of targeting APE1 should not be 
restricted to the modulation of the DNA repair activity. APE1 is considered an 
ubiquitous multifunctional protein essential for the regulation of cellular response to 
oxidative stress and vital for the maintenance of genome stability and cell integrity [69–
71]. Importantly, APE1, also designated redox effector factor 1 (Ref-1), has another 
major function since it independently acts as a reduction/oxidation signalling protein 
modulating the activation and DNA binding ability of several transcription factors which 
promote the expression of genes implicated in cell survival and in tumour promotion 
and progression (Fig. 1.5) [71–73]. Moreover, the understanding of the regulation as 
well as the role of distinct APE1 activities in cellular homeostasis is required to 
efficiently develop inhibitors of the different APE1 functions.  
APE1 is a member of the Xth family of class II AP endonucleases due to its structural 
homology with the exonuclease III (Xth) enzyme of Escherichia coli [73–76]. In 
mammalian cells APE1 contributes for approximately 95% of the endonuclease activity 
in eukaryotic organisms [73,74]. APE1 is a monomeric α/β globular protein with 318 
amino acid in length and a molecular weight of approximately 35 kDa [71,77]. Despite 
lacking the initial N-terminal fragment of 35 residues, the first X-ray crystal structure of 
APE1 revealed two main domains displaying similar topologies [77]. Both N-terminal 
and C-terminal domains have a six-stranded β-sheet encircled by α-helices folding 
together to form the four layered α/β sandwich structural core and resembling the 





[71,77]. The first 40 N-terminal amino acids of APE1 structure have a disordered 
folding [78,79]. Notably, the C-terminal region is highly conserved among organisms 
from different kingdoms while the N-terminal fraction is almost restricted to mammals 
[80–82]. Noteworthy, the protein structural organization enables both DNA repair and 
redox activity to be physically and functionally independent since they are encoded by 
non-overlapping domains of APE1 [71,72,83]. While the catalytic site responsible for its 
endonuclease activity is located within the C-terminal domain, the redox regulatory 
function of APE1 is assigned to N-terminal portion which also harbours a complex 
bipartite nuclear localization signal (NLS) (Fig. 1.6) [71,81,83–85]. 
 
Figure 1.5 APE1 is a DNA repair protein with an independent redox function. APE1 participates in 
base excision repair pathway. The inhibition of APE1 endonuclease activity increases the DNA damage 
and might improve the cytotoxic effects of anticancer agents causing the tumour cells death. The inhibition 
of the reduction/oxidation signalling function of APE1 reduces the activation of several transcription factors 
modulating the expression of genes involved in cancer promotion and progression [71,72]. Abbreviations: 
AP – apurinic/apyrimidinic; AP-1 – activator protein 1; Egr-1 – early growth response protein 1; HIF-α – 
hypoxia inducible factor 1 alpha; NF-кB – nuclear factor-kappa B; STAT3 –  signal transducer and activator 





The DNA repair function of APE1, particularly its endonuclease activity, is essential 
for the repair of toxic AP sites spontaneously generated, chemically induced or 
resulting as intermediate products in the enzymatic hydrolysis of DNA bases damaged 
by alkylating and oxidising agents (e.g. ROS) carried out during BER [86]. In the 
intracellular milieu, AP sites are an equilibrium mixture of four species corresponding 
99% to a mixture of equal parts of the two hemiacetal enantiomers α- and β-2-deoxy-D-
ribofuranose and approximately 1% to the ring-opened aldehyde and hydrated 
aldehyde forms [87]. The ring-opened forms are highly reactive providing a site for 
DNA cleavage by a β-elimination reaction [87,88]. If left unrepaired, non-coding AP 
sites can be cytotoxic and mutagenic threatening the integrity of cell function and 
survival [87,89]. The cytotoxicity of AP sites may result from the ability to induce 
replication forks stalling with the generation of SSBs which can be converted into DSBs 
after replication [87,89,90]. The ring-opened AP sites can also react with nuclear 
proteins yielding DNA-protein complexes which can hamper the DNA replication 
[87,89]. Another cytotoxic mechanism of AP sites may be related with the interference 
with topoisomerases DNA cleavage activity or the irreversible trapping of 
topoisomerase-DNA covalent complexes [87,89,91]. 
 
Figure 1.6 Schematic representation of the primary structure of human APE1. The active domains 
and their major functions are displayed. The essential residues for APE1 redox function are highlighted in 
blue and the amino acids involved in the endonuclease activity are depicted in grey. Adapted from 





The APE1 endonuclease activity is the major responsible for the recognition and 
repair of regular AP sites. After the recognition of the abasic nucleotide, APE1 performs 
the hydrolytic cleavage of the phosphodiester backbone 5’ to the AP site in a Mg2+-
dependent reaction. A SSB containing a 3’-hydroxyl group and a dRP termini is 
generated. This DNA intermediate is channeled into one of the BER sub-pathways to 
complete the repair [71,73,89]. The APE1’s active site that catalyses the 
endonucleolytic cleavage is located in the C-terminal domain in an hydrophobic pocket 
located at the top of the α/β sandwich and surrounded by loop regions [71,77,79]. 
Besides its primary role as an apurinic/apyrimidinic endonuclease, APE1 has also a 3’-
phosphodiesterase and a weak 3’-phosphatase activity to remove non-conventional 
3’-blocking groups generated by the AP lyase function of bifunctional DNA 
glycosylases or induced by IR, ROS or radiomimetic anticancer drugs, such as 
bleomycin. The 3’-phosphodiesterase activity eliminates the 3’-phosphoglycolate (3’-
PG) group created by the fragmentation of the sugar moiety while the 3’-phosphatase 
activity removes 3’-phosphate residues to render a SSB with a 3’-OH termini which is 
required to continue BER [10,71,92]. APE1 also exhibits a 3’-5’ exonuclease activity 
although it had been suggested to be weaker than its endonuclease activity. The 3’-5’ 
exonuclease function displays an important role in the removal of 3’ mispaired 
nucleotides at nicked DNA providing a proofreading activity and ensuring the fidelity of 
the DNA repair during BER [89,93,94]. The APE1 exonuclease activity was also shown 
to remove the nucleoside analogues incorporated at the 3’ end of the DNA strand and 
thus contributing for the therapeutic effects and toxicity of anticancer drugs such as 
troxacitabine, an unnatural L-deoxycytidine analogue [89,95]. The ability to remove the 
RNA strand from a RNA-DNA complex through a RNase H activity was also attributed 
to APE1 [71,89]. These repair functions seem to share the same active site reported for 
the APE1 endonuclease activity in the C-terminal domain [89,96]. 
In addition to the crucial roles in both BER sub-pathways, APE1 was also proposed to 
participate in the nucleotide incision repair (NIR) which requires the APE1 incision of 
the phosphodiester backbone immediately 5’ to the oxidatively damaged base. 
Although NIR proceeds in a glycosylase-independent manner, BER and NIR have 
overlapping substrate specificities. Therefore, NIR can be an alternative pathway to 
BER for the repair of potential genotoxic oxidative DNA lesions [97]. Differently from 
the other repair functions, NIR activity has been suggested to be regulated by the N-





Regarding its DNA repair functions APE1 is preferentially located in the nucleus, 
although the extra-nuclear activities attributed to this protein require the intracellular 
trafficking to the cytoplasm. Mitochondria are one of the predominant APE1 
cytoplasmic locations highlighting the importance of APE1 participation in BER of 
mitochondrial DNA which is subjected to high levels of oxidative stress during aerobic 
metabolism [89,98,99]. Although the mitochondrial translocation mechanism of APE1 is 
not clarified it requires the mitochondrial targeting sequence (MTS) identified in the C-
terminal domain and corresponding to the sequence of residues 289-318 [100]. 
The N-terminal domain holds the redox activity of APE1. The mechanism probably 
involves a thiol-mediated redox reaction with a Cys residue from APE1 acting as 
nucleophilic residue to reduce the Cys residues located in the DNA binding domains or 
in other regulatory regions of the transcription factor. Therefore, APE1 operates as a 
redox signalling protein by modulating the activation and DNA binding of several 
transcription factors to gene target sequences involved in cell survival and stress 
response. Indirectly, the redox function of APE1 is an important regulator of gene 
expression [71,72,89]. 
Along with the aforementioned roles in the repair of ROS-induced DNA damage and 
redox signalling, APE1 suppressed intracellular oxidative stress and apoptosis in 
endothelial cells by modulating ROS production through the regulation of the Rac1-
dependent activation of NADPH oxidase [101]. ROS, Rac1 and NADPH oxidase 
participate in several processes required for cell motility and migration probably 
through the regulation of the constant re-organization of actin cytoskeleton. Therefore, 
APE1 may be indirectly involved in cell migration by controlling the intracellular ROS 
levels which contribute to the modulation of the restructuring of actin filaments [71,101]. 
It was also demonstrated the ability of APE1 to control ROS generation via a negative 
regulation of Rac1 and NADPH oxidase during the Helicobacter pylori infection of 
gastric and intestinal epithelial cells [102]. 
APE1 has also an intrinsic RNase H activity although its ability to degrade the RNA 
from a DNA-RNA complex is relatively inefficient and the biological relevance is not 
well understood [103]. More recently, an endoribonuclease activity was also 
attributed to APE1 suggesting a potential function in the RNA quality control process 
and in the regulation of mRNA expression [104–106]. APE1 is capable of cleave 
damaged RNA including abasic single-stranded RNA [105,107,108]. The 
endonucleolytic activity of APE1 was also found to perform the cleavage of the coding 





in cells [105]. Although endoribonuclease and other nuclease activities of APE1 appear 
to share the same active site in the C-terminal domain, the mechanisms for incising 
injured RNA or DNA are not completely identical [107]. The N-terminal domain is also 
required for the stable binding of APE1 to RNA and to the interaction with proteins 
involved in ribosome biogenesis and ribosomal RNA (rRNA) cleansing processing 
[106]. The nucleolar protein nucleophosmin 1 (NPM1) is one of APE1 interacting 
partners. The formation of the complex NPM1-APE1 seems to have a stimulatory effect 
on the endonuclease activity of damaged DNA and an inhibitory effect on the 
endoribonuclease activity of APE1 probably by making unavailable the vital residues 
for APE1 binding to the RNA [106,109]. 
The physical and functional interactions of APE1 are not restricted to proteins involved 
in BER, such as DNA glycosylases, XRCC1, PCNA, FEN1, Polβ and PARP1, or in 
RNA metabolism [58,106,109–113]. In fact, the APE1 interactome network is wide, as 
reviewed in [71,114,115] and it encloses interactions with non-canonical proteins 
involved in APE1 redox chaperone activity (e.g. thioredoxin), cell death pathways (e.g. 
granzyme A and Bcl2), cytoskeleton rearrangement and cellular stress response 
signalling pathways (e.g. heat shock protein 70 (Hsp70)), among others [81,115–117]. 
The disordered N-terminal domain appears to mediate the APE1-protein interactions 
[71,82,106,114,115]. 
APE1 was also found to function as a trans-acting factor with a Ca2+-dependent 
transcriptional repressor activity on the parathyroid hormone (PTH) [118]. High levels of 
PTH trigger an increase in extracellular Ca2+ which regulates the binding of a protein 
transcriptional complex containing APE1 to the negative calcium responsive elements 
(nCaRE-A and nCaRE-B) to inhibit the transcription of PTH gene [71,89,118]. Similarly, 
nCaRE-A and nCaRE-B elements were also identified in the human APE1 promoter 
gene suggesting that APE1 itself may integrate the transcriptional complex and 
regulate its expression through a negative feedback mechanism [71,89,119]. APE1 
acetylation at N-terminal residues Lys6 and Lys7 seems to enhance its binding affinity 
to nCaRE elements of PTH promoter. APE1 endonuclease activity probably is not 
affected by this post-translational modification of mammalian APE1, since the best 
candidates to be acetyl acceptors are located in the N-terminal region of the protein 
[120,121]. Ca2+-activated histone acetyltransferase p300 was proposed as the major 
responsible for APE1 acetylation, which is required for its co-repressor activity [120]. 
The acetylation of APE1 also appears to be required for the early growth response 
protein 1 (Egr-1)-mediated activation of phosphatase and tensin homolog (PTEN) 





box-binding protein 1 (YB-1) enhancing the assembly, recruitment and binding of the 
complex containing APE1, YB-1 and p300, and promoting the loading of the basic 
transcription factor RNA polymerase II on the promoter of the multidrug resistance 
gene MDR1 [123,124]. The acetylated APE1-mediated transcriptional activation of 
MDR1 has shown a potential role in the sensitivity of tumour cells to doxorubicin, 
cisplatin and etoposide [123,124].  
Finally, other post-translational modifications have been reported for APE1, including 
phosphorylation, S-nitrosation and ubiquitination [71]. The in vivo biological significance 
of APE1 phosphorylation is not elucidated and in vitro studies were not able to 
understand its importance in gene regulation. While Yacoub et al. [125] revealed the 
ability of casein kinase II-mediated phosphorylation of APE1 to inactivate its 
endonuclease activity, Fritz et al. [126] found an enhancement in the redox activation of 
transcription factor activator protein 1 (AP-1) without affecting the endonucleolytic 
function. The S-nitrosation of the residues Cys93 and Cys310 may coordinate the 
APE1 translocation from the nucleus to the cytoplasm and the reversible S-
glutathionylation of Cys99 seems to reduce the APE1 incision activity [127,128]. The N-
terminal lysine residues are also the preferred ubiquitination sites which are regulated 
by the p53-mouse double minute 2 (MDM2) signalling pathway. APE1 ubiquitination 
may retain the BER protein in the cytoplasm and interfere with the interactions of APE1 
with nucleic acids and other proteins [82,114,129]. Due to the pleiotropic nature of 
APE1, post-translational modifications may be crucial for the regulation of many 
biological activities being also potential targets for the APE1 functions modulation [71]. 
1.4. DNA REPAIR ACTIVITY OF APE1 AS A THERAPEUTIC TARGET IN 
CANCER 
Several preclinical and clinical lines of evidence supported APE1 as a prospective 
target for cancer therapy and highlighted a potential role as predictive biomarker 
[16,71,73,130]. The targeting of APE1 DNA repair activity with small-molecule inhibitors 
appears to be a clinically useful strategy to counteract the resistance of tumour cells to 
conventional anticancer agents, namely IR, alkylating and antimetabolite drugs 
[16,72,73,89,131]. Moreover, the pharmacological inhibition of APE1 endonuclease 
activity may also be a promising personalised monotherapy approach since it can lead 
to synthetic lethality in tumours harbouring mutations in proteins associated with 





repair active site to consider in the development of APE1 inhibitors and the currently 
reported compounds with an inhibitory activity of DNA repair function will be addressed. 
1.4.1. Structural insights into the DNA repair active site of APE1 in the 
context of drug discovery 
The development of potent and effective small-molecule inhibitors of the APE1 
endonuclease function requires the knowledge of the protein-ligand interactions and 
protein structure, namely the binding site and the stoichiometry of metal ion(s) present 
in the active site. Although the role of APE1 endonuclease activity in BER is 
recognized, the catalytic mechanism of the cleavage reaction is not completely 
elucidated. 
The availability of numerous X-ray crystallographic structures of APE1 bound or 
unbound to DNA substrates enabled the identification of the active site with one or two 
metal ions depending on the acidic or neutral conditions used to solve the structures. 
The APE1 crystal structures obtained under an acidic pH commonly revealed a single 
metal ion in the active site (Protein Data Bank (PDB) codes: 1BIX, 1HD7, 4LND, 4IEM, 
4QHE, 4QH9 and 5DFF) while crystallization at a neutral pH (PDB code: 1E9N) 
suggested that APE1 might bind to two divalent metal ions in its active site, raising the 
controversy [77,134–138]. 
The first crystal structure of APE1 was solved by Gorman et al. [77] at a resolution of 
2.2 Å and deposited in PDB with the code 1BIX. Although lacking the 35 N-terminal 
amino acids, this truncated APE1 was previously shown to be fully active. In this 
structure, the active site was found within a hydrophobic pocket where the hydrogen 
bonds established between several amino acids, namely the residues His309, Asp283, 
Thr265, Tyr171, Glu96, Asn68, Asp210, Asp70 and Asn212, form a hydrogen bond 
network [77]. A single samarium ion bound to the side chain of Glu96 and Asp70 was 
also present in close proximity to the metal ion being a potential participant in the metal 
binding [77]. APE1 endonuclease activity was shown to require the presence of a 
divalent metal ion, presumably, the magnesium ion (Mg2+) [139]. In this case and as a 
consequence of the experimental conditions used to obtain APE1 crystals with good 
quality, samarium ion is probably occupying the location of the more physiological Mg2+ 
ion in the APE1 active site [77]. These structural findings supported a catalytic 
mechanism with His309 abstracting a proton from a water molecule to generate the 
nucleophile able to attack the DNA phosphodiester bond while Asp283 interacts with 





metal ion to Glu96 could also be required to the stabilization of the transition state 
intermediate [77]. 
The determination of co-crystal structures of APE1 bound to DNA substrates containing 
synthetic AP sites (PDB codes: 1DEW, 1DE8 and 1DE9) and representing pre- and 
post-cleavage complexes displayed the molecular steps for substrate recognition [79]. 
The APE1 active site is rigid and pre-formed for the recognition of the DNA substrate, 
which undergoes conformational changes to allow the insertion of APE1 residues into 
the major and minor grooves of DNA helix. The binding of APE1 to DNA requires a 
bending of the DNA of approximately 35° which might assist the displacement of the 
DNA glycosylase and channeling to APE1 [79]. Arg177 and Met270 insertion in the 
major and minor groove, respectively, restraints the AP-DNA into APE1 active site [79]. 
Mol et al. [79] proposed that the APE1 hydrophobic pocket is lined by Phe266, Trp280 
and Leu282 allowing the specific binding of the α-anomers of extrahelical AP sites 
generated by DNA glycosylases and avoiding the release of toxic intermediates during 
the initial steps of BER. According to [79], the divalent metal ion and the interactions 
with APE1 active site residues Trp280, Asn222, Asn226, Asn229, Asn212, Asn174 and 
His309 orientate the flipped-out AP-DNA. The phosphodiester bond cleavage involves 
an hydroxyl nucleophile activated by the buried Asp210 with the generation of a 
pentavalent transition state stabilised by the metal ion coordinated by Asp70 and 
Glu96, which also stabilises the leaving group of the cleavage reaction. The collapse of 
the transition state leads to the cleavage of the phosphodiester bond 5’ to the AP site 
[79]. 
Beernink et al. [134] described the structures of two new crystal forms of unbound 
APE1. The structure solved at an acid pH (PDB code: 1HD7) revealed only one metal 
binding site designated as site A, while APE1 crystals grown at a neutral pH (PDB 
code: 1E9N), corresponding to a physiological pH for APE1 endonuclease activity, 
showed two metal binding sites [134,140]. The second divalent metal binding site was 
named site B [134]. The site A is present in all crystallographic structures previously 
identified and the metal ion is coordinated by carboxylate groups of residues Asp70 
and Glu96 and with a water molecule which interacts with Asn68 and Asp308 through 
hydrogen bonds [77,79,134]. On the other hand, site B is formed by the side-chains of 
Asp210, Asp212 and His309. The divalent metal ion in site B also interacts with a water 
molecule bound to Tyr171 [134]. The carboxylate groups of Glu96 and Asp210 interact 
with the metal ions. According to the structures showing two metal ions in the catalytic 
active site, Beernink et al. [134] proposed a two metal-assisted catalytic mechanism for 





located at site B and generates an hydroxyl ion to perform the nucleophilic attack to the 
5’-P termini of the AP site [134]. The Mg2+ bound to site A coordinates and stabilises 
the 3’ leaving group [134]. The presence of two metal binding sites was further 
supported by biochemical assays yielding biphasic inhibition curves for APE1 [134]. 
Based on experimental evidences and molecular dynamic simulations Oezguen et al. 
[141,142] suggested an alternative “moving metal mechanism”. The authors proposed 
that APE1 has only one metal ion which could move between the two sites during the 
cleavage reaction [141]. In the pre-cleavage complex the divalent metal ion interacts 
with the residues of the catalytically more active and buried site B [141]. After the 
reaction, the metal ion moves to site A to facilitate the retention of the cleaved product 
and the binding of the next BER enzyme which should process the DNA [141]. 
 Nuclear magnetic resonance (NMR) spectroscopy was also used as an alternative 
method to X-ray crystallography to describe the APE1 metal binding site(s) [143]. A 
single specific Mg2+ binding site was identified in a functional APE1-DNA complex 
consistent with site A [134,143]. The crystal structure of APE1 bound to a double-
stranded DNA containing an AP site mimetic (PDB code: 4IEM) also showed only one 
Mg2+ ion in the active site directly coordinated by Glu96, 3’-ribose oxygen, phosphate 
from DNA and three water molecules in a tetrahedral arrangement [135]. These 
findings were recapitulated by a high resolution (1.92 Å) crystal structure of DNA-free 
APE1 with a single Mg2+ bound in the active site (PDB code: 4LND) obtained by 
Manvilla et al. [136]. The position of Mg2+ is similar to the previously described site A 
[134,136] and the ion is coordinated in an octahedral geometry by carboxylate groups 
of Asp70 and Glu96 and four water molecules [136]. Both methods and structures had 
no evidences of a metal ion in site B [135,136,143]. He et al. [137] corroborated the 
presence of a pre-formed single metal binding site in APE1 and suggested the initial 
capture of the metal ion in the active site. In addition to Asp70 and Glu96, Asp308 may 
also participate in the stabilisation of the Mg2+ ion. Similarly to the findings of Lipton et 
al. [143], the crystal structure with the PDB code 4QHE also showed a disordered Mg2+ 
ion, which exhibited two partially occupied binding sites due to the ability of Glu96 to 
present different conformations [137]. These evidences highlight the structural plasticity 
of the active site during catalysis [137]. 
The most recently catalytic mechanism interpretation was proposed by Freudenthal et 
al. [138] by capturing key snapshots of APE1-DNA structures (Fig. 1.7). Overall, AP 
site is flipped by APE1 into the active site to position the DNA for the cleavage reaction. 
In the precleavage (or ground) state, a single metal ion is bound to Asp70, Glu96 and a 





with Asn212 and Asp210 for the nucleophilic attack to the phosphorus atom 5’ to the 
AP site. A pentacovalent transition state-intermediate is generated and stabilised by 
Mg2+, Tyr171, His309, Asp210 and Asn212. The active site Mg2+ coordinates with an 
oxygen from the DNA product and with an oxygen of the 3’ leaving group. In the final 
product state, Asn212 rotates acting as an hydrogen-bond donor to stabilise the 
product. 
 
Figure 1.7 Scheme of the suggested catalytic mechanism of APE1 endonuclease activity. The 
mechanism interpretation was based on the structural snapshots of DNA-bound APE1 crystal structures 
obtained by Freudenthal et al. [138]. The transition state was predicted from the ground and product state 
structures. Adapted from [138]. 
1.4.2. Currently available small-molecule inhibitors of APE1 DNA repair 
activity 
The modulation of the DNA repair function of APE1 has been widely studied in cancer 
therapy and several authors have been dedicated to the identification and development 
of small-molecule inhibitors of the DNA repair activity of APE1. 
The most studied inhibitor of APE1 endonuclease function is methoxyamine 
hydrochloride (MX), also known as TRC102 (Fig. 1.8) [16]. MX was the first APE1 
inhibitor to be identified and, as aforementioned, the first to be evaluated in human 
clinical trials in combination with alkylating or antimetabolite drugs. MX is an 
alkoxyamine derivative that indirectly inhibits the DNA repair function of APE1 
[144,145]. The reaction of MX with the aldehyde group of the ring-open form of 
deoxyribose moiety present in the AP site after the removal of the damaged nucleotide 
by the DNA glycosylase creates a blocked AP site [131,144,145]. The covalently bound 
MX-AP sites are refractory to the APE1 endonuclease activity inhibiting BER 
progression and inducing the accumulation of cytotoxic AP sites in cells [131,145]. 
Moreover, the stable adducted MX-AP sites also target the topoisomerase II and 





death [145]. In vitro and in vivo preclinical studies showed the MX sensitisation towards 
the cytotoxic effects of TMZ [145–149], 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) 
[150], pemetrexed [151] and 5-iodo-2’-deoxyuridine (IdUrd) [152] as well as the 
potentiation of IdUrd-mediated radiosensitisation [153] in several solid tumour models. 
These results provided the proof-of-concept to conduct clinical trials with MX as 
adjuvant therapy of anticancer agents. The already completed phase I clinical trial of 
oral administered MX (TRC102) in combination with pemetrexed in patients with 
advanced refractory cancer showed that the APE1 inhibitor was well-tolerated at 
clinically relevant doses [154]. A phase I clinical trial of the combination of MX 
(TRC102) with fludarabine phosphate in patients with relapsed or refractory 
haematologic malignancies was also completed showing no dose limiting toxicity in 
low-grade lymphoma and chronic lymphocytic leukemia with relapses after fludarabine-
containing regimens [155]. Clinical trials with the combination of MX with TMZ or 
cisplatin and pemetrexed are also planned (Table 1.2) 
Although the potential of MX as an inhibitor of APE1 endonuclease function, many 
efforts have been made to develop direct inhibitors of this enzyme. In fact, direct 
enzyme inhibitors are considered more specific with a subsequent decrease of 
secondary targets which probably reduces the therapy-related side effects [131].  
7-nitro-1H-indole-2-carboxylic acid (CRT0044876) (Fig. 1.8) was identified in a high-
throughput screening (HTS) assay of a commercially available library of “drug-like” 
compounds as a direct inhibitor of APE1 with an IC50 of approximately 3 µM [156]. 
CRT0044876 revealed promising in vitro results showing an increase in the cytotoxicity 
of methyl methanesulfonate (MMS) and 5-hydroxymethyl-2’-deoxyuridine [156]. 
However, some authors were not able to reproduce the effects reported by 
Madhusudan et al. [156] for this compound [73]. 
Lucanthone (Fig. 1.8) was shown to act as a nonspecific direct inhibitor of APE1 since 
topoisomerase II is also a target of lucanthone which is also able to intercalate into the 
DNA [157,158]. Nevertheless, the interaction of lucanthone with other cellular targets 
and the resultant toxicity prevented its therapeutic use as APE1 inhibitor [131,157,158].  
Different strategies have been used to identify novel direct small-molecules of APE1 
DNA repair activity including the HTS of commercially available chemical libraries 
[156,159–162], the drug design approaches based on structure-activity relationship 
studies [163,164], ligand-based pharmacophore models [164–166] and structure-based 
virtual screening (SBVS) as well as molecular docking studies [165,167–169]. 





endonuclease activity (reviewed in [85]). Although structurally diverse (Fig. 1.8), the 
majority of the already described putative APE1 inhibitors share some basic chemical 
features namely a) an hydrophobic core, b) hydrogen-bond acceptors and c) negatively 
ionisable groups to anchor compounds to the active site residues of APE1. 
 
Figure 1.8 Structures of several reported inhibitors of APE1 DNA repair activity. The strategies 






The approach adopted by Mohammed et al. [165] comprised the construction of 
pharmacophore models based on the compound CRT0044876 and prototypical 
molecular scaffolds designed to fit into the APE1 ligand-binding site. These structures 
were used to perform a SBVS study and docking analyses to select potential bioactive 
molecules [165]. The biochemical and cell-based assays in melanoma, glioblastoma 
and HUVEC endothelial cell lines in combination with MMS, TMZ and doxorubicin 
(Dox) led to the identification of N-(4-fluorophenyl)-2-(4-phenylsulfonyl)-2-(p-
tolyl)oxazol-5-yl)sulfanyl-acetamide (Fig. 1.8) as a promising inhibitor of APE1 [165]. A 
similar strategy involving a receptor-based virtual screening and a docking study 
contributed to the identification of a compound containing a quinoxaline core which can 
be a scaffold for novel small-molecule inhibitors of APE1 [168]. 
Table 1.2 Clinical trials completed or planned with methoxyamine (MX) in cancer. 
 
The arylstibonic acids identified by Seiple et al. [162] are among the most potent 
inhibitors of APE1 in biochemical assays, being active in the low nanomolar range and 













Pemetrexed Phase I Completed [154] 




Phase I Completed [155] 
Lymphomas and 
relapsed solid tumours 
Temozolomide Phase I Recruiting www.traconpharma.com 
Recurrent glioblastoma Temozolomide Phase II Recruiting www.traconpharma.com 





Phase I/II Recruiting www.traconpharma.com 
Stage IIIA-IV non-small 




Phase I Recruiting www.traconpharma.com 
Advanced solid tumours Temozolomide Phase I Recruiting www.traconpharma.com 





bind to both the enzyme and the enzyme-substrate complex. However, these 
compounds did not show an increase of the toxicity of DNA-damaging agents in cell 
culture suggesting that issues of permeability might hinder their entry into the cells 
[162]. Moreover, carboxylate and stibonate groups appear to be positioned in the APE1 
binding pocket similarly to the arrangement of the 3’ and 5’ phosphates of a DNA 
strand containing an AP site. This suggests that arylstibonic acids may mimic the 
phosphate groups of APE1 substrate [162]. This finding indicates that these 
compounds may be capable of binding other DNA-processing proteins disclosing a 
possible lack of specificity for APE1 [162]. 
Using a set of three-dimensional (3-D) pharmacophore models based on the 
interactions between APE1 and the abasic DNA, Zawahir et al. [166] reported a series 
of active compounds containing at least two terminal negatively ionisable chemical 
functions or bioisostere groups of negatively ionisable features. This highlights the 
requirement of these groups to the recognition of the potential inhibitors by APE1 and 
the subsequent inhibition of its DNA repair function [166]. 
The HTS assay performed by Simeonov et al. [160] revealed numerous and structurally 
diverse compounds as APE1 inhibitors. The aurintricarboxylic acid was the most potent 
hit. Although being active at low nanomolar concentrations it may form a stable radical 
homopolymer and inhibit other RNA- and DNA-processing enzymes [160]. 
Consequently, it was discarded from further analyses. Moreover, the most promising 
bioactive molecules were Reactive Blue 2, 6-hydroxy-DL-DOPA and myricetin (Fig. 
1.8) which were already reported to have other molecular targets being non-specific 
inhibitors of APE1 endonuclease activity [160]. More recently, these authors performed 
the largest-scale HTS assay already described to identify novel inhibitors of APE1 and 
uncovered several potential scaffolds that can be chemically optimised [161]. In fact, 
one of these compounds was further used as lead chemotype in the first reported 
medicinal chemistry optimization campaign of a potential APE1 inhibitor [163]. The 
structure-activity relationship studies resulted in the synthesis of other possible APE1 
inhibitors [163]. The molecule termed as compound 52 (Fig. 1.8) was more active than 
the lead compound (N-(3-(benzo[d]thiazol-2-yl)-6-isopropyl-4,5,6,7-
tetrahydrothieno[2,3-c]pyridin-2-yl)acetamide) in the biochemical assays [163]. Thus, 
compound 52 was also tested in cellular models and pharmacokinetic properties of 
both the lead and the optimized compound were evaluated in in vitro and in vivo 
models [163]. Although both compounds showed favourable solubility and permeability 
properties in in vitro models, compound 52 appeared to be rapidly metabolized by 





cytotoxicity profile while the lead compound was more efficient to cross the blood-brain 
barrier [163]. 
A quinoline derivative designated as AR03 (Fig. 1.8) and identified in a HTS assay 
performed by Bapat et al. [159] appeared to be a specific APE1 inhibitor in the low 
micromolar range. It revealed also a sensitising effect of the cytotoxicity of MMS and 
TMZ in the SF767 glioblastoma cell line [159]. 
Several 3-carbamoylbenzoic acid derivatives (Fig. 1.8) were designed based on 
pharmacophore models previously reported and tested by Aiello et al. [164] showing 
APE1 catalytic activity inhibition in the micromolar range. Structure-activity relationship 
studies emphasised the role of 3-carbamoylbenzoic acid lead scaffold in the 
development of a new class of APE1 inhibitors [164]. 
Srinivasan et al. [167] also reported a putative APE1 inhibitor active in biochemical 
assays at nanomolar concentrations. This compound has a 2-methyl-4-amino-6,7-
dioxolo-quinoline structure (Fig. 1.8) and potentiated the toxicity of a DNA-damaging 
agent that selectively induces N3-methyladenine lesions in T98G glioma cells. In 
addition, this compound was also tested in the NCI-60 cell line panel and revealed a 
synergic effect in SK-MEL-5 melanoma cell line exposed also to vemurafenib, a 
V600E-mutated B-type Raf (B-Raf) kinase targeting drug [169]. 
Although the advances towards the discovery of inhibitors of APE1 endonuclease 
activity, the abovementioned compounds still lack the potential to be translated to the 
clinical setting. In view of the increasing evidence supporting APE1 DNA repair function 
as an attractive therapeutic target, the development of pharmacologically active APE1 
inhibitors to be used in cancer chemotherapy and to allow the understanding of the 
biological role of different functions of this enzyme remains a challenge [71,89]. 
1.5. REDOX FUNCTION OF APE1 AS A THERAPEUTIC TARGET IN CANCER 
The maintenance of ROS homeostasis is required for the normal cell function. In non-
tumour cells, a small increase in the basal low levels of ROS has a proliferative effect 
[171,172]. Regarding tumour cells, an increase in intracellular ROS levels can inhibit 
cell proliferation and induce cell death [171,172]. These differences are explained by 
tumour cells ability to adapt to higher levels of ROS [173,174]. Actually, tumour cells 
are under a persistent oxidative stress due to their high metabolic rate [171,173]. In 
general, tumour cells have low antioxidant defences and higher basal ROS level than 





ROS concentrations in tumour cells are frequently close to the toxicity threshold a 
further increase in ROS levels can be pro-apoptotic [171]. 
Several conventional anticancer agents, including anthracyclines, taxanes, platinum-
based drugs and IR, are known to generate ROS [172,175–179]. However, the 
opportunities of redox-based therapeutic approaches in cancer are not restricted to the 
use of anticancer agents in combination with pro-oxidants drugs to induce oxidative 
stress leading to DNA damage and cell death. A redox-based strategy also includes 
the modulation of antioxidant systems to counteract the toxicity of current available 
chemotherapeutic drugs [180]. For example, the life-threatening cardiotoxicity induced 
by the anthracycline Dox has been attributed to a ROS-dependent mechanism and 
antioxidant enzyme mimetics as well as intracellular metal chelators have been studied 
to improve the therapeutic index of the anticancer drug without affecting its 
chemotherapeutic effect  [180–182]. 
Moreover, ROS are essential players in the cellular signal transduction pathways being 
required to the initiation of redox signalling cascades [183,184]. Upon the activation of 
a given pathway a series of coordinated redox reactions at the thiol groups of protein 
cysteine residues occur to convey the signal that will elicit the cell response [183,184]. 
ROS have been associated to the regulation of pathways involved in tumour cell 
survival, proliferation, invasion, migration and in angiogenesis [183–185]. Therefore, 
targeting of redox proteins of the signal transduction cascades is an attractive 
therapeutic alternative to disrupt redox signalling networks in tumour cells and abrogate 
important steps of cancer progression. In view of this, the redox activity of the 
multifunctional APE1 protein is an emerging upstream target for the modulation of 
several redox signalling pathways fundamental for cancer development [72,183–185]. 
1.5.1. APE1 in redox signalling 
Mammalian APE1 can also function as a nuclear reduction/oxidation signalling factor 
and thus modulates the transcription of multiple genes involved in survival, proliferation 
and cancer promotion. Nuclear factor-kappa B (NF-кB), AP-1, hypoxia-inducible factor 
1 alpha (HIF-1α), p53, Egr-1, signal transducer and activator of transcription 3 
(STAT3), cAMP response element-binding protein (CREB) as well as tissue-specific 
proteins (e.g. paired box protein Pax-5 and -8) are some of the transcription factors 
under APE1 redox-mediated activation [71,72,186–191]. 
A redox mechanism has been proposed to involve the reduction carried out by APE1 of 





the regulatory regions of the transcription factors enhancing their affinity and binding to 
DNA [71,72]. In a typical thiol-disulfide exchange mechanism the attack of the 
nucleophilic cysteine to the disulfide bond of the inactive transcription factor results in 
the generation of a disulfide bond between the redox factor and the transcription factor. 
This bond has to be further resolved by an additional cysteine residue of the redox 
factor in order to generate the reduced transcription factor and the oxidised redox 
protein (Fig. 1.9) [71,72,81]. 
APE1 has seven cysteine residues in its structure and three are located in the N-
terminal redox domain (Cys65, Cys93 and Cys99). Cys65 has been suggested as the 
nucleophile which reduces the transcription factors since its substitution by the amino 
acid alanine renders a redox inactive APE1 [192,193]. Moreover, the redox function 
and Cys65 are both present only in mammalian APE1 proteins supporting the critical 
role of Cys65 in APE1 redox activity [80]. 
Cys93 and/or Cys99 may be the residues involved in the resolution of the disulfide 
bond established between Cys65 and the transcription factor (Fig. 1.9). In fact, the 
substitution of Cys93 by alanine resulted in a decrease of the redox activity while the 
double substitution of Cys93 and Cys99 provided a redox inactive mutant APE1 protein 
as evaluated by an electrophoretic mobility shift assay (EMSA) [193]. 
Cys65 is a buried residue in APE1 structure being inaccessible to interact with the 
target transcription factor. Similarly, the position of Cys93 and the distance to Cys65 
hampers the formation of a disulfide bond between these APE1 residues. In view of 
this, it was found that the redox mechanism requires a conformational alteration of 
APE1 to a partially or locally unfolded state allowing the exposure of the critical 
residues [80,193,194]. 
However, the mechanism of APE1 redox activity is not completely clarified. It has been 
suggested that the formation of additional disulfide bonds might occur and a third thiol-
containing protein might also be implicated in the regeneration of oxidised APE1 
[71,72,193]. In fact, thioredoxin was shown to interact with APE1 and the 
thioredoxin/thioredoxin reductase pathway also cooperates with APE1 in the control of 






Figure 1.9 Scheme of the hypothesised mechanism of activation of transcription factors by APE1 
redox function. Cysteines at position 65 and 93 are required for the reduction-oxidation reaction that 
reduces the transcription factors. Thioredoxin might be the third thiol-containing protein that regenerates 
the previously oxidised APE1 re-establishing its redox activity. Adapted from [81]. Abbreviations: DBD – 
DNA-binding domain. 
1.5.2.  Currently available small-molecule inhibitors of APE1 redox 
function 
The APE1 redox activity participates in the downstream activation of transcription 
factors from several signal transduction pathways. Targeting of APE1 redox function 
may modulate different processes required for cancer promotion and progression. The 
currently available small-molecule inhibitors of APE1 redox function are presented in 
Fig. 1.10. 
The compound (2E)-2-[(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-
yl)methylene] undecanoic acid, also known as E3330 (Fig. 1.10),  was initially 
suggested to be an anti-inflammatory drug and an inhibitor of NF-кB DNA-binding 
activity [197–199]. The inability of E3330 to affect the degradation of IƙBα, the nuclear 
translocation of NF-кB or the phosphorylation of the p65 subunit leads to the 
hypothesis that a redox nuclear cofactor should be required for NF-кB activity and act 
as the target of the quinone derivative E3330 [199]. APE1 has been shown to interact 
and activate NF-кB [186] and Shimizu et al. [200] identified APE1 as the protein being 
specifically inhibited by E3330. 
The nature of the interaction of E3330 with APE1 has been widely studied in an 





E3330 to a partially unfolded conformation of APE1 was suggested by Su et al. [194]. 
In addition to protein stabilization, the establishment of the interaction APE1-E3330 
allows the exposure of buried Cys residues essential for the redox activation of the 
transcription factors. E3330 might also induce the reversible activation of a Cys residue 
which will be more vulnerable to the nucleophilic attack by a reduced Cys of the 
protein. Therefore, E3330 increases the disulfide bond formation probably between 
Cys65 and Cys93 of APE1 decreasing the redox active molecules of the enzyme 
[193,194]. 
 
Figure 1.10 Structures of APE1 redox inhibitors. These compounds were described in [200–205]. 
The redox inhibitor binding site in APE1 has been postulated to be located near Cys65 
which has been considered a vital residue for APE1 redox activity. Using a NMR shift 
assay and docking studies, Manvilla et al. [206] proposed that E3330 binds to APE1 in 
a pocket of the DNA-binding cleft adjacent to the catalytic site responsible for the 
endonuclease activity. This evidence indicates that E3330 could act as an allosteric 
inhibitor suppressing the conformational change of APE1 required for its redox activity, 
disrupting the binding and activation of transcription factors or hindering the redox 
chaperone activity of APE1 [206]. Manvilla et al. [206] also showed that E3330 may not 
selectively inhibit the redox function of APE1 in cells. However, inhibition of APE1 





[206]. In the presence of contradictory information about the inhibition mechanism of 
APE1 redox activity Zhang et al. [201] adopted hydrogen-deuterium exchange (HDX) 
mass spectrometry to provide novel insights into the APE1-E3330 interaction. Two 
sites of interaction for E3330 were identified close to the DNA repair active site [201]. 
Nevertheless, these interactions are probably established by the favorable electrostatic 
interactions between the carboxylate group of E3330 and the positively charged 
residues of APE1 DNA-binding site while its effectiveness as redox inhibitor is 
attributed to the quinone group [201]. E3330 revealed a poor inhibitory effect of the 
endonuclease activity in vitro which was observed only for concentrations higher than 
100 µM [201]. A destabilization of APE1 structure was also detected during the 
interaction with E3330, supporting the findings of Su et al. [194] and highlighting the 
requirement of the compound binding to a partially unfolded state of the enzyme to 
inhibit its redox function [201]. 
E3330 has been shown to decrease not only the DNA-binding activity of NF-ƙB 
[186,199,201,207,202,208] but also of the transcription factors AP-1 [201,207,209], 
HIF-α [207,208,210] and STAT3 [190]. Therefore, the therapeutic potential of E3330 is 
associated to the targeting of different components of tumour progression. Several 
preclinical studies in diverse cellular models highlighted the role of E3330 in the 
modulation of a) cell differentiation and cellular growth [190,207,210,211], b) tumour 
microenvironment (inflammatory responses) [198,209,212], c) migration [210,213] and 
d) angiogenesis [213–215]. Furthermore, in a pancreatic tumour xenograft model 
E3330 induced a decrease of tumour growth rate and promising pharmacokinetic and 
pharmacodynamic properties [207]. 
E3330 was used as the scaffold for the development of novel and more potent quinone 
analogues able to inhibit the APE1 redox function. The naphthoquinone analogues 
were more potent than the lead compound and the benzoquinone analogues [203]. The 
most potent naphthoquinones RN7-60, RN8-51 and RN10-52 (Fig. 1.10) presented a 
10-fold lower in vitro IC50 value for the APE1 redox activity when compared with the 
IC50 of E3330 [202]. They also blocked more efficiently the activation of NF-ƙB in 
ovarian cancer cell lines than E3330 [202]. Although the promising effects, compounds 
RN10-52 and RN7-60 showed to be highly reactive and to induce apoptosis at higher 
levels being more prone to the development of toxic side effects [202]. 
E3330-amide (Fig. 1.10), the methoxy amide derivative of E3330 is expected to have 
an improved solubility than the parent compound. Moreover, E3330-amide was a more 





IC50 value of 8.5 µM while E3330 presented an IC50 value of 20 µM [201]. E3330-amide 
had also a more pronounced effect in the blockage of the growth of SKOV-3X ovarian 
cancer cell line [201]. 
The compound PNRI-299 (Fig. 1.10) was identified through a combinatorial library 
approach using a template designed to act as a reversible inhibitor of redox proteins 
[204]. PNRI-299 selectively inhibited AP-1 transcription and affinity-labeled studies 
showed that APE1 is the target of PNRI-299 [204]. 
The naturally occurring compounds resveratrol and soy isoflavones had also been 
proposed as redox inhibitors of APE1 [205,216]. Resveratrol (Fig. 1.10) was identified 
using a structure-based approach and docking studies [205]. This compound interfered 
with APE1-activated AP-1 DNA binding and APE1 endonuclease activity [205]. 
However, these findings were not supported by other authors and resveratrol is 
probably a non-selective inhibitor [72,217]. Similarly, the inhibition of APE1 redox 
activity by soy isoflavones was not corroborated by other authors [72,217]. Soy 
isoflavones were implied in the decrease of APE1 levels in prostate cancer cell lines 
which was correlated with a reduced DNA-binding of NF-ƙB [216]. 
1.6. APE1 IN CANCER 
According to the estimated demographic features of worldwide population, the global 
cancer burden and cancer-related mortality is expected to increase substantially over 
the next years. In 2030, global cancer burden is predicted to achieve 20.3 million new 
cancer cases and 13.2 million cancer-related deaths compared to the 14.1 million new 
cancer cases and 8.2 million cancer-related deaths forecasted for 2012 and presented 
in the GLOBOCAN series of the International Agency for Research on Cancer 
[218,219]. 
Several lines of evidence support APE1 as a prospective target for personalised 
medicine in oncology. In fact, the multiplicity of functions, the correlation of alterations 
in the expression and subcellular distribution of APE1 with the prognosis of several 
types of cancer and preclinical studies suggesting that the knockdown or impairment of 
APE1 endonuclease activity sensitises cancer cells to chemo- and radiotherapy, 
granted the rationale for targeting APE1 in cancer therapy and highlighted a potential 
role as biomarker [16,71,73,130]. 
In general, the expression and intracellular localization pattern of APE1 is 





localization is predominantly nuclear while in cell types with a high metabolic and 
proliferative rates APE1 can be located in cytoplasm [115,220]. Although APE1 cellular 
compartmentalization is not fully clarified, nuclear localization has been mainly 
assigned to its roles in DNA repair and to the requirement of APE1 for DNA-binding of 
transcription factors [115,220]. On the other hand, APE1 identification in cytoplasm can 
be related to extra-nuclear functions of the protein including the mitochondrial BER, its 
association with the endoplasmic reticulum membranes, the redox activity required to 
maintain recently synthesised transcription factors in a reduced state during their 
translocation to the nucleus and APE1 accumulation as a consequence of cellular 
inability to perform its degradation [98,115,220–222]. 
In human tumours the APE1 subcellular distribution pattern is usually disrupted when 
compared with the corresponding non-tumoural tissue. In tumours APE1 has shown a 
nuclear, cytoplasmic or nuclear/cytoplasmic localization (reviewed in [89]). These 
alterations have been correlated with tumour aggressiveness and prognosis in different 
types of cancer including colorectal [223], hepatocellular [224], ovarian [225–229], 
gastro-oesophageal [226],  pancreatico-biliary [226,230], head and neck [231], non-
small cell lung cancer (NSCLC) [232,233] and breast cancer [234–236]. The pattern of 
APE1 subcellular localization was also evaluated in platinum-based neoadjuvant-
treated patients with gastro-oesophageal cancer [226]. In the platinum-treated group, 
nuclear APE1 expression was associated with a lower overall survival and cytoplasmic 
APE1 distribution with tumour differentiation [226]. 
In addition to APE1 subcellular dysregulation, APE1 levels in tumour tissue and/or in 
other biological samples can be important prognostic and predictive biomarkers of 
cancer progression and tumour sensitivity to anticancer agents [89]. Alterations in 
APE1 expression were reported in prostate [237], osteosarcoma [238], ovarian [229], 
non-small cell lung [233,239], bladder [240], hepatocellular [224], pancreatic [230], 
gastric [241], germ cell [242] and breast [235] cancer. Koukourakis et al. [231] reported 
that a high nuclear expression of APE1 in head and neck cancer was associated with a 
poor response to chemoradiotherapy. Similarly, APE1 overexpression was also 
associated with the resistance of NSCLC to cisplatin-based chemotherapy and with a 
protective effect against bleomycin and IR in germ cell tumour cell lines [233,242]. 
Interestingly, Sak et al. [240] found an improved patient survival in muscle-invasive 
bladder cancer following radical radiotherapy in tumours with high protein expression 
levels of APE1 and XRCC1. The authors suggested that this unexpected finding could 
be related to the tumour grade since the majority of patients enrolled in the study 





APE1 gene expression levels in blood of patients with NSCLC or squamous cell 
carcinoma of the head and neck (SCCHN). A positive correlation between APE1 gene 
level in blood and SCCHN tissue was found suggesting the potential to be used in the 
clinical setting as a possible blood based gene expression prognostic and predictive 
biomarker [239]. APE1 protein was also elevated in the serum of bladder cancer 
patients being a possible serological biomarker in this type of cancer [243]. 
In functional preclinical studies, the downregulation of APE1 with small-interfering 
RNAs (siRNAs) or antisense oligonucleotides sensitised several mammalian cancer 
cell lines to MMS [244,245], hydrogen peroxide (H2O2) [245,246] and to numerous 
therapeutic DNA-damaging agents, namely TMZ [244,247,248], BCNU [244,248], 
gemcitabine [249], IR [250–252] and bleomycin [251].  Moreover, a dominant-negative 
form of APE1 lacking the endonuclease activity enhanced the cellular sensitivity to 
MMS, H2O2, 5-FU, 5-fluorodeoxyuridine, streptozocin, TMZ and BCNU [253,254]. 
Several polymorphic variants have been described in the repair domain of APE1 gene 
as well as their possible influence in cancer susceptibility and treatment sensitivity. The 
APE1 polymorphisms include Asp148Glu, Gln51His, Ile64Val, Leu104Arg, Glu126Asp, 
Arg237Ala, Asp283Gly, Gly306Ala, Gly241Arg and Thr141Gly [130,255,256]. The 
functional characterization revealed that the variants Leu104Arg, Glu126Asp, 
Arg237Ala and Asp283Gly had a reduced endonuclease activity [256]. Although the 
lack of effect of Asp148Glu polymorphism in APE1 endonuclease or DNA binding 
activity, this polymorphic variant has been the most studied and it was associated with 
an increased risk of lung and gastric cancer [130,256–258]. 
Overall, these findings support the key value of APE1 as a predictive and prognostic 
biomarker as well as a promising pharmacological target in cancer therapy. 
1.7. APE1 IN BREAST CANCER: ROLE AND THERAPEUTIC OPPORTUNITIES 
Breast cancer is the second most frequently diagnosed neoplasm and it is the fifth 
cause of death from cancer in the world [219]. Although the high incidence rate of 
breast cancer, mortality has been decreasing, especially in the high-income countries, 
as a result of the advances in early diagnosis and the improvements in adjuvant 
therapy [219,259]. Nevertheless, breast cancer is the leading cause of cancer-related 
deaths in women due to the development of metastatic disease [219,259,260]. 
Actually, 5% to 10% of breast cancers are metastatic at diagnosis with only one-fifth of 





The guidelines for metastatic breast cancer treatment typically include therapeutic 
combinations of chemotherapy, radiotherapy, surgical resection and endocrine therapy 
[261,262]. Chemotherapeutic drugs are frequently recommended as adjuvant systemic 
therapy in several types of primary breast tumours and in neoadjuvant treatment of 
patients with advanced disease remaining the leading treatment for triple-negative 
advanced breast cancer [261–263]. Despite the selection of the most appropriated 
therapeutic agent(s), treatment schedule and duration should be individualised. 
Anthracyclines as single agent or in combination regimens are usually established as 
first-line therapy while taxanes are the second-line drugs in triple-negative advanced 
breast cancer [261,262]. Moreover, taxane-based regimens can be also selected as 
first-line therapy since they are the standard alternative treatment for patients with 
refractory disease to adjuvant anthracycline-based chemotherapeutic regimens 
[261,262]. 
However, the intertumoural and intratumoural heterogeneity of primary breast tumours 
and the heterogeneous metastatic pattern have been commonly associated to 
therapeutic failure and, subsequently, to poor outcomes in the treatment of advanced 
breast cancer [260,264,265]. Thus, the development of targeted therapies is an 
attractive field to improve the overall survival in advanced breast cancer. 
Based on the current available chemotherapeutic drugs which act primarily by induction 
of DNA damage (e.g. anthracyclines) in cancer cells, the possibility of modulating the 
DNA repair pathways is an emerging approach to allow the enhancement of the 
efficacy of a given agent. Moreover, the presence of abnormalities in genes affecting 
the DNA repair pathways (e.g. BRCA1/2, PTEN) is frequently observed in breast 
cancers rendering an alternative DNA repair pathway as an appealing target to 
potentiate cancer cell killing while possessing tolerable side effects [266]. In this 
context, APE1, an upstream protein of BER, is a rationale target for DNA repair-
directed therapies in cancer treatment. Furthermore, APE1 redox function may also be 
involved in molecular and cellular processes required for cancer progression and 
metastases development, namely cell adhesion, migration, invasion and angiogenesis 
[72]. Therefore, the combination of an APE1 redox inhibitor with taxanes (e.g. 
docetaxel) might also be a novel therapeutic alternative to advanced breast cancer 
(Fig. 1.11). 
In addition to the aforementioned differential APE1 subcellular distribution observed in 
breast tumours [234–236], several evidences support APE1 as a potential druggable 





relatively to non-tumoural breast tissue [235,267]. In a cohort of triple negative breast 
cancer (TNBC), APE1 was found to be overexpressed when compared to non-tumoural 
breast tissue [268]. Moreover, a dysregulation of the acetylation of APE1 was also 
observed by the detection of a heterogeneous staining pattern among breast cancer 
tissue. Since acetylated APE1 was previously linked to the modulation of APE1 
endonuclease activity, concurrently with total protein overexpression, this post-
translational modification may constitute an additional marker for breast cancer 
aggressiveness [268]. 
 
Figure 1.11 Rationale for the combination of standard chemotherapeutic drugs used in the 
advanced breast cancer treatment with APE1 inhibitors [2,72,261,262]. 
Genetic variations in APE1 may contribute to breast cancer risk and to the 
susceptibility to anticancer agents. Although some studies were not conclusive about 
the relation of APE1 variants and breast cancer risk [269,270], in a Caucasian 
population, the carriers of the genotype APE1 148DD (rs3136820) were associated 
with an increased risk of breast cancer [271]. The APE1 single-nucleotide 
polymorphism –656 T>G had also a significant role on the incidence and progression 
of breast cancer in a case-control study in a Chinese population [272]. The variant 
APE1 148Glu was correlated with a decreased risk of acute skin reactions after 
radiotherapy in breast cancer patients with normal weight [273]. 
Therefore, the development of APE1 inhibitors should be an important research area in 
the field of personalised medicine to improve the treatment of advanced breast cancer. 
Breast Cancer1
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The aim of this work is the evaluation of a strategy for the improvement of standard 
breast cancer treatment by combining the use of APE1 pharmacological inhibitors with 
conventional anticancer agents in a highly aggressive human breast cancer cell line 
(MDA-MB-231 cells). As mentioned in Chapter 1, APE1 is a multifunctional protein with 
critical roles in the DNA repair and in the reduction/oxidation signalling by modulating 
the activation of multiple transcription factors involved in cancer progression. These 
features render APE1 as a potential target for anticancer drugs design and 
development. To achieve this general aim the following specific objectives are 
proposed: 
a) Characterisation of the cytotoxicity, genotoxicity and migration/invasiveness 
profiles of standard therapeutic drugs for MBC; 
b) Assessment of the combinations of commercially available inhibitors of the 
endonuclease and redox function of APE1 with the current chemotherapeutic drugs 
used in MBC in terms of cytotoxicity, genotoxicity and migration/invasion modulation;  
c) Identification of novel small-molecule inhibitors of APE1 endonuclease activity by a 
computer-aided drug design campaign; 
d) Evaluation of the effect of the selected compounds in APE1 endonuclease activity; 
e) Assessment of the cytotoxicity of active compounds in off-target cells, namely in 
non-tumour breast cells. 
In this thesis, we expect to be able to highlight the relevance of the APE1 inhibitors to 
sensitise breast cancer cells to anticancer drugs and identify novel chemical scaffolds 
which can be further optimised leading to clinically useful compounds.  
Therefore, the Chapter 3 describes the effects of MX, the most studied and 
commercially available indirect inhibitor of the APE1 endonuclease activity, in 
combination with Dox, an anthracycline antibiotic, in human breast cancer MDA-MB-
231 cells. MDA-MB-231 cell line was selected because it is a representative in vitro 
model of MBC. In this context, Dox was the anticancer drug used since it is a DNA-
damaging agent which also undergoes redox-cycling producing ROS and it has been 
widely used in the treatment of MBC. The cytotoxicity and genotoxicity of the APE1 
inhibitor/Dox combination was assessed with complementary endpoints to evaluate the 
therapeutic potential of this modality of combined chemotherapy.  
Chapter 4 reports the identification with a structure-based virtual screening (SBVS) 





library of National Cancer Institute/Developmental Therapeutics Program (NCI/DTP) 
with ability to inhibit the APE1 endonuclease activity. The cytotoxicity of the most 
promising inhibitors of APE1 DNA repair activity was also evaluated in the non-
tumourigenic human breast epithelial MCF10A cell line. 
The APE1 redox function is also a promising target to be used in combination with 
standard chemotherapeutic drugs. Chapter 5 describes the effects of E3330, the most 
studied redox inhibitor of APE1, combined with DTX in MDA-MB-231 cells. DTX is a 
taxane drug widely used in MBC refractory to adjuvant anthracycline-based therapeutic 
regimens. The viability, proliferation, cell cycle profile, the migratory properties and 
invasion ability of MDA-MB-231 cells treated with both compounds were assessed to 
evaluate the impact of this novel therapeutic strategy based on the targeting of APE1 
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Pharmacological inhibition of DNA repair is a promising approach to increase the 
effectiveness of anticancer drugs. The chemotherapeutic drug Dox may act, in part, by 
causing oxidative DNA damage. The BER pathway affects the repair of many DNA 
lesions induced by ROS. MX is an indirect inhibitor of apurinic/apyrimidinic 
endonuclease 1 (APE1), a multifunctional BER protein. We have evaluated the effects 
of MX on the cytotoxicity and genotoxicity of Dox in MDA-MB-231 metastatic breast 
cancer cells. MX has little effects on the viability and proliferation of Dox-treated cells. 
However, as assessed by the cytokinesis-block micronucleus (CBMN) assay, MX 
caused a significant 1.4-fold increase (P < 0.05) in the frequency of micronucleated 
binucleated cells induced by Dox, and also altered the distribution of the numbers of 
micronuclei. The fluorescence probe dihydroethidium (DHE) indicated little production 
of ROS by Dox. Overall, our results suggest differential outcomes for the inhibition of 
APE1 activity in breast cancer cells exposed to Dox, with a sensitising effect observed 
for genotoxicity but not for cytotoxicity. 
Keywords 
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The effectiveness of many anticancer drugs depends on their ability to damage the 
DNA, generating lesions that ultimately induce cell death. Cancer cells are often 
resistant to DNA-damaging agents, due to increased activity of DNA repair pathways 
(reviewed in [1,2]). Study of these repair systems has led to the development of 
pharmacological inhibitors of DNA repair, with a view to overcoming resistance to 
anticancer therapies and improving clinical outcomes. 
BER pathway is the main system acting to remove and replace oxidised and alkylated 
bases. BER also repairs AP sites, spontaneously generated as a result of cellular 
metabolism or formed during the repair of lesions imposed by exogenous 
genotoxicants (e.g., TMZ, MMS, IR, and H2O2). BER also plays a critical role in the 
repair of SSBs generated by the attack of ROS on deoxyribose and the excision of 
uracil bases from DNA (reviewed in [3,4]). 
BER proceeds via five coordinated steps: recognition and excision of damaged or 
inappropriate bases by a lesion-specific DNA glycosylase; incision of the abasic site by 
APE1 or by the AP lyase function of a bifunctional glycosylase; removal of the 5’- or 3’-
terminal blocking groups by a lyase or phosphodiesterase; DNA synthesis (DNA 
polymerase), for filling the resulting gap; and finally, nick sealing, carried out by DNA 
ligase [3,4]. APE1 is a promising target for cancer therapy, since this multifunctional 
protein is of great importance for the repair of AP sites [5]. This ubiquitous enzyme is 
involved in both BER sub-pathways [5], although APE-independent DNA repair 
mechanisms have also been reported [6,7]. Additionally, APE1 plays an important role 
as a nuclear reduction/oxidation signalling protein, modulating the activation of multiple 
factors involved in cell survival, proliferation, and cancer promotion, such as NF-κB, 
AP-1, HIF-1α, and p53 [5]. Moreover, the expression and the subcellular distribution of 
APE1 are altered in several tumours. These alterations have been correlated with 
aggressiveness and poor prognosis in breast cancer [8] and other solid tumours 
(colorectal, hepatocellular, and epithelial ovarian carcinomas and non-small cell lung 
cancer) [9–12]. 
MX, a small-molecule inhibitor of BER, covalently binds to the aldehyde group of an AP 
site in the DNA and consequently prevents APE-catalysed hydrolytic cleavage of the 
phosphodiester bond. AP sites blocked by MX are stable adducts that preclude repair 
carried out by the downstream enzymes of BER [13–15]. Thus, these intermediates 





the cytotoxic effects of chemotherapeutic drugs, such as TMZ [15–17], BCNU [18], 
pemetrexed [19], and IdUrd, and it potentiates IdUrd-mediated radiosensitisation 
[20,21]. Currently, MX is one of the most promising inhibitors of APE1; it is being 
evaluated in clinical trials in combination with the anticancer agents TMZ [22,23], 
pemetrexed [24], and fludarabine. Nevertheless, there is little information on the effect 
of MX on other DNA-damaging chemotherapeutic drugs, such as Dox. 
Dox, an anthracycline antibiotic, is widely used for treatment of haematological 
malignancies and solid tumours such as breast cancer. The multiple mechanisms of 
Dox action are still incompletely elucidated. The antitumour activity of Dox seems to be 
mainly mediated through its DNA-damaging effects, which can be a consequence of 
poisoning topoisomerase IIα, DNA binding and alkylation, establishment of DNA 
interstrand crosslinks, and formation of base damage and strand breaks induced by the 
generation of ROS. Dox may also interfere with DNA unwinding, DNA strand 
separation, and helicase activity (reviewed in [25,26]). 
ROS, including superoxide anion (O2•-) and H2O2, may be generated as a result of 
reductive bioactivation of the Dox quinone moiety. Besides redox cycling, the 
enhancement of intracellular ROS levels that follows drug exposure can also be a 
response to perturbations of metabolism [25]. Since Dox presents multiple mechanisms 
of DNA damage, which may depend on drug concentration and cell type [25–27], one 
anticipates that multiple DNA repair pathways are activated by Dox. In fact, NER, HR, 
and NHEJ have been implicated in the repair of Dox-DNA adducts and DSBs [28–30]. 
Importantly, oxidative DNA lesions and SSBs induced by Dox may be repaired 
primarily by the BER pathway [31]. 
In this Chapter, we evaluated the effects of MX on the cytotoxicity and genotoxicity of 
Dox in MDA-MB-231 human breast cancer cells. Cell viability and proliferation were 
assessed using complementary endpoints, a tetrazolium reduction assay (MTT assay), 
the crystal violet staining (CV) assay, and the colony-formation assay. Since Dox-
induced ROS may be involved in the formation of DNA lesions recognized by APE1 
and repaired by BER, the fluorescence probe DHE was used to evaluate the 
production of ROS by Dox. Finally, the CBMN assay was performed to assess 
chromosomal damage induced by Dox in the presence of MX. Overall, the results show 
differential outcomes following APE1 and BER inhibition in malignant breast cancer 
cells exposed to Dox. 
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3.3. MATERIALS AND METHODS 
3.3.1. Chemicals 
Dulbecco’s Modified Eagle’s Medium (DMEM), fetal bovine serum (FBS), penicillin-
streptomycin solution, thiazolyl blue tetrazolium bromide (MTT), CV, phosphate-
buffered saline (PBS; 0.01 M, pH 7.4), trypsin, Dox, methoxyamine hydrochloride (MX, 
purity 98%), (2E)-2-[(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-
yl)methylene] undecanoic acid (E3330, purity ≥98%), 7-nitro-1H-indole-2-carboxylic 
acid (CRT0044876, purity ≥98%), tert-butylhydroperoxide (TBHP), cytochalasin B, 
glutaraldehyde, and dimethylsulfoxide (DMSO) were purchased from Sigma-Aldrich 
(St. Louis, MO, USA). Doxorubicin was dissolved in Milli-Q H2O and stored at -20 ºC. A 
stock solution of MX (2 M) in PBS was prepared; pH was adjusted with NaOH until 
neutral; aliquoted and stored at -20 ºC. E3330 (10 mM) was dissolved in DMSO, 
aliquoted, and stored at -20 ºC. H2O2, Giemsa dye, ethanol, methanol, and acetic acid 
were obtained from Merck (Darmstadt, Germany). DHE was acquired from Molecular 
Probes (Eugene, OR, USA). For this probe, a 10 mM stock solution was prepared in 
DMSO, aliquoted, and stored under N2 at -20 ºC.  
3.3.2. Cell culture 
The human breast cancer cell line MDA-MB-231 was obtained from ATCC (HTB-26) 
and cultured in monolayer in DMEM supplemented with 10% fetal bovine serum, 100 
U/mL penicillin, and 0.1 mg/mL streptomycin. Cells were maintained at 37 ⁰C, under a 
humidified atmosphere containing 5% CO2 in air. 
3.3.3. MTT reduction assay 
Cell viability was evaluated using the MTT reduction assay. In brief, MDA-MB-231 cells 
were seeded at a density of approximately 2,500-3,000 cells per well, in 200 µL culture 
medium, in 96-well plates and incubated for 22 h at 37 °C under a 5% CO2 
atmosphere. Cells were incubated for 2 h with MX (10 mM and 20 mM), E3330 (30 µM) 
or with both APE1 inhibitors. After pre-incubation with MX or E3330, Dox or H2O2 (300 
µM) were added and MDA-MB-231 cells were incubated for 24 h. Following drug 
treatments, cells were washed with culture medium and allowed to grow for a further 72 
h in drug-free medium. An additional protocol was carried out, consisting of evaluation 
of cell viability after a 96 h period of continuous exposure to APE1 inhibitors and Dox or 
H2O2. The final concentration of DMSO in the culture medium did not exceed 0.3% 





[32,33]. Absorbance values presented by MDA-MB-231 cell cultures without addition of 
any compound (control cultures) corresponded to 100% cell viability. The number of 
independent experiments is indicated in the figure legends. Eight replicate cultures 
were used in each independent experiment.  
3.3.4. Crystal violet (CV) staining assay 
The CV staining assay was carried out as a confirmatory assay. 2,000-2,500 cells were 
plated in culture medium (200 µL per well) in 96-well plates and incubated for 24 h at 
37 °C, 5% CO2. Exposures were performed as for the MTT assay. The CV assay was 
then carried out according to a previously described protocol [32,33]. Absorbance 
values for untreated cells (control) correspond to 100% viability. The number of 
independent experiments is indicated in the figure legends. Eight replicate cultures 
were used in each independent experiment. 
3.3.5. Colony formation assay 
The colony formation assay was performed according to Franken et al [34] with minor 
modifications. Briefly, MDA-MB-231 cells were seeded into 6-well plates at cell density 
between 100 and 2,000 cells per well and maintained in a humidified incubator for 16 h, 
37 °C, 5% CO2. Cells were exposed to MX (10 mM) for 2 h before treatment with Dox 
(12.5 or 100 nM). After 24 h incubation with MX and Dox, the medium was removed 
and each well was rinsed with 1.0 mL PBS before addition of drug-free medium. 
Cultures were incubated 10-12 days to form colonies, with medium changed twice 
weekly. Cells were then fixed and stained with 6% (v/v) glutaraldehyde and 0.5% (w/v) 
crystal violet for 30 min. Colony fixation-staining solution was removed, colonies were 
thoroughly rinsed with tap water, and plates were dried at room temperature overnight. 
Colonies ≥ 50 cells were visually scored by two investigators. Results are presented as 
surviving fraction relative to untreated cells. All experiments were performed in 
duplicate for each drug treatment and three independent experiments were carried out. 
3.3.6. DHE fluorimetric assay 
Approximately 4 × 104 cells per well were cultured for 24 h in 96-well plates (black-
wall/clear-bottom, Costar 3603). Thereafter, the culture medium was replaced and cells 
were exposed to Dox (0.1, 0.5, 1, or 2 µM) in the presence of DHE (10 µM) for 3 h. 
Tert-butylhydroperoxide (TBHP; 2 mM) was used as positive control [32,33]. After 
treatment, cells were carefully washed with PBS. PBS (200 µL) was added to each well 
and the fluorescence was determined at 37 °C in a multi-mode microplate reader, using 
λexcitation = 485 nm and λemission = 590 nm [32,33,35]. Results were expressed as 
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percentages of untreated control cells, after subtracting background fluorescence. The 
number of independent experiments is indicated in the figure legend, each comprising 
four replicate cultures for each experimental point. 
3.3.7. Cytokinesis-block micronucleus (CBMN) assay 
3.3.7.1. Experimental protocol 
Approximately 5,000 MDA-MB-231 cells were seeded in culture medium, 500 µL per 
well, in 8-well Lab-Tek™ II Chamber Slide™ System (Nunc) and incubated for 22 h at 
37 °C. Afterwards, the cells were incubated with MX (20 mM) for 2 h and Dox (12.5 nM) 
was then added to the medium. Cells were grown for a further 24 h. After the 
treatment, cells were washed with culture medium, and cytochalasin B was added at a 
final concentration of 3.0 µg/mL to arrest cytokinesis [36]. Cells were allowed to grow 
for a further 28 h.  MDA-MB-231 cells were then rinsed with PBS and the slides were 
fixed with ice-cold methanol for 20 min at -20 °C. After air drying, the Lab-Tek™ II 
Chamber Slide™ Systems were dismantled and slides were stained with Giemsa (4% 
v/v in 0.01 M phosphate buffer, pH 6.8) for 8 min. The slides were then coded for 
further microscopic analysis. Three independent experiments were performed for each 
drug treatment. 
3.3.7.2. Micronucleus (MN) scoring 
For the assessment of MN frequency, 1,000 binucleated (BN) cells with well-preserved 
cytoplasm were scored using 1250x magnification on a light microscope (Leitz), 
according to described criteria [36]. The frequency of micronucleated cells (% MNBN) 
present in 1,000 BN cells was used as the genotoxicity index. This index represents the 
frequency of DNA damaged cells (micronucleated) regardless of the number of 
micronuclei present in each damaged BN cell [37]. Moreover, the distribution of BN 
cells according to the number of MN and the total number of MN were also recorded 
[38]. 
3.3.7.3. Cell proliferation assessment 
The decrease in cell proliferation for the experiments describe above (CBMN assay) 
was evaluated by two standard indices, the percentage of binucleated cells (% BN) and 
the nuclear division index (NDI) [36,37,39]. For these indices, 500 cells were classified 







3.3.8. Statistical analysis 
All values presented correspond to mean values and standard deviations (SD). The 
Kolmogorov-Smirnov test was used to assess the normality of continuous variables. 
For variables with normal distribution, homogeneity of variances was evaluated using 
the Levene test and the differences in mean values of the results observed in cultures 
with different treatments were evaluated by Student’s t-test. For non-normal variables, 
the nonparametric Mann-Whitney test was used. All statistical analyses were 
performed using SPSS statistical package (version 21, SPSS Inc., Chicago, IL, USA) 
and the level of significance considered was P < 0.05. 
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3.4. RESULTS  
3.4.1. Cytotoxicity profile of Dox in MDA-MB-231 cells 
The effect of Dox on cell viability was first assessed by the MTT reduction assay 
(mitochondrial activity, Fig. 3.1). The CV staining (cell biomass) was used as a 
confirmatory assay (data not shown). In these experiments, MDA-MB-231 cells were 
treated with Dox for 24 h and then incubated in drug-free medium for 72 h. The dose-
response profiles from both assays were roughly similar. Exposure to Dox 
concentrations up to 5 μM induced a concentration-dependent decrease in the cell 
viability, which was significant at Dox concentrations ≥ 50 nM (P < 0.05). The IC50 
values obtained by non-linear regression were 328 nM and 259 nM for MTT and CV 
assays, respectively. 
 
Figure 3.1 Cytotoxic effects of doxorubicin (Dox) in MDA-MB-231 cells. The decrease in the viability 
of Dox-treated cells (24 h) was evaluated 72 h after the exposure to Dox by MTT reduction (n= 2–14). 
Inset: Effect of low concentrations of Dox (up to 0.50 µM). Values represent mean ± SD and are expressed 
as percentages of the non-treated control cells. 
3.4.2. Effect of MX on Dox cytotoxicity  
The combination of MX (10 mM) with Dox (100 nM) showed a slight decrease in cell 
viability, as evaluated by the MTT assay when compared with cells treated with Dox 
(100 nM) only (Fig. 3.2A). A similar marginal effect of MX was observed in MDA-MB-
231 cells exposed to the lower Dox concentration, 12.5 nM. For Dox 250 nM, cell 









































Figure 3.2 Doxorubicin-induced cytotoxicity in the presence of methoxyamine (MX) in MDA-MB-231 
cells. Effect of MX (10 mM) in the viability of Dox-treated cells assessed by (A) MTT (n= 2–10) and (B) CV 
staining assays (n= 3–5). (C) Effect of MX (20 mM) in the viability of Dox-treated cells assessed by the 
MTT assay (n=4). In (A) to (C), MDA-MB-231 cells were pre-incubated for 2 h with MX and afterwards 
simultaneously exposed to Dox and MX for 24 h. Cells were then grown for a further period of 72 h in drug-
free medium. (D) Effect of MX (10 and 20 mM) in the viability of Dox-treated cells assessed by the MTT 
assay. MX was pre-incubated for 2 h and cells were then simultaneously exposed to MX and Dox for a 96 
h period (n= 3–4). H2O2 (300 µM) was used as a positive control (A, B and D). Values represent mean ± 
SD and are expressed as percentages relative to non-treated control cells. *P < 0.05. 
In the CV assay the small reduction in cell viability of cells treated with MX 10 mM and 
Dox 100 nM was confirmed (Fig. 3.2B). In this case, a decrease of approximately 8% in 
terms of cell viability was significant (P < 0.05). MDA-MB-231 cells were also exposed 
to H2O2 (300 μM), which is a well-known inducer of oxidative DNA lesions that can be 
repaired by BER [40–42]. As shown in Fig. 3.2A and 3.2B, cell viability was 
dramatically reduced (P < 0.05) upon the combination of MX with H2O2 as assessed by 
both MTT and CV assays. MX (10 mM) alone was not particularly toxic to MDA-MB-
231 cells. In fact, this inhibitor decreased cell viability less than 5% for MTT (P < 0.05) 
and about 6% for the CV assay (N.S.). The effect of a higher concentration of MX (20 
mM) towards the cytotoxicity of Dox (12.5 and 100 nM) using the MTT assay was 
further evaluated (Fig. 3.2C). The results revealed that the cell viability presented by 
Dox-treated cells was roughly in the same range in the presence or absence of MX. 
The results presented in Fig. 3.2A–C were obtained using an experimental protocol 
that consisted in a pre-incubation with MX for 2 h, followed by a 24 h exposure to the 
combination of MX and Dox. Afterwards the cells were grown for a further 72 h period 
- 10      20     - 10      20      - 10      20      - 10
0                         12.5                      100                    0      






































- +        - +         - +        - +
- - 100     100     250     250     - -




















- +        - +        - +        - +        - +
- - 12.5   12.5   100    100    250    250     - -



















- +        - +         - +        
- - 12.5    12.5     100     100     
MX (20 mM)
Dox (nM)
Differential effects of methoxyamine on doxorubicin cytotoxicity and genotoxicity 
in MDA-MB-231 human breast cancer cells 
 
 71 
in drug-free medium prior to the assessment of cell viability. In addition, a protocol with 
continuous exposure to both MX and Dox for 96 h was also included. These results 
showed that the cytotoxicity of Dox (12.5 nM and 100 nM) was not considerably altered 
by the presence of MX (10 mM and 20 mM) (Fig. 3.2D), as previously noted with the 
first treatment protocol. As in Fig. 3.2A and 3.B, MX 10 mM also showed a marked 
sensitising effect in the viability of MDA-MB-231 exposed to H2O2 300 µM (P < 0.05; 
Fig. 3.2D). 
 
Figure 3.3 Colony formation assay of MDA-MB-231 cells treated with methoxyamine (MX) and 
doxorubicin (Dox). MDA-MB-231 cells were pre-incubated with MX (10 mM) for 2 h and then 
concomitantly exposed to Dox (12.5 and 100 nM) for 24 h. Cells were incubated in drug-free medium for 
10-12 days to allow colony formation (n = 3). The surviving fraction after drug exposure was normalised to 
survival (plating efficiency) of non-treated control cells. Values represent mean  SD. 
Long-term effects of MX (10 mM) in the proliferation of MDA-MB-231 cells treated with 
Dox (12.5 and 100 nM) were assessed using the colony formation assay (Fig.3.3). Dox 
presented a more pronounced decrease in cell survival when compared with the effects 
in cell viability evaluated by the MTT reduction or CV assays (Fig. 3.1 and 3.2). MX per 
se only marginally reduced the colony forming ability when compared to non-treated 
controls (N.S.). Importantly, as shown in Fig. 3.3, MX did not affect the colony forming 
ability of Dox-treated MDA-MB-231 cells. 
In order to evaluate the effect of simultaneous inhibition of DNA repair activity and the 
redox function of APE1 in the cytotoxicity of Dox, E3330, a well-known redox inhibitor 
of APE1 was used [43–47]. The results presented in Fig. 3.4 show that E3330 (30 μM) 
alone or in combination with MX 10 mM was not cytotoxic to MDA-MB-231 cells in both 
treatment protocols. Moreover, the simultaneous inhibition of DNA repair function and 
redox activity of APE1 also did not show a sensitising effect in the cytotoxicity of Dox 
(100 nM) as assessed by the MTT reduction assay (Fig. 3.4). 
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Figure 3.4 Effect of the simultaneous inhibition of the DNA repair activity and redox domain of 
APE1 in the viability of MDA-MB-231 cells treated with doxorubicin (Dox) as assessed by the MTT 
assay. Cells were pre-incubated with MX (10 mM) and E3330 (30 µM) for 2 h and then concomitantly 
exposed to Dox for (A) 24 h followed by a 72 hours period in drug-free medium (n= 3-4) or (B) a 
continuous 96 h period (n= 3). Values represent mean  SD and are expressed as percentages relative to 
non-treated control cells. 
3.4.3. Dox-induced ROS in MDA-MB-231 cells 
To evaluate the ability of Dox to generate ROS, particularly O2•-, the DHE assay was 
performed. Cells were exposed to Dox (0.1-2 µM) for 3 h. Under these conditions, Dox 
did not induce noticeable cell death. Dox, 2 µM, led to a small but significant increase 
(~10%; P < 0.05) in the intracellular level of superoxide radical anion, as evaluated by 
the fluorescence resulting from the oxidation of DHE probe (Fig. 3.5). Lower 
concentrations of Dox did not increase superoxide radical formation. TBHP, a model of 
acute oxidative stress, was used as a positive control and induced an increase in 
fluorescence intensity (1.6-fold; data not shown), similarly to results previously reported 
by our group with other cells [32,33]. 
 
Figure 3.5 Effect of doxorubicin (Dox) in the intracellular levels of superoxide anion in MDA-MB-231 
cells evaluated by the dihydroethidium (DHE) probe. Values (mean  SD; n = 2-4) represent relative 
fluorescence units (RFU) and are expressed as percentages of non-treated control cells. *P< 0.05 when 
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3.4.4. Assessment of the effect of MX in the genotoxicity of Dox 
The results depicted in Fig. 3.6 indicate that the combination of MX (20 mM) with Dox 
(12.5 nM) did not affect cell proliferation at the concentrations selected, as observed by 
the absence of large alterations in the % BN (Fig. 3.6A) and NDI index (Fig. 3.6B). In 
view of this result, the effect of MX on the induction of micronuclei by Dox was 
evaluated at these concentrations. 
 
Figure 3.6 Effect of methoxyamine (MX) in the proliferative indices of Dox-treated cells associated 
with the cytokinesis-block micronucleus (CBMN) assay. MDA-MB-231 cells were pre-incubated for 2 h 
with MX (20 mM) and then simultaneously treated with Dox (12.5 nM) for 24 h. (A) the percentage of 
binucleated cells (% BN) and (B) nuclear divison index (NDI). Values represent mean  SD (n= 3). 
MDA-MB-231 cells presented a relatively high background frequency of MNBN cells 
(approximately 9%, Fig. 3.7) which may be a consequence of the intrinsic 
chromosomal instability of this cell line [48,49]. Moreover, MX seems to have no effect 
in the basal level of micronuclei (N.S.), suggesting an absence of genotoxicity under 
these conditions (Fig. 3.7).  Dox was genotoxic, increasing the MNBN index from 8.90 
to 17.27% (P < 0.05, Fig. 3.7A). Importantly, the combination of MX and Dox increased 
the frequency of micronucleated binucleated cells to 23.33%, which corresponds to a 
significant increase of ~ 1.4 fold when compared to MDA-MB-231 cells treated with 
Dox only (P < 0.05, Fig. 3.7A). A significant increase in the total number of micronuclei 
(1.5-fold) was also observed upon treatment with MX and Dox (data not shown). The 
sensitising effect observed was primarily due to an increase of BN cells with three or 
more MN (P < 0.05) as shown by the pattern of distribution of DNA damaged cells 
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Figure 3.7 Effect of methoxyamine (MX) in Dox-induced micronuclei in MDA-MB-231 cells as 
evaluated by cytokinesis-block micronucleus (CBMN) assay. MDA-MB-231 cells were pre-incubated 
for 2 h with MX (20 mM) and then simultaneously treated with Dox (12.5 nM) for 24 h. (A) The frequency of 
micronucleated binucleated (% MNBN) cells and (B) distribution of the number of micronuclei per 
binucleated cell. Results are expressed as mean  SD (n = 3). *P < 0.05 when compared with MDA-MB-
231 cells treated only with Dox. 
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The effectiveness of a therapeutic strategy based on the pharmacological modulation 
of DNA repair proteins depends on the knowledge of the types of lesions induced by a 
given drug as well as on the DNA repair status of tumour cells. BER is primarily 
involved in the repair of damaged bases, abasic sites, and SSBs. These types of 
lesions have been identified or anticipated in the context of Dox exposure [50–52]. 
Among BER proteins, APE1 plays a pivotal role. We assessed the effect of MX, a 
standard inhibitor of APE1’s DNA repair activity, on the cytotoxicity and genotoxicity of 
Dox in MDA-MB-231 breast cancer cells. This cell line was selected as a model of 
highly aggressive and metastatic breast cancer, a typical indication for Dox. APE1 was 
found to be increased after anthracycline-based therapy in post-surgical samples from 
breast tumours [53]. 
In order to evaluate the impact of MX in Dox-treated MDA-MB-231 cells, we first 
selected adequate Dox concentrations to be further used. For this purpose the 
cytotoxicity profiles of Dox in MDA-MB-231 cells were characterised using the MTT and 
CV assays. The protocol consisted of a 24 h incubation, approximately the duration of 
one cell cycle, followed by 72 h of growth in drug-free medium. This transient-exposure 
protocol has been adopted by other authors in cell-based assays [29,54] and 
resembles the clinical drug administration schedule. In the conditions described, MDA-
MB-231 cells exhibited similar cytotoxicity profiles for both assays, with IC50 values in 
the same range as those described for MDA-MB-231 cells exposed to Dox for a 96 h 
period [55]. Moreover, Dox at 100 nM was selected as the primary concentration to be 
used in the viability assays in combination with MX. This concentration corresponded to 
a level of cell viability appropriate to study the potential modulator effect of MX, since 
much higher concentrations may lead to severe toxicity. 
To test the effect of APE1 inhibition by MX, different experimental approaches were 
designed, including different Dox treatment schedules, MX concentrations and multiple 
endpoints, namely the MTT reduction and CV staining assays as well as the colony 
formation assay. This latter assay evaluates long-term effects on cell proliferation, and 
is considered by some to be the “gold standard” assay to study the effects of 
chemotherapeutic agents in tumour cells [56]. 
For both short-term MTT and CV assays, a minor effect in cell viability of MDA-MB-231 
cells was detected following the exposure to MX, 10 mM, and Dox. Although MX at 10 





abasic sites and to enhance the cytotoxic effect of distinct compounds [19,20,42,45], 
some authors suggested the use of higher MX concentrations in cell-based assays 
[15,17]. Thus, in an attempt to observe a more clear effect, we also studied MX at 20 
mM. Also at this concentration, MX did not increase Dox cytotoxicity, demonstrating 
that the absence of a sensitising effect was not MX concentration-dependent. 
Dox rapidly enters cells and, due to its lipophilic properties and affinity to DNA, it is 
trapped and accumulates in the intracellular compartment [26,57,58]. Since resistance 
to Dox may be related to a decrease in drug uptake or an increase in drug efflux, we 
also evaluated the effects of continuous exposure to MX and Dox. The results 
described above for the transient exposure protocol were recapitulated when MDA-MB-
231 cells were exposed to both drugs continuously for 96 h. Moreover, and in respect 
to the colony formation assay, our results also showed an absence of sensitising effect 
by MX in Dox-treated cells. In these studies, Dox alone induced a decrease in colony 
formation more extensive than the effect observed in MTT and CV assays. These 
findings were anticipated, because Dox triggers senescence in different cell types 
[59,60], including MDA-MB-231 cells. This may explain the different sensitivity of MDA-
MB-231 cells to Dox when different techniques are compared. 
The work reported here focused on MX, since this compound is the reference inhibitor 
of APE1 activity, particularly relevant due to its use in clinical trials [22–24]. 
Nevertheless, we also tested the effect of a distinct BER inhibitor, the compound 
CRT0044876, which has been reported to directly inhibit APE1 [61]. Preliminary 
experiments using the MTT assay showed that APE1 inhibition by CRT0044876 did not 
modify the viability of Dox-treated MDA-MB-231 cells (data not shown). A recent study 
addressing the discovery of novel direct APE1 inhibitors towards different genotoxic 
agents also showed an absence of sensitising effects in melanoma and glioma cells 
treated with Dox [62].  
Interestingly, the silencing of APE1 by short-hairpin RNA (shRNA) has been recently 
reported to increase the sensitivity of the human lung cancer H1299 cells towards Dox 
treatment, as well as to enhance the intracellular ROS generation and DNA damage 
[63]. In this context, and since E3330 is considered an effective inhibitor of the redox 
activity of APE1 [43–45], we also tested the effect of simultaneous inhibition of both 
DNA repair and redox functions of APE1. Although E3330 has been described to 
possess an endonuclease inhibitory activity, this was considered poor [46,47]. The 
concomitant treatment with MX and E3330, however, also did not improve the 
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sensitivity of MDA-MB-231 cells to Dox. These conflicting results may be a 
consequence of the distinct experimental approaches adopted.  
Dox is an inducer of superoxide radical and other ROS [25,26,32]. While ROS have 
been considered the main responsible for Dox-induced cardiotoxicity [26,64], their 
contribution to the cytotoxic and genotoxic properties of Dox in cancer cells has been 
controversial, particularly at clinically relevant concentrations (up to 250 nM) [25,26]. 
Nevertheless, a few authors reported the presence of oxidised DNA bases after 
exposure to Dox concentrations achieved in vivo [51,52], which is important in the 
context of this work since this type of lesion can be repaired by the BER pathway. In an 
attempt to evaluate the intracellular production of ROS in breast cancer cells, the DHE 
assay was performed. The results showed a slight increase in the intracellular level of 
superoxide anion detected only at a high Dox concentration, these findings being 
consistent with other authors, who were able to detect ROS only at supraclinical Dox 
concentrations [25,65]. The apparent low contribution of ROS may partially explain the 
results from the MTT, CV and clonogenic assays. It is, however, important to note that 
Dox induces other types of lesions besides oxidised bases that could be repaired by 
the BER pathway, including SSBs [50]. 
A further aspect of this work was to evaluate whether an effect of MX could be 
observed at the chromosome damage level. In fact, since Dox is a DNA damaging 
drug, and a well-known clastogen, it seemed relevant to evaluate the effect of MX in 
terms of Dox-induced genotoxicity, specifically MN formation, using the CBMN assay 
[36,39]. The observed increase in the % MNBN along with the altered pattern of MN 
distribution pointed to an enhancement of damage severity by Dox upon BER 
inhibition. These findings suggest that MX promoted the accumulation of unrepaired 
lesions in Dox-treated MDA-MB-231 cells, increasing chromosomal damage. 
Importantly, this higher genotoxic burden was, however, not associated with a 
corresponding increment in cytotoxicity, which is ultimately the goal of chemotherapy. 
The reasons for this are unknown but these results suggest that the impairment of BER 
led to an increase in DNA lesions induced by Dox that can be somehow tolerated by 
MDA-MB-231 breast cancer cells. Although the correlation between survival and 
genotoxicity has been described, including for MN [66,67], there are also other reports 
addressing an apparent lack of correlation between these two events [68,69].  
In summary, these results suggest a differential role of MX in terms of cytotoxicity and 
genotoxicity of Dox in human MDA-MB-231 breast cancer cells. Due to the absence of 





on APE1 inhibition may not be relevant to enhance the efficacy of Dox in clinical terms. 
However, MX seems to be involved in the genotoxicity of Dox by a distinct mechanism. 
Therefore, the discrimination of the mechanisms underlying the effect of MX in Dox-
induced cytotoxicity and genotoxicity should be further exploited in respect to cell death 
pathways and gene expression in different cell types. 
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The DNA repair activity of APE1 has been recognized as a promising target for the 
development of small-molecule inhibitors to be used in combination with anticancer 
agents. In an attempt to identify novel inhibitors of APE1 we present a SBVS study 
based on molecular docking analysis of the compounds of NCI/DTP database using 
the GOLD 5.1.0 (Genetic Optimization for Ligand Docking) suite of programs. 
Compounds selected in this screening were tested with a fluorescence-based APE1 
endonuclease activity assay. Two compounds (37 and 41) were able to inhibit the 
multifunctional enzyme APE1 in the micromolar range while compound 22 showed 
inhibitory effects at nanomolar concentrations. These results were confirmed by a 
plasmid DNA nicking assay. In addition, the potential APE1 inhibitors did not affect the 
cell viability of non-tumour MCF10A cells. Overall, compounds 22, 37 and 41 appear to 
be important scaffolds for the design of novel APE1 inhibitors and this study highlights 
the relevance of in silico based approaches as valuable tools in drug discovery.  
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Multiple DNA repair pathways are involved in the repair of DNA lesions induced by 
standard chemotherapeutic drugs and radiotherapy. Therefore, the development of 
DNA repair inhibitors constitutes a promising approach for cancer therapy [1,2]. By 
inhibiting specific DNA repair enzymes, the therapeutic effect of a given agent in 
cancer cells could be improved, and drug resistance may even be overcome. The 
importance of DNA repair inhibitors has been extensively reviewed in the last decade 
[1,2]. Several cell-based experiments conducted with numerous small-molecule DNA 
repair inhibitors revealed important sensitising effects towards cytotoxic drugs from 
different classes [1–7] and IR [8–12]. Moreover, a few DNA repair inhibitors have been 
recently evaluated in clinical trials [13,14], which clearly emphasize the importance of 
this therapeutic strategy. 
As mentioned in Chapters 1 and 3, BER is a key pathway responsible for the removal 
and replacement of oxidised and alkylated bases. This system is also involved in the 
repair of AP sites, SSBs and in the excision of uracil from DNA (reviewed in [15,16]). 
APE1 is a multifunctional enzyme that plays a fundamental role in BER, being 
responsible for the incision of the DNA phosphodiester backbone 5’ to the AP site with 
the generation of terminal groups recognized and repaired by the downstream proteins 
of BER [15,17]. APE1 has other minor DNA repair functions which include 3’-
phosphodiesterase, weak 3’-phosphatase, 3’-5’ exonuclease and RNase H activity 
[15,17]. APE1 also acts as a nuclear reduction/oxidation signaling protein, modulating 
the activation of several transcription factors (e.g. NF-кB, AP-1, HIF-1α, p53 and 
others) implicated in cancer cell survival, proliferation, migration/invasion, angiogenesis 
and metastases formation (reviewed in [16,17]). In addition, alterations in the 
subcellular distribution and/or protein levels of APE1 have been associated to more 
aggressive tumour phenotypes with a poor prognosis and resistance to 
chemo/radiotherapy. These alterations have been found in a variety of tumours such as 
gliomas [18], hepatocellular [19], colorectal [20], prostate [21], breast [22], 
osteosarcoma [23] and non-small cell lung cancer [24]. In view of this, APE1 is 
considered an attractive key target for the discovery of novel DNA repair inhibitors. 
Several APE1 inhibitors have been developed in the last years. MX, an indirect inhibitor 
[16,25,26] and CRT0044876, a direct inhibitor of the DNA repair activity of APE1, are 
the most usually studied compounds [27–29]. MX increased the cytotoxicity of 
chemotherapeutic drugs such as TMZ [7,26], BCNU [30], pemetrexed [6] and IdUrd 





alkylating or antimetabolite drugs in different tumour types [13,14]. Despite the 
promising effects reported, MX acts indirectly by reacting and binding to the AP sites in 
the DNA strand [25,26]. Direct enzyme inhibitors are usually preferable because they 
are more specific with a subsequent decrease of potential side effects. CRT0044876 
was the first direct inhibitor of APE1 endonuclease activity identified by an in vitro HTS 
assay of a chemical library of 5000 “drug-like” compounds performed by Madhusudan 
et al. [27]. However, the role of CRT0044876 as an APE1 inhibitor is not clear and a 
few authors were not able to reproduce the in vitro results initially reported for this 
compound [29,31]. Lucanthone has also been regarded as a nonspecific direct inhibitor 
of APE1 since it also inhibits topoisomerase II and intercalates into the DNA [32,33]. 
Therefore, several authors proposed other classes of APE1 inhibitors using different 
approaches, which include the HTS of commercially available chemical libraries 
[29,34–36], the rationale design with structure-activity relationship studies [37] and also 
ligand-based pharmacophore models [28,38–41], and SBVS and molecular docking 
studies [28,42]. Nevertheless, there is still a need for additional studies to identify novel 
pharmacologically active APE1 inhibitors with clinical application as combination 
therapy in cancer treatment. 
When the crystallographic structure of the target is available, SBVS is nowadays one of 
the most valuable tools for the identification of hit-compounds during the early stages of 
a drug discovery pipeline. This cost- and time-effective approach includes structure-
based and ligand-based techniques. While the first one uses the information of the 
known or inferred 3D structure of the target and exploits the molecular recognition 
between a ligand and the residues of the target protein to identify chemical entities that 
bind strongly to the active sites, the second entails information of known ligands [43–
45]. The aim of virtual screening is to speed up the initial stages of drug discovery, 
potentiating the rapid identification of hit molecules that can subsequently be 
biologically evaluated. Despite a relatively high number of false positives associated 
with virtual screening [46], the procedures are becoming progressively more accurate 
and the reliability of the results obtained is also increasing [47]. 
In this context, in this Chapter we report a successful computer aided drug design 
campaign combining a SBVS approach and molecular docking studies to the discovery 
of novel potent small-molecule inhibitors that target APE1 endonuclease activity (Fig. 
4.1). NCI/DTP database containing 265 242 compounds (release 4, May 2012) was 
sequentially screened using GOLD 5.1.0 (Genetic Optimization for Ligand Docking) 
software [48,49]. The most promising compounds were tested with a fluorescence-
based APE1 endonuclease activity assay and cytotoxicity was evaluated in non-tumour 
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MCF10A cells. Using our methodology we were able to identify novel small-molecule 
inhibitors with IC50 values in nanomolar (one compound) and low micromolar range 
(two compounds), that provide relevant chemical motifs for the rationale development 






4.3. MATERIALS AND METHODS 
4.3.1. Chemicals 
Human recombinant APE1 was obtained from New England Biolabs (Ipswich, MA, 
USA). Potential APE1 inhibitors and the arylstibonic acid NSC 13755 were obtained 
from the Drug Synthesis and Chemistry Branch, Developmental Therapeutics Program 
of National Cancer Institute (Bethesda, MD, USA). Stock solutions of the candidate 
inhibitors were prepared in DMSO at a final concentration of 10 mM, aliquoted and 
stored at -20 °C. The structure of active compounds was confirmed by proton nuclear 
magnetic resonance (1H NMR) spectroscopy and high-resolution electrospray 
ionization mass spectrometry (HR-ESI-MS) (Annex, Materials and methods S1). 
Compound purity was determined by high-performance liquid chromatography with a 
diode array detector (HPLC-DAD) and found to be higher than 90% in all cases. The 
17-mer oligonucleotides 5’-TAMRA-TC ACC *TC GTA CGA CTC-3’ and 3’-BHQ-2-AG 
TGG GAG CAT GCT GAG-5’ (in which TAMRA is the fluorophore 
carboxytetramethylrhodamine, BHQ-2 is black hole quencher-2 and * is 
tetrahydrofuran, a stable AP site analogue) [35] were custom-made by NZYTech 
(Lisbon, Portugal). Both oligonucleotides were dissolved in TE buffer (1 mM EDTA, 10 
mM Tris-HCl pH 8.0) at a concentration of 100 µM, aliquoted and stored at -20 C. 
Dulbecco’s modified Eagle’s medium/nutrient mixture F-12 Ham (DMEM/F-12), horse 
serum (HS), penicillin-streptomycin solution and trypsin were purchased from Gibco® 
(Life Technologies, Madrid, Spain). Phosphate buffered saline (PBS) 0.01 M, pH 7.4, 
recombinant human insulin, hydrocortisone, cholera toxin, human epidermal growth 
factor, dimethylsulfoxide (DMSO) were acquired from Sigma-Aldrich (St. Louis, MO, 
USA). 
4.3.2. Virtual screening library 
A library of 265 242 compounds retrieved from the NCI repository was screened in this 
work. This collection of compound structures was built and is maintained by the 
Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis of 
the National Cancer Institute, National Institute of Health (Bethesda, MD, USA). 
4.3.3. Structure-based virtual screening (SBVS) and molecular docking 
studies 
A SBVS protocol based on molecular docking studies of the NCI compounds database 
using the GOLD 5.1.0 suite of programs [48,49] was performed to identify potential 
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inhibitors of APE1. All the compounds included in this library were previously 
protonated (at pH = 7 and 300 K) and partial charges were assigned using MMFF94x 
force field as implemented in the Molecular Operating Environment (MOE) 2011.10 
software package [50]. Compounds for which initially attributed protonation states were 
found to be incorrect were further energy minimized ahead of the protonation 
procedure. GOLD package has implemented a genetic algorithm (GA) that performs 
searches for the best ligand interaction/binding poses which are then ranked in 
agreement with a defined scoring function. After testing several scoring functions, the 
GoldScore scoring function [48,49,51] was selected. 
In order to prepare the enzyme structure for the SBVS calculations, all atoms other 
than the receptor were deleted from PDB 1BIX except for the metal (Sm3+) in the active 
site which coordinates were conserved. The ion (Sm3+) was later replaced by the 
preferred metal cofactor of the human APE1 enzyme, Mg2+, by using the Mutate 
Residue functionality of MOE 2011.10 [50]. The AMBER99 force field [52] was then 
used to assign atom types and charges to each atom in the receptor. Hydrogen atoms 
were added and the protonation states assigned using the Protonate-3D tool within 
MOE 2011.10 software package [50]. The histidine residue His309 at the binding site 
was protonated in agreement with the observations in the NMR study performed by 
Lowry et al.[53]. The enzyme structure was then energy minimized in MOE with the 
AMBER99 force field for a final backbone root mean square deviation (RMSD) from the 
original X-ray structure of 0.997 Å. In order to validate this refined APE1 structure for 
the SBVS calculations, two well-known inhibitors of APE1 – lucanthone and 
hycanthone [32] – were docked into the targeted enzyme active site. The binding site 
was defined to be circumscribed by the amino acids Asp70, Glu96, Arg177, His309, 
Asp210, Asn212, Trp280, Phe266, and Leu282 with a 10 Å radius. Each of the latter 
compounds was constructed and had its energy minimized with the GizMoe minimizer 
in MOE (MMFF94x force field). The terminal amine was protonated in both cases 
according to what is predicted in the literature [32]. Docking calculations were 
performed with standard settings and 500 GA operations. 
In the present study, SBVS of the NCI database was performed with speed-up settings, 
50 GA operations/runs and 30% search efficiency. The top 1000 highest ranked 
compounds in SBVS were selected for posterior molecular docking (final refinement) 
studies (Figure 4.1). Refining molecular docking studies were performed using the 
GoldScore fitness scoring function with 500 GA runs and a search efficiency of 100% 
to select the representative pose of each compound. The final GoldScore scores were 





the selected compounds were subjected to visual inspection using specific criteria: 
similar docking poses to hycanthone and lucanthone described by Naidu et al. [32]. 
After visual inspection, potential inhibitors with appropriate pocket fitting were selected 
to be acquired and evaluated for activity against human APE1. 
4.3.4. Fluorescence-based APE1 endonuclease activity assay 
The fluorescence-based APE1 endonuclease activity assay was performed as 
described previously by Simeonov et al. [35] with modifications. In this methodology, 
the fluorescence of TAMRA in the double-stranded DNA is quenched due to the 
proximity of the BHQ-2 quencher. When APE1 cleaves the double-stranded DNA at the 
position 5’ of the AP site, a small single-stranded DNA fragment containing the 
fluorophore TAMRA is released, resulting in an increase in fluorescence. The presence 
of APE1 inhibitors should prevent this reaction. 
In this assay, the complementary single-stranded oligonucleotides at 100 M were 
mixed at a 1:1 ratio and annealed in assay buffer (50 mM Tris pH 7.5, 25 mM NaCl, 2 
mM MgCl2, 1 mM DTT, 0.01% Tween-20) at 95 °C for 5 min to generate the double-
stranded substrate of APE1 [35]. After the annealing, the reaction mixture was allowed 
to cool to room temperature. The assay was carried out in 96-well black plates with flat 
bottom (Costar®, Corning Inc., NY, USA) at a final reaction volume of 100 µL. The 
reaction mixtures containing 2.5 U of human recombinant APE1 (6 µL) were incubated 
in the assay buffer abovementioned, in the absence or presence of the putative APE1 
inhibitors (5 µL), at room temperature for 15 min. The reaction was initiated by the 
addition of double-stranded substrate (6 µL) to obtain the final concentration of 250 nM. 
DMSO was maintained at a concentration of 0.5% (v/v) in all assays (negative control). 
Fluorescence readings were acquired at 1 min intervals over an incubation period of 30 
min at 37 C using a SpectraMax GeminiTM EM microplate plate reader (Molecular 
Devices, Berkshire, UK) in the kinetic mode at excitation wavelength 550 nm, emission 
wavelength 584 nm and cut-off at 570 nm. For each reaction, the rate values obtained 
from the tangent to the linear range of the progress curves were used to calculate the 
percentage of APE1 endonuclease activity. The reaction of APE1 in the presence of 
DMSO 0.5% (v/v) was considered to present 100% of activity (negative control). APE1 
activity in the presence of compounds was calculated relatively to the negative control. 
The arylstibonic acid NSC 13755 was used as a positive control for APE1 
endonuclease activity inhibition. The potential APE1 inhibitors identified from the 
SBVS/docking studies were first screened at a final concentration of 50 µM in duplicate 
and two independent experiments were performed for each compound. Those 
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compounds showing more than 85% inhibition of APE1 endonuclease activity were 
selected for IC50 determination. GraphPad Prism® 6.0 (GraphPad Software, Inc., La 
Jolla, CA, USA) was used to estimate the IC50 values, by fitting the data to a four-
parameter logistic equation. Each value is presented as the mean and the SD of three 
to seven experiments performed in triplicate. 
4.3.5. Fluorescence quenching assay 
The interference of the identified compounds with the fluorescence signal of the 
fluorophore TAMRA was evaluated to discard false positive hits. The 17-mer 
oligonucleotide 5’ TAMRA-TC ACC *TC GTA CGA CTC-3’, at a final concentration of 
250 nM, was incubated with potential APE1 inhibitors in assay buffer (50 mM Tris pH 
7.5, 25 mM NaCl, 2 mM MgCl2, 1 mM DTT, 0.01% Tween-20). Fluorescence readings 
were obtained at 1 min intervals over 30 min of incubation at 37 C as 
abovementioned. 
4.3.6. Plasmid DNA nicking assay 
A plasmid DNA nicking assay was performed to confirm the ability of identified 
compounds to inhibit APE1’s endonuclease activity [32,54]. This assay evaluates the 
conversion of supercoiled plasmid DNA to a relaxed form by APE1 incision at an AP 
site [32,54]. Plasmid pcDNA3.1 (+) was amplified in Escherichia coli strain DH5α and 
extracted using NZYMidiprep kit (NZYTech) according to the manufacturer’s protocol. 
AP sites were generated in plasmid pcDNA3.1 (+) by incubating plasmid DNA (163.6 
µg/mL) in depurination buffer (10 mM sodium citrate, 100 mM NaCl, pH 5.0) at 70 °C 
for 20 min. Depurinated DNA was recovered by extraction with QIAamp DNA Mini Kit 
(Qiagen, Hilden, Germany) and eluted in TE buffer (1 mM EDTA, 10 mM Tris-HCl, pH 
8.0). DNA quantification was performed by measuring the absorbance at 260 nm, using 
a SPECTROstar Omega microplate reader in combination with an LVis plate (BMG 
Labtech, Offenburg, Germany). Depurinated plasmid was aliquoted and stored at -20 
°C. 
Depurinated plasmid DNA (100 ng) was added to assay reactions containing 0.5 U of 
human recombinant APE1 in assay buffer (50 mM Tris pH 7.5, 25 mM NaCl, 2 mM 
MgCl2, 1 mM DTT, 0.01% Tween-20) and different concentrations of the inhibitor 
compounds, in a final reaction volume of 18 µL. After an incubation period of 15 min at 
37 °C, the reactions were stopped by cooling the solutions on ice and addition of 2 µL 
of 10× loading buffer (5 PRIME Inc., Gaithersburg, MD, USA), containing 0.21% 





samples were electrophoresed in 0.8% agarose gel containing GelRedTM (Biotium Inc., 
Hayward, CA, USA), in 1× Tris-acetate-EDTA buffer at 60 V for 1 h. Assay reactions 
were prepared in duplicate for each compound concentration and two independent 
experiments were performed. 
4.3.7. Cytotoxicity evaluation of active compounds 
The non-tumourigenic human breast epithelial MCF10A cell line was obtained from 
ATCC (Manassas, VA, USA). MCF10A cells were cultured in monolayer in DMEM/F12 
medium supplemented with 5% horse serum, 100 U/mL penicillin, 0.1 mg/mL 
streptomycin, 0.01 mg/mL insulin, 0.5 µg/mL hydrocortisone, 100 ng/mL cholera toxin 
and 20 ng/mL human epidermal growth factor. Cells were maintained at 37 °C, under a 
humidified atmosphere containing 5% CO2 in air. 
The effect of APE1 inhibitors on cell viability was evaluated by the MTS tetrazolium 
assay using the CellTiter 96® AQueous One Solution Cell Proliferation Assay kit 
(Promega, Madison, WI, USA). A 20 mM stock solution of APE1 inhibitors in DMSO 
was prepared to test compounds at concentrations up to 100 µM. MCF10A cells were 
seeded at a density of 3 × 103 cells per well, in 200 µL of culture medium, in 96-well 
plates and incubated for 24 h at 37 °C under a 5% CO2 atmosphere. Cells were treated 
with APE1 inhibitors for 48 h. Following the drug treatments, the medium was removed 
and each well was rinsed with PBS. 20 µL of CellTiter 96® AQueous One Solution 
Reagent were added to each well containing 100 µL of culture medium and plates were 
incubated for 1 h. H2O2 (1 mM) was used as a positive control. The final concentration 
of DMSO in the culture medium was maintained at 0.5% (v/v). The optical density 
values were obtained at 490 nm in a SPECTROstar Omega microplate reader (BMG 
Labtech, Offenburg, Germany). 
Three independent experiments were performed and three replicate cultures were used 
for each concentration in each independent experiment. Statistical analysis was 
performed as described in Chapter 3 (Section 3.3.8). 
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4.4. RESULTS AND DISCUSSION 
4.4.1. SBVS and docking studies 
A virtual screening protocol (Figure 4.1) was implemented to identify novel chemical 
entities from the NCI database showing high affinity for the APE1 domain responsible 
for the endonuclease activity and aiming to inhibit the BER pathway.  
 
Figure 4.1 Virtual screening protocol and experimental methodologies to identify novel chemical 
entities from the NCI database showing a high affinity for the APE1 enzyme. 
The crystal structure of human APE1 was already resolved. When this work was 
initiated there were several different 3D structures (PDB codes: 1BIX, 1HD7, 1DE8, 
1DEW, 1E9N and 1DE9, for example), complexed with different ligands and having 
different resolutions (2.2 to 3.0 Å). From all the available structures of APE1, the APE1 
X-ray structure deposited in the PDB with the code 1BIX (Figure 4.2A) and a resolution 
of 2.2 Å [55] was selected for the docking calculations. The metal-binding site identified 
in this APE1 structure, usually referred to as the “A” site, is in agreement with the 
binding site of Mg2+ or other divalent metals in structures of other members of DNase I 
superfamily [56,57]. Supported by the similarities amongst the active sites of the 





the higher resolution PDB entry 1HD7 [58] since it has no missing residues in the 
catalytic domain and its crystals were grown at a physiological pH of 7.4. 
 
Figure 4.2 APE1 X-ray structures. (A) The crystallographic structure deposited in Protein Data Bank with 
the code 1BIX (resolution of 2.2 Å) was selected for the docking calculations. (B) Superposition of APE1 X-
ray structures with PDB ID: 1BIX (green with the metal in light blue) and PDB ID: 4LND (red with metal in 
brown), showing a total RMSD of 0.8 Å. 
Recently, a new structure of the human APE1 at neutral pH [59] has been solved with a 
resolution of 1.92 Å. Unfortunately, the latter was not available by the time this work 
was initiated. Nevertheless, we confirmed that the Mg2+ binding site in this new 
structure, typically referred as the ‘A site’, is the same as that observed for Sm3+ and 
Pb2+ in previous structures of DNA-free APE1 (Figure 4.2B). 
These features support the use of the PDB 1BIX [55] and the option for a structure 
containing a single metal cofactor at the “A” site despite the ongoing controversy on 
whether the DNase I superfamily enzymes need the presence of two Mg2+ (or Ca2+) 
ions for its catalytic activity [58,60–62] or a single Mg2+ cofactor moving from the “A” 
site in the free enzyme to the “B” site in the enzyme–substrate complex [63].  
The initial stages of SBVS of an extensive database such as the one in use are 
computationally very demanding. In view of this, an approach that optimises the 
balance between the precision of docking and the computational resources required 
was used. SBVS is generally performed with speed-up settings with the intent of 
discarding many compounds in a suitable amount of time while retains only those 
which better fit the pocket. A preliminary virtual screening was performed using all the 
265 242 small-molecules belonging to the NCI database (Figure 4.1) which were 
docked into the APE1 active site (obtained from the 1BIX crystallographic structure) 
and ranked using the GoldScore scoring function. From the compounds preliminarily 
screened for high-affinity with APE1, only the 1000 highest top-ranked compounds 
A                  B 
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were retained for posterior refinement with exhaustive docking analyses that predict 
with higher precision the corresponding binding pose and interactions within the 
receptor binding pocket. These compounds were re-ranked by their optimised 
performance. The final 200 highest ranked compounds were visually inspected and 
only the compounds that presented favorable binding conformations, surface 
complementarity with the enzyme and important interactions with key pocket residues 
were selected. Fifty-four compounds were acquired to be experimentally tested. 
4.4.2. Inhibition of APE1 endonuclease activity 
In this work we choose a fluorescence-based APE1 endonuclease activity assay to 
screen the ability of the fifty-four selected compounds to inhibit the endonuclease 
activity of the recombinant APE1. This methodology is based on the cleavage by APE1 
of a double-stranded DNA carrying an internal AP site mimetic (THF) and termini 
labeled with 5’ TAMRA and a 3’ BHQ-2 quencher moiety [35,64] is valuable because is 
less susceptible to the potential autofluorescence of the compounds. In fact, 
fluorescence-based assays for the identification of small-molecule inhibitors may be 
affected by the inherent fluorescence of a given compound. In this case, by adopting 
an assay with an APE1 substrate detected in the red-shifted spectral region, this 
interference can be minimized [35,36,64]. 
Amongst the 54 acquired compounds only 30 compounds were tested (Annex, Table 
S1). The remaining compounds were excluded due to poor solubility or precipitation in 
the assay conditions. In this screen, 30 compounds were evaluated at a concentration 
of 50 µM. Five compounds (16, 22, 37, 41, and 49) showed ≥ 85% of inhibition of APE1 
endonuclease activity. 
To exclude the possibility of an non-specific inhibition of APE1 endonuclease activity 
due to an intrinsic ability of the compounds to quench the fluorescence signal of 
TAMRA, the five positive hits were tested only in the presence of the DNA strand 
carrying the fluorophore. Although compound 16 clearly inhibited APE1 activity, it also 
presented a decrease of more than 25% in the fluorescence intensity of the control 
(data not shown). Therefore this compound was discarded from further analyses. The 
remaining compounds 22, 37, 41 and 49 were fully analysed in terms of proof-of-
structure criteria. Compound 49, which is closely related to compounds 37 and 41 
revealed, however, some issues concerning proof-of-structure criteria (1H NMR, HR-
ESI-MS) and was therefore excluded. The mass spectrometry data for the remaining 
compounds 22, 37 and 41 are presented in Annex, Figure S1. The purity of compounds 





DAD. Therefore, the IC50 values were calculated for compounds 22, 37 and 41. 
Compound 22 is our best hit, showing an IC50 of 253 ± 11 nM (Figure 4.3A), a 
remarkable inhibition of APE1 activity. The other two compounds identified, 37 and 41, 
showed good inhibitory activities considering the already known APE1 inhibitors, 
displaying IC50 values in the low micromolar range, 7.76 ± 0.44 µM and 8.85 ± 0.48 µM, 
respectively (Figure 4.3C and 4.3E). Table 4.1 summarizes all this information and 
compare the obtained docking scores with the respective IC50 values. 
 
Figure 4.3 Effect of the identified compounds in the APE1 endonuclease activity. The IC50 values 
were obtained from the dose-response curves for compounds (A) 22 (n = 3–7), (C) 37 (n = 2–4) and (E) 41 
(n = 3–4) established with a fluorescence-based APE1 endonuclease activity assay. Values represent 
mean ± SD and are expressed as percentage of activity relative to the negative control. The plasmid 
nicking assay was performed to confirm the ability of identified compounds to inhibit APE1 endonuclease 
activity. Representative agarose gels electrophoresis show a decrease in the relaxed circular DNA band in 
the presence of increasing concentrations of compounds (B) 22, (D) 37 and (F) 41. Two independent 
experiments were performed in duplicate. 
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In an attempt to characterize the enzymatic inhibition mode of the most promising 
compound, we adopted the graphical procedure based on normalised rates (the degree 
of inhibition) described by Antunes et al. [65]. The linear decrease of the degree of 
inhibition with increasing substrate concentrations in the presence of compound 22 
suggests a competitive inhibition mechanism (Annex, Figure S2). 
Table 4.1 Structure, lipophilicity (LogP), GoldScore, and IC50 values of the identified APE1 
inhibitors. 
A counterscreen assay was performed to confirm these findings and validate the 
compounds as APE1 inhibitors. The plasmid DNA nicking assay is a gel-based assay, 
where the supercoiled plasmid DNA containing AP sites is converted into the relaxed 
form in the presence of APE1. The results of this assay showed that the compounds 
were able to inhibit the enzyme APE1. In fact, compound 22 at 5 µM inhibited 
completely the enzyme APE1, producing supercoiled and relaxed bands with 





enzyme (Figure 4.3B). Compound 37 also presents a decrease in the intensity of the 
relaxed band that is dose-dependent and apparently inhibit APE1 endonuclease 
activity completely at the highest concentration tested (Figure 4.3D). For compound 41 
only a slight effect was observed (Figure 4.3F) which means that a higher 
concentration should be considered. It should be noted that the compounds were 
tested at higher concentrations in the gel-based assay when compared to the 
fluorescence-based assay due to methodological differences as well as assay 
conditions. Besides being used as a qualitative assay, the plasmid nicking assay 
recapitulated the results of the fluorescence-based assay. 
4.4.3. Ligand docking binding modes 
An analysis of the best ranked ligand docking poses resulting from the SBVS 
calculations revealed that all 30 assayed molecules fit well within the APE1 binding 
site, occupying the pocket defined by the amino acids Asp70, Glu96, Arg177, His309, 
Asp210, Asn212, Trp280, Phe266, and Leu282, which was quite promising for good 
ligand-enzyme interactions. Overall, the predicted binding poses highlight in general a 
close proximity with the metallic cation, hydrogen bonding interactions with the active 
site residues His309, Asp210, Asn212, Gly231 and Arg177 and a few hydrophobic and 
π-π interactions of the ligands with Phe266, Trp280 and His309. 
A more detailed analysis was performed for the best docking poses of the three active 
compounds against APE1. In fact, the high docking scores obtained for these 
compounds, ranging from 75 to 71, already suggested a strong interaction with APE1 
when compared with the affinities (docking scores) achieved for lucanthone and 
hycanthone (scores in the range of 50-55). 
Compound 22 (5-(acetylamino)-2-[2-(4-isothiocyanato-3-sulfophenyl)ethenyl] 
benzenesulfonic acid disodium salt) displays an IC50 value consistent with a good 
inhibitory activity against APE1 in vitro. This compound displays structural features 
which are consistent with the 3D pharmacophore models that were generated by 
Zawahir et al., based on a set of interactions of the abasic DNA within the APE1 
catalytic active site [38]. In that work the most potent and selective inhibitors showing 
IC50 values below 10 μM displayed two terminal negatively-charged groups and a 
central hydrophobic core in agreement with the arrangement of the 3’ and 5’ 
deoxyribose phosphate groups on abasic DNA. In compound 22 the two negatively-
charged sulfonate groups (SO32-) establish important hydrogen bond interactions with 
Asn212 (1.6 Å) and Arg177 (1.9 and 2.3 Å) (the interaction with His309 is very weak). 
This is in accordance with the interactions between the abasic DNA negatively-charged 
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phosphate group and the APE1 amino acid residues Asn174, Asn212, His309 in the 
co-crystal structure of the APE1 bound to abasic DNA (PDB code: 1DEW) [66]. This 
feature is shared by some of the compounds in Table 4.1. Also, compound 22 shows a 
biphenyl moiety, a group present in some already patented small-molecules inhibitors 
of APE1 and collected in a recent review by Al-Safi et al. [67]. In this review the authors 
describe all the patented small-molecule inhibitors of APE1 before 2011 and is an 
excellent starting point to understand the key features present in these compounds. 
They cover a comprehensive number of compounds with a large chemical diversity, 
containing molecules with “drug-like” and “non-drug-like” properties. Al-Safi et al. [67] 
describe several chemical structures containing a sulfonamide core showing moderate 
APE1 inhibitory activity (in the low micromolar range). However, to the best of our 
knowledge, no patented APE1 inhibitors show the sulfonate group, present in our 
active compounds. In addition, the presence of the isothiocyanate (R-N=C=S) group in 
compound 22 provides an additional interesting chemical feature since naturally 
occurring and synthetic isothiocyanates are emerging anticancer agents [68–70]. In 
fact, an extra interaction could be established between the terminal sulfur of the 
isothiocyanate group and Gly231 (at a distance of 3 Å). Interestingly the terminal sulfur 
is pointing to the center of Trp280 aromatic ring. We suggest that the high potency of 
compound 22 should result from the coincident presence of the biphenyl core and the 
sulfonate moieties coupled with a correct position given by the terminal sulfur 
interactions (Figure 4.4A). 
While not as potent as compound 22, compounds 37 (6-amino-4-hydroxy-5-[(4-nitro-2-
sulfophenyl)azo]-2-naphtalenesulfonic acid disodium salt) and 41 (6-amino-5-[(4-
amino-2-sulfophenyl)azo]-4-hydroxy-2-naphtalenesulfonic acid disodium salt) also 
revealed significant inhibitory activity. Predicted poses of the active compounds 37 and 
41 are shown in Figure 4.4B and 4.4C. These compounds share a very similar pose 
(nearly overlapped) inside APE1 binding site. In fact these compounds are structurally 
very similar, only differing on one substituent, -NO2 in the case of compound 37 and -
NH2 in the case of compound 41. Again, these compounds have two sulfonate (SO32-) 
groups, which interact with APE1 and establish important hydrogen bonds and ionic 
interactions. One of the sulfonate groups establishes two hydrogen bonds with His309 
(2.7 and 2.8 Å), and the other interacts with Arg177 (2 and 2.2 Å). The benzyl moiety 







Figure 4.4 Best poses of active compounds inside the APE1 binding pocket. 
Overall, these results are in agreement with previously reported studies in the literature 
by Simeonov et al. [35], where compounds resulting from a screen of 1280 compounds 
from the library of pharmacological active compounds (LOPAC) having sulfonate 
groups, like Reactive Blue 2 and PPNDS are able to inhibit the APE1 activity. As in our 
studies, some of the compounds identified demonstrate the importance of negatively 
ionisable groups for potent APE1 inhibition. By the analysis of the docking poses inside 
the APE1 binding site we consider that these compounds could be promising scaffolds 
to optimization to obtain improved APE1 inhibitors. 
4.4.4. Evaluation of the cytotoxicity of potential APE1 inhibitors in 
MCF10A cells  
Since APE1 is an ubiquitous protein we cannot exclude the possibility that a decrease 
in APE1 endonuclease activity may be cytotoxic for tumour but also for non-tumour 
cells. Therefore, the efficacy and safety of compounds targeting APE1 endonuclease 
activity can be impaired due to the development of off-target effects. To evaluate the 
cytotoxicity of the APE1 inhibitors in non-cancer cells, we performed the MTS 
tetrazolium assay in human mammary epithelial MCF10A cells. After a 48 h exposure 
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to the compounds at concentrations up to 100 µM, the results show that all the 
potential APE1 inhibitors are non-toxic to MCF10A cells (Figure 4.5). 
 
Figure 4.5 Effect of the compounds in the viability of MCF10A cells evaluated by the MTS assay. 
Cells were incubated with increasing concentrations of compounds (A) 22, (B) 37 and (C) 41 for 48 h. 








APE1 has emerged as a druggable target with important implications in cancer therapy. 
In fact, functional studies conducted not only with APE1 inhibitors [6,7] but with the 
presence of a dominant-negative APE1[71,72] and the decrease of expression by 
targeting the enzyme with small interfering RNA [73], revealed an enhancement of the 
cellular sensitivity to anticancer agents.   
In the present Chapter, we set out to identify three novel compounds (22, 37 and 41) 
that show a significant inhibitory activity on APE1 enzyme using a synergic campaign 
combining computational and experimental methodologies. Importantly, compound 22 
showed to be active against APE1 at nanomolar concentrations. In addition, when we 
compare the properties (e.g. molecular weight, logP, druggability) of the active 
compounds with the same properties for the already described APE1 inhibitors, we 
conclude that our compounds present adequate features to be an APE1 inhibitor. 
Furthermore, compounds 22, 37 and 41 are simple small-molecules with good spatial 
fitting in APE1 active site and establish important interactions with residues essential 
for the enzyme endonuclease activity (e.g. Trp280, Asn212, Arg177, His309) without 
toxicity in non-tumour MCF10A cells. Thus, these compounds have potential to be 
used as lead compounds for further development of more effective APE1 inhibitors. 
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THE APE1 REDOX INHIBITOR E3330 
REDUCES COLLECTIVE CELL MIGRATION OF 
HUMAN BREAST CANCER CELLS AND 
DECREASES CHEMOINVASION AND COLONY 





This Chapter was adapted from: 
Guerreiro PS, Corvacho E, Costa JG, Saraiva N, Fernandes AS, Castro M, Miranda 
JP, Oliveira NG. The APE1 redox inhibitor E3330 reduces collective cell migration of 
human breast cancer cells decreases chemoinvasion and colony formation when 





5.1. ABSTRACT  
APE1 is an ubiquitous multifunctional DNA repair enzyme and a redox signalling 
protein. Our work addressed the inhibition of APE1 redox function using E3330, as 
single agent or in combination with DTX, in human breast cancer MDA-MB-231 cells. 
E3330 decreased the colony formation of DTX-treated cells. In addition, E3330 alone 
significantly reduced the collective cell migration as assessed by the wound healing 
assay whereas the combined treatment decreased chemoinvasion. These results 
suggest that the inhibition of APE1 redox function might have therapeutic potential by 
modulating cell migration and invasion in metastatic breast cancer. 
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The APE1 redox inhibitor E3330 reduces collective cell migration of human breast cancer cells 




Breast cancer is the most common cancer diagnosed worldwide in women [1,2]. 
Despite the improvement in early diagnosis and the advances in adjuvant therapy, it 
remains one of the leading causes of tumour-related death [1–3]. The mortality of 
breast cancer is mainly caused by the development of metastases at distant sites from 
the primary tumour [3–5]. In addition to the clinical heterogeneity of primary tumours, 
the heterogeneous metastatic pattern usually impairs the efficacy of the current 
treatments contributing to the poor prognosis of advanced breast cancer [3–5].  
APE1 is an ubiquitous multifunctional protein of BER pathway. The endonuclease 
activity is the major DNA repair function of APE1 and it is essential for the recognition 
and processing of AP sites generated by exogenous and/or endogenous agents 
participating in the maintenance of the genome stability. APE1 has also other DNA 
repair functions which include 3’-phosphodiesterase, weak 3’-phosphatase, 3’-
5’exonuclease and RNase H activity [6,7]. APE1 is usually referred as a dual function 
protein because it has also an independent role as a reduction/oxidation signalling 
protein, modulating the activation of several transcription factors through the reduction 
of the cysteine residues in their DNA binding domains. Consequently, APE1 regulates 
the ability of transcription factors, such as NF-кB [8], AP-1 [9], Egr-1 [10,11], HIF-1α 
[12–14], p53 [15,16], STAT3 [17] among others, to bind to their specific DNA sequence 
and promote the expression of genes implicated in cancer cell survival, proliferation, 
migration/invasion, angiogenesis and metastases formation [6,7]. More recently, the 
redox function of APE1 has been shown to be involved in the regulation of WNT/β-
catenin signalling pathway in pancreatic cancer cells [18]. Furthermore, alterations in 
the expression and subcellular distribution of APE1 have been reported in numerous 
types of tumours [19,20], including breast cancer [21–23]. 
APE1 has gained increasing attention as an emerging drug target in cancer therapy. 
The DNA repair function has been the focus for the development of several novel 
small-molecule inhibitors in an attempt to address the resistance to current anticancer 
therapies and to improve the clinical outcomes by increasing cancer cell death [20,24]. 
In addition, the plethora of transcription factors modulated by APE1 redox function and 
their roles in a variety of cellular processes render APE1 as an important upstream 
effector in several diseases including cancer [7]. In fact, the modulation of APE1 redox 
function might simultaneously impair several pathways required for cancer 





E3330 (Fig.5.1) is a quinone derivative already described as a direct inhibitor of the 
redox function of APE1 [7,25] which has been used in different cell-based [14,26–28] 
and in vivo [29,30] assays revealing its therapeutic potential. The nature of E3330-
APE1 interaction has been widely studied to unveil the mechanism of the inhibition of 
APE1’s redox activity. Su et al. [31] proposed that E3330 binds to a partially unfolded 
conformation of APE1 stabilizing the protein and allowing the exposure of buried Cys 
residues critical for the redox activity which become available to reduce the 
transcription factors. Moreover, E3330 may facilitate the disulfide bond formation 
probably between the residues Cys65 and Cys93 decreasing the APE1 redox active 
molecules [31]. Using a NMR shift assay and docking studies, Manvilla et al. [32] 
suggested that the E3330 binding site in APE1 is located in the vicinity of the DNA 
repair active site. In this case E3330 could act as an allosteric inhibitor suppressing the 
conformational change of APE1 required for its redox activity and/ or disrupting the 
binding or activation of transcription factors [32]. More recently, the findings of Zhang et 
al. [33] were consistent with the E3330-APE1 binding mechanism proposed by Su et al. 
[31] supporting the binding of the redox inhibitor to a partially unfolded state of APE1 to 
inhibit its redox function. 
 
Figure 5.1 Chemical structure of the APE1 redox inhibitor (2E)-2-[(4,5-dimethoxy-2-methyl-3,6-
dioxo-1,4-cyclohexadien-1-yl)methylene] undecanoic acid (E3330). 
E3330 was found to suppress the inflammatory response of activated macrophages 
[26] and to prevent the induction of inflammatory cytokines (IL-8 and IL-6) expression in 
hepatic cancer cell lines [34] suggesting that this inhibitor can be used in inflammatory 
processes associated with tumours and liver pathologies. E3330 also inhibited the 
differentiation of adult human bone-marrow-derived mesenchymal stem cells (BM-
MSCs) and the growth of endothelial cell precursors and pancreatic cancer-associated 
endothelial cells [28]. Moreover, E3330 also impaired the migration and the endothelial 
cell tube formation of retinal vascular endothelial cells isolated from mice [30] as well 
as mitigated the progression of choroidal neovascularization in mouse eyes, supporting 
its role in the inhibition of angiogenesis [35,36]. In addition, E3330 has been shown to 
decrease the growth [14,17,18,29] and migration of human pancreatic cancer cells in in 
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vitro models [14]. The evaluation of this compound in a pancreatic tumour xenograft 
model revealed a decrease of the tumours growth rate and promising pharmacokinetics 
and pharmacodynamics properties [29]. Overall, these evidences suggest the 
usefulness of E3330 as a bioactive compound to reduce tumour invasion and 
metastatic disease in other unexploited cancer models. In this context, in the present 
Chapter we addressed this topic and performed the assessment of the impact of a 
novel therapeutic strategy based on targeting APE1 redox function with E3330 in 
human breast cancer MDA-MB-231 cells. In this innovative approach the effect of 
E3330 per se or in combination with DTX, a widely used taxane in breast cancer 
chemotherapy, were thoroughly evaluated. In fact, complementary endpoints were 
used to assess cell viability, colony formation and cell cycle distribution profile. Since 
the ability of cells to migrate and invade the surrounding tissues is essential for the 
development of metastases, both anti-migratory and anti-invasive properties were 
explored, revealing important findings either for E3330 as single agent or in 






5.3. MATERIALS AND METHODS 
5.3.1. Chemicals 
DMEM, PBS (0.01 M, pH 7.4), crystal violet (CV), glutaraldehyde, DMSO, RNase A, 
DTX (purity ≥ 97%), E3330 (purity ≥ 98%) were purchased from Sigma-Aldrich (Madrid, 
Spain). A 2 mM stock solution of DTX was prepared in DMSO, aliquoted and stored at -
20 °C. E3330 was dissolved in DMSO at 10 mM, aliquoted and stored at -20 °C. FBS, 
penicillin-streptomycin solution and trypsin/ethylenediaminetetraacetic acid solution 
were acquired from Gibco (Life Technologies, Madrid, Spain). Ethanol, acetic acid and 
propidium iodide (PI) were obtained from Merck (Darmstadt, Germany). Human 
recombinant APE1 was purchased from New England Biolabs (Ipswich, MA, USA). The 
17-mer oligonucleotides 5’ TAMRA-TC ACC *TC GTA CGA CTC-3’ and 3’ BHQ-2-AG 
TGG GAG CAT GCT GAG (in which TAMRA is the fluorophore 
carboxytetramethylrhodamine, BHQ-2 is black hole quencher-2 and * is 
tetrahydrofuran, a stable abasic site analogue) [37] were custom-made by NZYTech 
(Lisbon, Portugal). Both oligonucleotides were dissolved in TE buffer (1 mM EDTA, 10 
mM Tris-HCl pH 8.0) at a concentration of 100 µM, aliquoted and stored at -20 °C. 
MatrigelTM was purchased from BD Biosciences (San Jose, CA, USA).   
5.3.2. Cell culture 
The human mammary adenocarcinoma MDA-MB-231 cell line (HTB-26) was acquired 
from American Type Culture Collection (ATCC, Manassa, VA, USA). MDA-MB-231 
cells were cultured in monolayer in DMEM supplemented with 10% FBS, 100 U/mL 
penicillin and 0.1 mg/mL streptomycin, at 37 °C in a humidified atmosphere containing 
5% CO2 in air. 
5.3.3. Fluorescence-based APE1 endonuclease activity assay 
APE1 endonuclease activity in the presence of E3330 was evaluated with a 
fluorescence-based assay previously described by Simeonov et al. [37] with 
modifications. This assay was performed according to the procedure described in 
Chapter 4 (Section 4.3.4). Briefly, E333o was added to the reaction mixtures containing 
2.5 U of human recombinant APE1 in assay buffer. After 15 min incubation at room 
temperature, the reaction was initiated by the addition of the double-stranded DNA 
substrate to a final concentration of 250 nM. Fluorescence was measured at 1 min 
intervals for 30 min with incubation at 37 °C using a SpectraMax GeminiTM EM 
microplate plate reader (Molecular Devices, Berkshire, UK) in the kinetic mode at 
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excitation wavelength 550 nm, emission wavelength 584 nm and cut-off at 570 nm. The 
reaction of APE1 in the presence of DMSO 0.5% (v/v) was considered to represent 
100% of activity (negative control). APE1 activity in the presence of E3330 (30 or 50 
µM) was calculated relatively to the negative control. The arylstibonic acid NSC 13755 
was used as a positive control for APE1 endonuclease activity inhibition. Each value is 
presented as mean ± SD of three independent experiments performed in duplicate. 
5.3.4. Crystal violet (CV) staining assay 
The effect of DTX alone (0.5–1000 nM) or in the presence of E3330 (30 µM) in the 
MDA-MB-231 cells viability was first evaluated using the CV staining assay. Cells were 
seeded at a density of approximately 7 × 103 cells per well, in 200 µL of culture 
medium, in 96-well plates and incubated for 22 h. MDA-MB-231 cells were treated with 
E3330 (30 µM) for 2 h. Following the pre-incubation period, DTX (0.5 or 100 nM) was 
added and MDA-MB-231 cells were incubated for 24 h in the presence of both 
compounds. The final concentration of DMSO in the culture medium did not exceed 
0.5% (v/v). The CV assay was then performed according to a previously described 
protocol [38,39]. Absorbance values presented by MDA-MB-231 cells exposed to 0.5% 
DMSO (v/v) alone (vehicle-treated control cultures) corresponded to 100% cell viability. 
Three to seven independent experiments were carried out and eight replicate cultures 
were used for each condition in each independent experiment. 
5.3.5. MTS reduction assay  
The 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-
tetrazolium salt (MTS) reduction assay was carried out as a confirmatory assay to 
evaluate cell viability. Briefly, MDA-MB-231 cells were cultured at a density of 
approximately 6 × 103 cells per well, in 200 L of culture medium, in 96-well plates and 
incubated for 22 h. Cells were treated with DTX and/or E3330 according to the 
aforementioned protocol for the CV staining assay. Following the drug treatments, the 
assay was performed as described in Chapter 4 (Section 4.3.7). The absorbance 
values vehicle-treated control cultures measured at 490 nm corresponded to 100% cell 
viability. Two to three independent experiments were performed in triplicate. 
5.3.6. Colony formation assay 
The colony formation assay was performed according to a previously described 
procedure [20]. MDA-MB-231 cells were seeded into 6-well plates at a cell density 
ranging from 1 × 102 to 1 × 104 cells per well and maintained in a humidified incubator 





or 10 nM). After a 24 h incubation period with compounds, the cell cultures were 
washed with PBS and incubated in drug-free medium for 10 to 12 days to form 
colonies. Afterwards the assay was performed as described in Chapter 3 (Section 
3.3.5). Colonies greater than or equal to 50 cells were visually identified and counted 
by two investigators. The surviving fraction after drug exposure was normalised to the 
plating efficiency of vehicle-treated control cells. The drug treatments were evaluated in 
duplicate and four independent experiments were performed.  
5.3.7. Cell DNA content analysis 
For cell DNA content analysis, approximately 2.75 × 105 MDA-MB-231 cells were 
plated in 6-well plates and cultured for 22 h. Afterwards, cells were pre-incubated with 
E3330 (30 µM) for 2 h. DTX (0.5 or 100 nM) was then added and cells were cultured 
for a further 24 h period in the presence of both drugs. Cells were harvested using 5 
mM EDTA in PBS at 37 °C, washed with cold PBS and fixed with chilled 80% ethanol. 
Cells were stained with propidium iodide (PI; 10 µg/mL) in the presence of RNase A 
(20 µg/mL) for 15–20 min and were analysed using a FACSCalibur flow cytometer (BD 
Biosciences) [40]. Data were acquired with CellQuest® software (BD Biosciences) and 
analysed with FlowJo® X.0.7 (Tree Star Inc., San Carlos, CA, USA). At least three 
independent experiments were performed. 
5.3.8. In vitro wound healing assay 
The in vitro wound healing assay was performed using a previously described protocol 
[41]. MDA-MB-231 cells were cultured in 24-well plates at a seeding density of 2.75 × 
105 cells per well. Cells were incubated in complete growth medium for 22 h. The 
culture medium was removed and a scratch was executed on the confluent cell 
monolayer with a 200 µL sterile pipette tip resulting in a gap of approximately 0.6–0.7 
mm in width. Cells were immediately rinsed twice with serum-free DMEM to remove the 
detached cells and were cultured in serum-free DMEM in the presence of E3330 (30 
µM) and/or DTX (0.5 nM) for 24 h. Wound closure was evaluated microscopically with a 
Motic AE2000 inverted microscope. Photographs of the same areas of the scratch 
were taken at an amplification of 40x using a Moticam 2500. The scratches width was 
measured using Motic Images Plus version 2.0 software at different time points, 
namely 0, 8 and 24 h post-scratch and compounds addition. Cellular motility was 
analysed in relation to the initial distance between the two scratches edges which was 
considered as 0% of wound closure. Each condition was evaluated in triplicates and 
four to six independent experiments were performed.  
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5.3.9. Chemotaxis and chemoinvasion assays  
The chemotactic migration and chemoinvasion of MDA-MB-231 cells was evaluated by 
adopting a protocol already described [41]. The chemotaxis was assessed in 24-well 
plates by seeding 1 × 105 cells in serum-free medium on the top of a transwell insert 
with transparent PET membranes containing 8 µm pores (BD Biosciences, USA). 
Culture media containing 10% FBS as chemoattractant was added to the lower 
compartment. Compounds were added to both chambers and cells were allowed to 
migrate through the membrane for 24 h. After the incubation period, non-migrating cells 
were gently removed from the upper compartment with a cotton swab. Migrated cells 
present in the bottom of each membrane were fixed with cold 96% ethanol for 15 min 
and stained with 0.1% crystal violet in 10% ethanol for 10 min. The inserts were rinsed 
with water and the remaining cell-attached dye was resuspended in 96% ethanol with 
1% acetic acid. Absorbance was measured at 595 nm with a SPECTROstar Omega 
microplate reader (BMG Labtech, Offenburg, Germany). The results were expressed 
as percentages of vehicle-treated control cells. Five independent experiments were 
performed. 
A procedure similar to the aforementioned for the chemotactic migration assay was 
used for the assessment of chemoinvasion. In this case, the porous membranes of the 
transwell inserts were coated with 50 µL of MatrigelTM at a concentration of 0.3 mg/mL 
in serum-free medium. Following the compounds addition, MDA-MB-231 cells were 
incubated for 16 h. Five independent experiments were performed. 
5.3.10. Statistical analysis 
The values presented correspond to mean values and respective standard deviations 







5.4.1. APE1 endonuclease activity in the presence of E3330  
In order to assure that the E3330 effects observed in this work were due to the 
modulation of APE1 redox function and not due to the inhibition of its DNA repair 
function, a fluorescence-based endonuclease activity assay previously described [37] 
was performed. In this work, none of the E3330 tested concentrations (30 and 50 µM) 
inhibited APE1 endonuclease activity under these conditions (Fig. 5.2). 
 
Figure 5.2 APE1 endonuclease activity in the presence of the redox inhibitor E3330. A fluorescence-
based enzymatic assay based on the cleavage of a double-stranded DNA containing an abasic site and 
labeled with a fluorophore (TAMRA) and a quencher (BHQ-2) was performed. Values represent mean ± 
SD (n = 3) and are expressed as percentage of activity relative to the negative control. 
5.4.2. Effect of E3330 alone or in combination with DTX on the viability 
and colony formation of MDA-MB-231 cells 
The cytotoxicity of DTX in MDA-MB-231 cells was first evaluated by the CV staining 
assay. The cell viability obtained after a 24 h exposure to DTX (0.5–1000 nM) showed 
a concentration-dependent decrease for concentrations up to 50 nM (Fig. 5.3) and then 
reached a plateau with higher DTX concentrations. The cytotoxic effect of DTX was 
significant at concentrations ≥ 5 nM (P < 0.05), showing that MDA-MB-231 cells are 
sensitive to DTX at low nanomolar concentrations. In addition, the MTS reduction 
assay was used as a confirmatory methodology for the assessment of the cytotoxicity 
of DTX and the dose-response profiles obtained were similar for both assays (Fig. 5.3). 
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Figure 5.3 Cytotoxic effects of docetaxel (DTX) in MDA-MB-231 cells. The viability of cells treated with 
DTX for 24 h was evaluated by CV staining (n = 3–7) and MTS reduction (n = 2–3) assays. Inset: effect of 
concentrations of DTX up to 100 nM. Values represent mean ± SD and are expressed as percentages of 
vehicle-treated control cells. 
The CV and MTS reduction assays revealed that E3330 (30 µM) alone was not 
cytotoxic for MDA-MB-231 cells (Fig. 5.4A and 5.4B). For the evaluation of the 
combined treatment of E3330 with DTX, MDA-MB-231 cells were pre-incubated for 2 h 
with the APE1 redox inhibitor and then simultaneously exposed to DTX at low (0.5 nM) 
or high (100 nM) clinically achievable concentrations [42–45]. It should be noted that 
DTX at 0.5 nM induced a decrease in cell viability of only 3.7% in CV assay (N.S.) and 
2.6% in the MTS assay (N.S.). E3330 did not modify the viability of DTX-treated cells 
(Fig. 5.4A and 5.4B). 
The colony formation assay was also performed to evaluate the impact of the inhibition 
of APE1 redox function in the proliferation of cells exposed to DTX. In the conditions 
tested, the decrease induced by DTX (0.5 nM) in the cell survival of MDA-MB-231 cells 
was more pronounced than the effects of this chemotherapeutic drug in the cell viability 
assays (Fig. 5.4). In addition, MDA-MB-231 cells revealed to be highly sensitive to DTX 
at 10 nM concentration (data not shown). E3330 induced a decrease in the surviving 
fraction of MDA-MB-231 cells when compared to vehicle-treated control cells (N.S.). 
Conversely, the combination of E3330 with DTX 0.5 nM revealed a significant decrease 
in the colony forming ability when compared to vehicle-treated control cells (P < 0.01), 






Figure 5.4 Effect of E3330 on viability and colony formation of MDA-MB-231 cells treated with 
docetaxel (DTX). Cells were pre-incubated with E3330 (30 µM) for 2 h and then simultaneously exposed 
to E3330 and DTX for 24 h. Cell viability was evaluated by A) CV staining assay and B) MTS reduction 
assay. Values represent mean ± SD (n = 2–4) and are expressed as percentages relative to vehicle-
treated control cells. The colony forming ability was assessed with C) colony formation assay. After the 24 
h incubation period with both compounds, MDA-MB-231 cells were grown in drug-free medium for 10–12 
days to allow the formation of colonies. Values represent mean ± SD (n = 4). (*P < 0.05, **P < 0.01 and 
***P < 0.001 when compared with vehicle-treated control cells). 
5.4.3. Cell cycle distribution of MDA-MB-231 cells treated with E3330 
alone or in combination with DTX 
The cell DNA content was analysed by flow cytometry to establish the cell cycle 
distribution of MDA-MB-231 cells exposed to E3330 and/or DTX. The results depicted 
in Fig. 5.5 show a 2-fold increase in sub-G1 population (P < 0.01) and a decrease in 
G2/M fraction (N.S.) for cells treated with a low DTX concentration (0.5 nM) when 
compared with vehicle-treated control cells. In addition, DTX at a concentration of 100 
nM induced an increase in sub-G1 (7.0 ± 1.0%; P < 0.001) and G2/M populations (68.6 
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± 7.6%; P < 0.001) while decreasing G0/G1 (16.8 ± 6.5%; P < 0.001) relative to control 
cells. The APE1 redox inhibitor E3330 (30 µM) did not significantly modify the cell cycle 
distribution of vehicle-treated or DTX-treated MDA-MB-231 cells. Representative 
histograms are presented in Fig. 5.5A. All the independent experiments carried out led 
to coherent results. 
 
Figure 5.5 Cell cycle distribution of MDA-MB-231 cells treated with E3330 and/ or docetaxel (DTX). 
Cells were incubated for 2 h with E3330 before the addition of DTX (0.5 or 100 nM). Cell DNA content was 
analysed by flow cytometry after a 24 h exposure period to both compounds. A) Representative flow 
cytometry histograms. B) Summary results of sub-G1, G0/G1, S and G2/M populations. C) Sub-G1 
population percentage. Values represent mean ± SD (n = 3–4). (*P < 0.05, **P < 0.01 and ***P < 0.001 





5.4.4. Migration of MDA-MB-231 cells treated with E3330 alone or in 
combination with DTX 
Non-cytotoxic concentrations of E3330 and DTX were selected to evaluate the effect of 
both compounds on the migration of MDA-MB-231 cells. Collective cell migration was 
first evaluated by the wound-healing assay. E3330 (30 µM) markedly reduced the % of 
wound closure to one-third of that of vehicle-treated control cells after a 24 h period of 
exposure. As shown in Fig. 5.6A, while control cells presented 44.2 ± 9.9% of wound 
closure, cells treated with the APE1 redox inhibitor displayed 14.6 ± 11.6% of wound 
closure (P < 0.001). DTX (0.5 nM) also decreased cell motility with cultures presenting 
33.3 ± 14.4% of wound closure (N.S.). Cells treated with the combination of E3330 and 
DTX showed a % of wound closure of 17.0 ± 18.3% (P < 0.05) which is similar to the 
decrease in cell motility induced by E3330 alone. 
The chemotactic single-cell migration was evaluated by a transwell assay (Fig. 5.6B). 
E3330 (30 µM) had no effect on the migration of cells exposed to the compound for 24 
h. Similarly, the chemotherapeutic drug DTX (0.5 nM) did not significantly modify the 
migration of vehicle-treated control cells. The simultaneous exposure of cells to E3330 
and DTX resulted in 90.9 ± 21.3% of cell migration (N.S.). 
 
Figure 5.6 Effect of the simultaneous exposure to E3330 (30 µM) and docetaxel (DTX; 0.5 nM) on 
the migration of MDA-MB-231 cells after a 24 h period of incubation with compounds. Cell migration 
of MDA-MB-231 cells was evaluated by A) wound healing assay and B) chemotaxis assay. Values 
represent mean ± SD (n = 4–6). (*P < 0.05 and ***P < 0.001). 
5.4.5. E3330 reduces invasion of DTX-treated MDA-MB-231 cells 
The degradation of basement membranes is essential for the invasion of surrounding 
tissues by cancer cells during the metastatic process. E3330 (30 µM) alone had no 
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impact on the proteolytic invasion of MDA-MB-231 cells while a relatively non-toxic 
concentration of DTX (0.5 nM) decreased cell invasion to 85.8 ± 7.3% of vehicle-
treated control cells (P < 0.05) as shown in Fig. 5.7. However, a more pronounced 
effect was observed for the combination of E3330 with DTX, which significantly 
decreased the chemoinvasion to 72.1 ± 3.5% of control cells (P < 0.001). When 
compared with MDA-MB-231 cells exposed only to DTX, the reduction in cell invasion 
induced by the combined treatment corresponds to a decrease of approximately 13.8% 
(P < 0.05). 
 
Figure 5.7 Effect of the simultaneous exposure to E3330 (30 µM) and docetaxel (DTX; 0.5 nM) on 
the invasion of MDA-MB-231 cells. A) Chemoinvasion was evaluated after a 16 h period of incubation 
with compounds. Values represent mean ± SD (n = 5). B) Representative microscopy images of invading 







The development of breast cancer metastases involves a sequence of cellular and 
molecular events, which require the coordinated activation of several signalling 
pathways. A successful invasion-metastasis cascade initiates with the invasion of 
surrounding tissues by cells from the primary tumour. In addition, the loss of cell 
adhesion and the increase of cell motility allow the intravasation into the blood and/or 
lymphatic vessels, facilitating the dissemination to distant organs. The homing to the 
metastatic site also requires that surviving circulating tumour cells leave the vessels 
lumina towards the underlying tissues where they have to survive, regain the ability to 
proliferate and promote the formation of new vessels (angiogenesis) to generate a 
secondary tumour (reviewed in [46,47]). The complexity of the metastatic process 
involves a multiplicity of effector molecules which can be targeted to impair the 
formation of metastases. 
In the last years, APE1 has been studied as a relevant therapeutic target not only 
because of its role as an endonuclease involved in DNA repair, but also due to its 
redox function. Although the role of APE1 redox domain is not completely uncovered, 
several transcription factors and signalling pathways implicated in metastases 
development have been found to be modulated by APE1’s redox function [6,7]. In view 
of this, the present study aimed to evaluate the role of the combination of DTX with the 
APE1’s redox function inhibitor E3330 on the viability, migration and invasion of 
metastatic MDA-MB-231 breast cancer cells.  
E3330 was the first APE1 redox inhibitor to be identified [25] and it has been the most 
widely studied. Recently, it was reported that E3330 might bind to the DNA repair 
active site of APE1 and consequently inhibit the endonuclease activity of the enzyme 
[32]. However, E3330 seems to be a very weak endonuclease inhibitor since this effect 
was shown to occur only for concentrations above 100 µM [32,33]. In our study, E3330 
at 30 or 50 µM had no effect in APE1 endonuclease activity while these concentrations 
were reported to inhibit the redox function of APE1 by several authors [14,17,33,48–
50]. In addition, in a previous work from our group, E3330 (30 µM) did not modify the 
viability of MDA-MB-231 cells [20]. Therefore, this concentration was selected to be 
further used in cell-based assays. 
Chemotherapy is the leading treatment for triple-negative advanced breast cancer and 
taxane-containing regimens are the main therapeutic alternative for metastatic disease 
refractory to adjuvant anthracycline-based regimens [51].  
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Taxanes act primarily by binding to the β-subunit of tubulin and inducing the 
microtubules hyperstabilization which prevents their depolymerization. This disruption 
of the microtubules dynamics impairs cell proliferation and cell cycle progression and 
ultimately induces cell death [45,52,53]. In this work, DTX was selected because it has 
been suggested as the more effective taxane in advanced breast cancer [54]. 
Moreover, anti-migratory, anti-invasive and anti-angiogenic properties were reported for 
DTX in different cell lines [55–58]. 
The dose-response curve of DTX in MDA-MB-231 cells was first established using two 
different cytotoxicity assays to select the concentrations of the antimicrotubule agent 
for further assays. The cytotoxic profiles obtained with both CV and MTS assays were 
similar for the wide range of DTX concentrations tested (0.5–1000 nM). Recently, it 
was reported a biphasic growth curve for increasing concentrations of DTX in MDA-
MB-231 cells with a higher cellular sensitivity at lower concentrations of the drug [45]. 
Under our experimental conditions MDA-MB-231 cells did not present a biphasic 
response. In fact, they were sensitive to low nanomolar concentrations but sensitivity to 
DTX did not increase for concentrations higher than 100 nM, as evidenced by cell 
viability values above 50%. This concentration-related plateau might be explained 
because DTX is a cell cycle-specific chemotherapeutic drug and cells were exposed to 
this compound for 24 h which is a period of time lower than the duration of one cell 
cycle [59,60]. Consequently, cells are not in the same cell cycle phase and only the 
proliferating cells are susceptible to the cytotoxic effects of DTX [61]. In this case, an 
increase of the exposure time should be more effective to decrease cell viability than 
the increase of drug concentration [62]. In view of this, DTX at 0.5 nM (non-cytotoxic) 
and/or 100 nM were selected to be tested in combination with E3330. The cell viability 
was not altered by the addition of E3330 as evaluated by the CV and MTS assays. 
Along with the short-term viability assays and since the toxic effects of DTX may be 
time-dependent, the colony formation assay was performed to evaluate the long-term 
effects of the combination of E3330 and DTX in the proliferation of breast cancer MDA-
MB-231 cells. The colony formation assay revealed a higher sensitivity to DTX when 
compared to the CV and MTS assays where this level of exposure was non-cytotoxic. 
A similar result was obtained for E3330 alone which decreased the proliferation of 
MDA-MB-231 cells in the colony formation assay. Additionally, the combination of the 
APE1 redox inhibitor with DTX also resulted in a minor decrease in the surviving 
fraction. These findings highlight the importance of time in the evaluation of drug 
cytotoxicity as well as the use of multiple endpoints. In addition, our results pointed to a 





Although the molecular mechanisms of DTX action remain to be completely elucidated 
it is recognized that its cytotoxicity depends on the cell cycle phase as 
abovementioned. DTX is active in S, G2 and M-phases cells and triggers different 
forms of cell death depending on drug concentration [45,52,59,60]. Thus, the 
development of more effective taxane-containing drug combinations for cancer therapy 
requires the understanding of the impact of each compound in the cell cycle profile. In 
this context, the effect of E3330 in the cell cycle of MDA-MB-231 cells was evaluated. 
Our results suggest the absence of alterations in cell cycle progression of MDA-MB-
231 cells upon exposure to the APE1 redox inhibitor. Although the modifications 
induced in cell cycle distribution by small-molecule inhibitors might be cell type-
dependent, similar results were reported for E3330 in pancreatic cancer PANC-1 cells 
[14] and in mitotic arrest deficiency 2 (Mad2) wild-type and deficient-hematopoietic 
progenitor (HPC) cells [63]. Moreover, Zou et al. [14] evaluated the expression of the 
proliferation antigen Ki-67 in PANC-1 cells and showed that E3330 might induce the 
exit of cell cycle by promoting the cells entry in G0 phase. More recently, a decrease in 
the S-phase population and an increase in the levels of p21 protein (cyclin-dependent 
kinase inhibitor) were described for two pancreatic cancer cell lines (PaCa-2 and 
PANC-1) after treatment with E3330 suggesting a delay in the progression from G1 to 
S-phase [29]. These conflicting data emphasise the importance of the future evaluation 
of the effect of E3330 in the effectors of the signalling pathways controlling the cell 
cycle to clarify the role of the APE1 redox inhibitor. Regarding the cell cycle profile of 
DTX in MDA-MB-231 cells, our results presented a minor increase in the sub-G1 
population for cells exposed to DTX 0.5 nM. The sub-G1 population corresponds to the 
accumulation of hypodiploid cells which are usually undergoing cell death mechanisms 
[45]. In addition to the increase in sub-G1 population, cells treated with DTX 100 nM 
evidenced the typical G2/M arrest induced by taxanes [45,52,60]. The combined 
treatment only marginally modified the cell cycle profile of cells exposed to DTX 100 
nM. 
APE1 is involved in the response to oxidative stress and in the redox regulation of 
several transcription factors of signalling pathways that may be implicated in tumour 
progression (reviewed in [6,7]). The levels of APE1 expression were also described to 
affect the expression of genes involved in cell adhesion, remodeling of extracellular 
matrix (ECM), reorganization of the actin cytoskeleton, microtubules structure and cell 
migration [64–66]. In recent studies, the decrease of APE1 expression presented 
contradictory results in terms of cell migration. The APE1 downregulation was 
proposed to enhance the migration of human lung carcinoma A549 cells by a 
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mechanism involving the regulation of TGF-β1 expression [65] while it was reported to 
reduce the migration and invasion of human hepatocellular carcinoma MHCC97-H cells 
[67]. Therefore the effects of APE1 in cell motility seem to be cell type-dependent. 
Nevertheless, the role of APE1 redox activity in cell migration and invasion still has to 
be clarified. 
In the migration assays performed we evaluated non-toxic concentrations of E3330 
and/or DTX because an impairment of cell viability would indirectly affect the cell 
migration. Moreover, E3330 at concentrations ranging from 1 to 30 µM inhibited the 
migration of pancreatic cancer cells [14] and retinal endothelial cells [30]. The anti-
migratory properties of DTX had also been reported to require lower concentrations 
than those required for the antiproliferative effects [57,68]. 
A complex set of molecular and morphological modifications have to occur to elicit cell 
migration [69]. Diverse types of cell migration, involving distinct mechanisms, have 
been implicated in cancer metastases [70,71]. In the case of breast cancer cells 
different types of single-cell and of collective cell migration are described [72]. For this 
reason, two different methodologies, the wound healing and the chemotaxis assays, 
were adopted to explore the role of E3330 and the combined treatment in the migration 
of MDA-MB-231 cells. E3330 significantly decreased collective cell migration measured 
by the wound healing assay but did not affect chemotaxis analysed by the transwell 
assay. Similarly, DTX slightly reduced the collective cell migration but not chemotaxis. 
This may be a consequence of the different methodologies and the distinct molecular 
and cellular mechanisms involved in these types of cell migration. In fact, in the wound 
healing assay, the horizontal motility of adherent cells is assessed, recapitulating the in 
vivo collective cell migration [69,73], while the chemotaxis assay is focused on the 
evaluation of the directional cell motility in response to a chemoattractant gradient. The 
chemotactic migration involves the horizontal and vertical migration and provides 
information about the single cell motility [69,73]. Moreover, despite the fact that the 
conditions of the chemotaxis assay better mimic the in vivo tumour microenvironment 
we cannot discard a possible binding of E3330 to the serum proteins [34] contributing 
to a decrease in the amount of E3330 available to enter in the cells and interact with 
the enzyme when compared to the wound healing assay. 
Along with migration, the ability of cancer cells to carry the proteolytic degradation of 
the extracellular matrix is essential for the invasion of surrounding tissues and 
metastases development. The APE1 redox inhibitor alone did not modify the invasion 





decrease in invasion was observed. Among the numerous players required for cell 
invasiveness the regulation of the expression of matrix metalloproteinases (MMPs) and 
the hyaluronan cell-surface receptor CD44 may be responsible for the abovementioned 
reduction in invasion upon treatment with the compounds. Alterations in the expression 
of CD44 and MMPs have been correlated with invasive phenotypes of breast cancer 
[74,75] and they participated in the invasion of MDA-MB-231 cells in in vitro models 
[75,76]. E3330 suppressed the expression of CD44 in pancreatic cancer cells probably 
via inhibition of the AP-1 activation and supporting our hypothesis [7,28]. MMPs 
expression is regulated by the transcription factor AP-1 and the NF-кB pathway. The 
last one is particularly relevant for the regulation of MMP-9 [75,77]. The WNT/β-catenin 
signalling pathway might also modulate the MMPs expression [77]. These effects could 
be assigned to the blocked AP-1 and NF-кB activation described for the E3330 as well 
as for the recently attributed role of APE1’s redox function in the modulation of WNT/β-
catenin signalling pathway [7,18]. Moreover, E3330 is a quinone-based compound 
which may also induce the generation of ROS [14,18] and APE1 is also involved in the 
intracellular redox regulation through a Rac-1 regulated NADPH oxidase activation 
[6,7]. In view of the multiple signalling pathways and cellular functions under ROS 
control that promote cancer development we cannot exclude a ROS-mediated 
contribution for the decrease in cell invasion presented by the treatment with E3330 
and DTX [7,41,78]. 
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In summary, the results presented in this Chapter suggest that E3330 should be further 
studied as a therapeutic tool in the treatment of advanced breast cancer. This APE1 
redox inhibitor reduced cell migration and when used in combination with DTX 
decreased cell invasion. However, the underlying mechanisms should be further 
explored by evaluating the alterations in the expression of the effectors from the 
several signalling pathways that might be affected as a consequence of targeting the 
APE1 redox function (e.g. NF-кB, AP-1, cadherins, integrins, and MMPs). Furthermore, 
the complexity of the APE1 interactome network results in the modulation of multiple 
targets upon inhibition of APE1 redox function that can have differential effects 
according to the cell type. Their knowledge is essential for the prediction of potential 
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APE1 is undoubtedly an enzyme of interest in different human diseases particularly in 
cancer field. During the last decades, APE1 has been regarded as the major 
endonuclease with a fundamental role in DNA repair. Targeting APE1 is fully justified 
by an increase in toxic lesions such as AP sites, which culminate in subsequent DNA 
strand breaks if left unrepaired. These lesions can thus contribute to boost the cytotoxic 
effects and cell death triggered by standard anticancer agents. Moreover, the APE1 
endonuclease activity inhibition by small molecules may constitute the rationale of 
different synthetic lethality strategies that aim to exploit DNA repair deficiencies in a 
given pathway along with the use of specific DNA repair inhibitors. Therefore, being the 
multifunctional enzyme APE1 an important target in the emerging field of DNA repair 
and a relevant therapeutic approach in cancer, we herein explored the in vitro 
modulation of APE1 for breast cancer therapy. Since the importance of APE1 in cancer 
is currently considered beyond its function in DNA repair, in this work the additional 
major role of APE1 in the redox modulation of key events in cancer progression and 
dissemination, namely cell migration and invasion was also addressed in the context of 
breast cancer.  
Breast cancer is still one of the most frequent malignancies, ranking as the fifth cause 
of cancer-related deaths in the world [1–3]. This disease is the most common cancer in 
women with the metastases development being the major cause of its high mortality 
rate. Although the improvements in treatment and diagnosis strategies, a remarkable 
number of breast tumours are already metastatic at diagnosis, being the majority of 
these cancers incurable [2,3]. 
Diverse findings have linked APE1 to breast cancer including the aforementioned 
differential expression levels of APE1 in malignant and non-tumoural tissues and the 
dysregulation of the intracellular distribution of this BER enzyme. In fact, the alterations 
in the subcellular localization of APE1 in tumours relatively to the normal tissues have 
been associated to higher aggressiveness and poor differentiation in breast cancers 
hampering the prognosis [4–6]. 
Human cancer cell lines have been widely used for study genetics and cancer biology, 
biomarkers development and novel therapies in tumours of different origins. MDA-MB-
231 cell line is a well-established and characterized human breast cancer line being 
recognized as a widely accepted metastatic cancer model as displayed by the large 
number of studies published in the last decades. It is considered a representative 
model of poorly differentiated and highly aggressive triple-negative breast cancer 
(TNBC) [7,8]. In addition to lacking the expression of progesterone receptor, estrogen 




receptor and the amplification of the human epidermal growth factor receptor 2 
(HER2/neu) typical of TNBC, MDA-MB-231 cells present a mutated p53 gene [7]. 
These cells are also highly invasive in vitro and tumorigenic in vivo [9–12], being one of 
the most commonly studied cell line particularly useful to the identification of cancer-
related genes, tumour markers of low and high aggressiveness and also in the drug 
discovery field [13,14]. In fact, these cells have been used in studies focused on the 
development of DNA repair inhibitors (e.g. PARP inhibitors) and compounds designed 
to abrogate the invasion and metastases progression [15–19]. In addition, in this work 
the human breast epithelial MCF10A cell line was also included as a non-tumourigenic 
cell type. These cells were specifically used to assess the cytotoxicity of the novel 
small-molecule inhibitors of APE1 endonuclease activity (Chapter 4). Over the years, 
these cells have been the most used in vitro model of normal-like breast cells. MCF10A 
cells are notably useful to investigate the normal human breast cell function and 
malignant transformation. They have also been particularly relevant in the Toxicology 
field, to explore the toxicological effects of xenobiotics with tropism for breast tissue, 
including some reports from our research group that employed these cells to study 
current toxicological issues and to obtain mechanistic insights on glycidamide [20] and 
cadmium deleterious effects [21].  
The treatment of triple-negative advanced breast cancer is almost exclusively based in 
DNA-damaging chemotherapeutic drugs. Currently, in the vast majority of metastatic 
TNBC tumours, the primary goal of therapy is palliative to improve the quality of life and 
extend the patient survival. In this type of cancer, anthracyclines as single agents or in 
combination regimens as well as taxanes are the mainstay treatment for advanced 
breast cancer [2,3].  
Dox is the most commonly used anthracycline antibiotic in numerous types of 
haematological malignancies and solid tumours, including breast cancer. Although 
being considered one of the most potent approved anticancer agents, tumour 
resistance to treatment and the toxicity profile are often unfavourable with the 
development of life-threatening cardiotoxicity [22]. Among the multiple and complex 
mechanisms currently proposed for Dox antitumour effects [23,24], the anthracycline-
mediated ROS generation may produce oxidised DNA bases that similarly to Dox-
induced strand breaks can be repaired by BER pathway. Moreover, Dox has also well-
established clastogenic and aneugenic properties being a recognized genotoxic agent. 
Overall, these features render Dox as a suitable candidate to be evaluated in 





On the other hand, taxane-based regimens are the main therapeutic alternative for 
patients with refractory disease to anthracycline-based regimens [2,3]. Taxanes are 
microtubule-targeting drugs since their primary mechanism of action is based on 
tubulin binding resulting in microtubules hyperstabilisation and disrupting their dynamic. 
Although using a completely different mechanism in comparison with Dox, taxanes also 
induce cell death by apoptotic and non-apoptotic processes [25]. Some evidences 
suggested that taxanes can also increase the intracellular ROS which can be involved 
in the impairment of cell proliferation, migration, invasion and angiogenesis attributed to 
these anticancer drugs [26,27]. Among the different drugs of this chemotherapeutic 
class DTX has been highlighted as the more effective compound in advanced breast 
cancer, being more potent than paclitaxel, the first isolated taxane [28], which is also 
widely used in cancer therapy.  
Despite the different functions of APE1, modulation of its endonuclease activity has 
been the most exploited towards a novel strategy in cancer treatment. In the presence 
of the numerous evidences described in Chapter 1 emphasising the potential role of 
the inhibition of APE1 endonuclease activity to sensitise different types of cancer cells 
to the standard anticancer agents, this work was firstly delineated to evaluate the 
effects of commercially available APE1 inhibitors in the cytotoxicity and genotoxicity of 
Dox (Chapter 3) and to identify novel APE1 endonuclease inhibitors using an in sillico 
approach (Chapter 4).  
MX is a commercially available indirect inhibitor of APE1 endonuclease activity widely 
evaluated in the preclinical setting and the only reported small-molecule inhibitor of 
APE1 DNA repair function that has been studied in phase I clinical trials. Therefore, 
this compound was selected to be used in combination with Dox. It should be noted 
that the therapeutic value of APE1 modulation in combination with Dox has not yet 
been fully investigated. 
In Chapter 3, distinct exposure schedules were established and different 
concentrations were evaluated to resemble the drug administration and levels 
achievable in the clinical setting. Cell viability was assessed with two mechanistically 
different methods. Long-term effects in proliferation of MDA-MB-231 cells were 
evaluated with the colony formation assay which has been widely regarded as the “gold 
standard” method in radiobiology and to study chemotherapeutic drugs in tumour cells. 
This method unveils cells that maintained the dividing and proliferation abilities to yield 
a large colony of progeny cells after a treatment expected to induce reproductive cell 
death [29]. Therefore, colony formation assay is able to distinguish cells retaining some 




capacity to synthesise biomolecules, such as proteins and DNA but unable to 
indefinitely divide which could be considered viable in cell viability assays based on 
enzymatic reactions catalysed by living cells as occurs in the MTT assay. Since the 
aforementioned compounds are DNA-damaging agents, the genotoxicity assessment is 
also of utmost importance. The CBMN assay was used to evaluate the effects of APE1 
endonuclease inhibitor in combination with anticancer drugs at the chromosome 
damage level. This emerging assay is the most useful method to determine the 
micronucleus frequency and it has been widely used in genetic toxicology to identify 
both clastogenic and aneugenic compounds [30]. Moreover, the CBMN assay is also 
able to provide insights about the cytostatic effects of compounds [30]. 
Although MX was not able to clearly sensitise MDA-MB-231 cells to Dox in terms of cell 
viability and proliferation, having only little effects, this APE1 inhibitor significantly 
increased the chromosomal damage by promoting the accumulation of unrepaired 
lesions upon Dox treatment. The apparent ability of MDA-MB-231 cells to tolerate 
additional genotoxic Dox-inflicted lesions in the presence of MX may preclude the use 
of this strategy in the clinical setting. The multiple mechanisms of action of Dox which 
can have different contributions for its cytotoxic and genotoxic properties may 
contribute for these differential results. In fact, different types of DNA damage have 
been associated to Dox with the involvement of different DNA repair pathways to cope 
with the Dox-induced lesions (Chapter 1). Moreover, the recognized redundancy of 
DNA repair pathways may have a role in the absence of more pronounced effects for 
the combination of MX with Dox. Additionally, the effects of known anticancer agents 
and DNA repair inhibitors may be cell-type specific due to the intrinsic DNA repair 
status of different tumour cells which is translated in distinct responses to these 
compounds. The importance of these aspects has been highlighted for the stumbling of 
some DNA repair inhibitors in clinical trials although promising results obtained in their 
preclinical development [31,32]. Furthermore, APE1 is the major endonuclease in 
human cells but a second endonuclease APE2 was also identified [33]. Conversely to 
APE1, APE2 has a weak endonuclease activity but displays a strong 3’-exonuclease 
and 3’-phosphodiesterase activity [34]. Despite being a minor endonuclease and its 
cellular roles are unclear, APE2 has been shown to interact with PCNA in the repair of 
oxidatively damaged DNA (e.g. 8-oxoG) [35]. APE2 also seems to be required for the 
recovery of lymphoid progenitors following bone marrow depletion by 5-FU [36]. 
Consequently, a possible contribution of APE2 to the repair of Dox-induced DNA 
damage via ROS generation should not be neglected. In view of this, to further 





and genotoxicity, additional studies should be performed, addressing this issue by 
using other cell types and regarding gene expression of cell death and DNA repair 
pathways.  
Since direct enzyme inhibitors are considered better drug candidates due to their 
higher specificity with a subsequent decrease in potential side-effects we also 
attempted to evaluate the putative effects of CRT0044876, a direct inhibitor of APE1 
endonuclease activity, in combination with Dox or H2O2. CRT0044876 was the first 
direct inhibitor of APE1 DNA repair function to be identified and described [37]. 
Nevertheless, this compound did not decrease the viability of cells treated with our 
oxidative DNA lesions inducer model H2O2 or Dox (data not shown). Moreover, the role 
of CRT0044876 as an APE1 inhibitor is not completely elucidated and some authors 
were not able to reproduce the in vitro results previously reported for this compound 
[38,39]. 
Besides CRT0044876 several other compounds have been identified as direct 
inhibitors of APE1 over the last years. However, evidences of their effectiveness as 
APE1 inhibitors are also still lacking, precluding their clinical application. In this context, 
the work herein presented also aimed at the identification of novel small-molecule 
inhibitors targeting directly APE1 endonuclease activity (Chapter 4). 
Computational tools have an overriding role in early stages of drug discovery and 
development. Since APE1 crystallographic structures were already resolved and 
essential amino acids of the active site had also been identified, a SBVS protocol 
based on molecular docking studies was established in this work to identify novel 
small-molecule inhibitors of APE1 endonuclease activity.  
SBVS adopts different modelling techniques to exploit the binding interactions and 
consequently the molecular recognition between ligands and the target protein. A 
SBVS approach was preferred over a ligand-based strategy which is based on 
similarities of known ligands due to the large chemical diversity of compounds 
described as APE1 inhibitors by other authors. The selection of the most suitable 
central similarity-property for optimisation of potential ligands to the identification of 
novel bioactive molecules was thus hampered. Although a higher resolution APE1 X-
ray structure was available by the time of the beginning of this work, the APE1 
crystallographic structure selected for the docking analysis also displays a high 
resolution, and importantly it has no missing residues in the catalytic domain being also 
obtained at a physiological pH. More recently, a higher resolution APE1 structure 
solved at neutral pH was published [40]. Since this work was already initiated by the 




time of the novel APE1 structure discovery, to validate the selection of the 
aforementioned structure and to ensure that important information was not missing, the 
position of catalytic active site ion was compared in both structures which showed an 
almost complete overlapping. 
The SBVS and docking studies were performed with compounds from the NCI 
repository. More than fifty compounds were selected to be acquired after docking 
analysis followed by visual inspection regarding appropriate binding conformations, 
fitting into the active site pocket and relevant interactions with key enzyme residues. 
Poor solubility and precipitation issues in assay conditions precluded the evaluation of 
all acquired compounds. From the thirty compounds tested in the fluorescence-based 
APE1 endonuclease activity assay, three compounds, namely compound 22, 37 and 
41 inhibited human recombinant APE1 and displayed high purity as evaluated by 
HPLC-DAD. Compound 22 presented a remarkable inhibition of APE1 activity in the 
nanomolar range with an IC50 value of about 250 nM while compounds 37 and 41 were 
active at micromolar concentrations. These promising results were recapitulated with a 
methodological distinct counterscreen assay, thus confirming their potential as APE1 
inhibitors. 
Compound 22 is among the most potent inhibitors of APE1 identified to date [37,41–
43,38,44–50]. The higher potency of compound 22 may be associated to the 
simultaneous presence of a biphenyl core with sulfonate moieties and an 
isothiocyanate group producing a more suitable compound positioning into APE1 active 
site. Several evidences in in vitro and in vivo models of the emerging interest of 
naturally occurring and synthetic isothiocyanates as anticancer agents [51,52] highlight 
the interest of this chemical feature in novel small-molecule inhibitors of APE1.  
Interestingly, although compounds 37 and 41 are less potent than compound 22, all the 
inhibitors have important sulfonate groups, similarly to the approved trypanocidal drug 
suramin which has been widely shown to have antitumour and antiangiogenic effects 
[53,54]. In fact, anticancer properties of suramin, a polysulfonated compound, have 
been revisited and a potential sensitising effect of cancer cells to IR mediated by 
inactivation of DNA-dependent protein kinase and impairment of DSB repair has been 
hypothesised [55]. Likewise, suramin has also been studied in combination with 
chemotherapeutic drugs to prevent the metastatic processes [56,57]. Sulfonate groups 
appear indeed to be essential for the establishment of hydrogen bonds and ionic 
interactions with APE1 residues to retain the inhibitors in the active site. Compounds 





them with interesting in vitro cytotoxic properties [54,55,58,59]. In addition, two 
compounds containing sulfonate groups have been suggested as APE1 inhibitors by 
another research group [41]. However, compounds 22, 37 and 41 described in this 
thesis are considerably less bulky than the compounds previously reported being more 
prone to cross cellular membranes and to further optimisation to obtain APE1 inhibitors 
more potent and with more favourable pharmacokinetic and pharmacodynamic 
features. Moreover, these compounds did not reveal cytotoxic effects in MCF10A cells. 
Importantly, to best of our knowledge, compound 22 is the first APE1 inhibitor with both 
isothiocyanate and sulfonate groups in its structure, being a potential lead compound 
for development of novel APE1 inhibitors. Further optimisation of these compounds 
may include the introduction of chemical moieties that would force the formation of 
hydrogen bonds with the APE1 portion with no apparent interactions according with the 
docking analysis results. These structural modifications may include the addition of a 
short alkane chain bearing an H-bond acceptor group in the compounds core structure 
to promote the binding to residues Tyr128 and Tyr171 of APE1 active site. The 
absorption, distribution, metabolism and excretion (ADME) studies and quantitative 
structure-activity relationship (QSAR) analysis of these compounds may also result in 
more stable and potent APE1 endonuclease activity inhibitors.  
The potential of compounds 22, 37 and 41 to sensitise the effects of chemotherapeutic 
drugs should be estimated in future studies to validate its development as APE1 
inhibitors. Nevertheless, preclinical studies of novel compounds with promising 
therapeutic properties should be carefully designed to elucidate their action mechanism 
and properly estimate the relevance of proceed with their development. Iniparib, which 
was initially considered a potent PARP1 inhibitor, is an important example of the 
relevance of preclinical stage of drug discovery and development. The promising 
results attributed to iniparib in a multicenter, open-label, randomized phase II trial in 
combination with gemcitabine and carboplatin in patients with metastatic TNBC were 
not recapitulated in a phase III clinical trial [31,60]. The further assessment of in vitro 
ability of iniparib to inhibit PARP1 revealed that probably this compound has a different 
mechanism of action [61,62]. Therefore, the sensitising potential of compounds 22, 37 
and 41 in terms of cytotoxic and genotoxic effects should be thoroughly evaluated in a 
panel of breast cancer cell lines with different degrees of aggressiveness and 
invasiveness due to possible cell type-specific effects. Since 3D cell culture models 
better mimic tumour microenvironment including cellular heterogeneity and hypoxic 
gradients, they should be also considered in this early phase of development [63]. 
Additionally, the complexity and redundancy of DNA repair pathways as well as the 




plethora of lesions that can be induced by standard chemotherapeutic drugs require 
the selection of several anticancer agents to evaluate the potential of APE1 inhibitors to 
be used in combination therapy in breast cancer.  
Therapeutic opportunities of targeting APE1 in breast cancer should not be restricted to 
the modulation of its DNA repair endonuclease activity. The emerging role of ROS and 
redox regulation as promising targets for anticancer drugs discovery emphasises the 
importance of elucidate putative anticancer effects of APE1 redox function modulation. 
In fact, APE1 redox-mediated activation of transcription factors renders this BER 
enzyme an interesting upstream effector of several signalling pathways essential for 
multiple cellular processes involved in cancer progression and development [64].  
The well-known commercially available redox inhibitor of APE1 E3330 was selected to 
unveil the effects of the inhibition of this attractive function of the enzyme. Since 
taxanes act by disrupting microtubules dynamic to affect cytoskeleton function and 
APE1 was also shown to participate in the cell adhesion, remodelling of ECM, 
reorganization of actin cytoskeleton and microtubules structure, cell migration and 
invasion, DTX was also evaluated in combination with E3330 (Chapter 5). 
Theoretically, a therapeutic approach based on the combination of DTX with the APE1 
redox inhibitor may lead to the impairment of migration and invasion of breast cancer 
cells and constitute a novel strategy in the treatment of metastatic disease. As far as 
we know, herein is reported the first study of this type of anticancer drugs combination 
in MDA-MB-231 cells.  
Cellular migration is a complex event that requires several molecular and 
morphological modifications [65,66]. For breast cancer cells, single-cell and collective 
cell migration have been implicated in cancer metastases [65,66]. Therefore two 
mechanistically different migration assays namely wound healing and chemotaxis 
assay were chosen to mitigate the limitations of both methods in the evaluation of the 
combination of E3330 with DTX in the migration of MDA-MB-231 cells. E3330 alone 
markedly reduced collective cell migration in the wound healing assay whereas the 
combined treatment with DTX decreased chemoinvasion. Another important aspect of 
metastases development is the cellular invasion of surrounding tissues. In the 
chemoinvasion assay, the combination of E3330 with DTX significantly decreased the 
invasion of MDA-MB-231 cells. Future work should include the assessment of the 
expression of transcription factors under APE1 redox control and involved in cell 
migration and invasion (e.g. NF-ƙB, AP-1, STAT3, MMPs). The understanding of the 





as the confirmation of these results with different concentrations of both drugs would be 
required to characterize the additive or synergistic effect of the drug combination and 
translate these findings to different cancer cell types. [67]. 
Overall, the multidisciplinary work herein presented integrated multiple endpoints being 
at the interface of intimately related disciplines essential for design and development of 
novel therapeutic approaches for cancer, namely Toxicology, Pharmacology and 
Chemistry. This innovative study included the evaluation of targeting different functions 
of APE1 with small-molecule inhibitors to improve the outcomes of conventional 
chemotherapeutic agents. Importantly, it further enabled the identification of three novel 
chemical entities suitable to be used as lead compounds to the development of more 
potent inhibitors of APE1 endonuclease function, placing APE1 as an attractive target 
in cancer field due to its unique properties as DNA repair enzyme and redox signalling 
factor. The assessment of similar endpoints in 3D cell models should be the next step 
to characterize the value of the described therapeutic strategy before considering the in 
vivo models. While important highlights about the role of APE1 as potential anticancer 
target were addressed, many questions in the vast field of DNA repair systems and 
surveillance mechanisms to maintain the integrity of genetic material remain to be 
uncovered.    
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EXPERIMENTAL DETAILS FOR STRUCTURE CONFIRMATION AND PURITY 
ASSESSMENT 
Purity of each compound was determined by HPLC-DAD on a Ultimate 3000 Dionex 
system, consisting of an LPG-3400A quaternary gradient pump and a diode array 
spectrophotometric detector (Dionex Co., Sunnyvale, California, USA), and equipped 
with a Rheodyne model 8125 injector (Rheodyne, Rohnert Park, California, USA). 
HPLC analyses were performed with a Luna C18 (2) column (250 mm × 4.6 mm; 5 µm; 
Phenomenex, Torrance, California, USA), at a flow rate of 1 mL.min−1. A 30 min linear 
gradient from 5 to 70% acetonitrile in 0.1% aqueous formic acid, followed by a 2 min 
linear gradient to 100% acetonitrile and an 8 min isocratic elution with acetonitrile, was 
used in all instances. The UV absorbance was monitored at 254 nm. 
Chemical identity was confirmed for all compounds by high-resolution mass 
spectrometry analysis on a Impact II ESI-Qq-TOF mass spectrometer (Bruker 
Daltoniks, Bremen, Germany). Mass spectra were obtained with the ESI interface 
operating in negative ion mode. The optimized ESI parameters were: ion spray voltage, 
4.5 kV; drying gas (nitrogen) temperature, 200 ºC; drying gas flow, 4 L/min; nebulising 
gas (nitrogen) pressure, 0.3 bar. The detection was performed considering a mass 
range of 100-2000 m/z. The accurate mass data of the molecular ions were processed 





STRUCTURE OF COMPOUNDS TESTED IN APE1 ENDONUCLEASE ACTIVITY 
ASSAY 
Table S1 Structure of the 30 compounds identified in the in silico study and selected to be tested in 
the first screen using the fluorescence-based APE1 endonuclease activity assay. Each compound 
was evaluated at the final concentration of 50 µM and the results of APE1 endonuclease activity are 













NSC 131122 >100 
 
Compound 6 
NSC 341953 >100 
 
Compound 7 

























NSC 624203 91.4a) 
 
Compound 14 
NSC 343026 89.1 ± 13.1 
 
Compound 16 
NSC 22908 5.8 ± 4.8 
 
Compound 18 
NSC 624205 >100 
 
Compound 22 
NSC 378144 0 
 
Compound 24 







NSC 338500 >100 
 
Compound 27 















NSC 647123 >100 
 
Compound 32 
NSC 22904 >100 
 
Compound 33 




































NSC 339934 >100 
 
Compound 36 
NSC 62628 >100 
 
Compound 37 
NSC 47703 10.9 ± 0.3 
   
Compound 38 
NSC 401341 >100 
 
Compound 41 
NSC 401610 4.7 ± 0.4 
   
Compound 47 



















NSC 47711 17.3 ± 3.1 
 
Compound 49 
NSC 16209 12.4 ± 0.1 
 
Compound 50 
NSC 45201 39.9 ± 10.7 
 
Compound 51 
NSC 45208 26.2 ± 1.9 
 
Compound 52 































NSC 45207 72.5 ± 6.3 
 
Compound 54 
NSC 97318 23.1 ± 2.6 

















DETERMINATION OF THE MODE OF ENZYMATIC INHIBITION OF COMPOUND 22 
 
Figure S2 Determination of the mode of enzymatic inhibition of compound 22. Compound 22 (250 
nM) seems to present a competitive mechanism of APE1 inhibition as evaluated by the plot of 1/εi (where 
εi is the degree of inhibition) versus substrate (ds-DNA) concentration. Values represent the mean ± SD (n 
= 3). 
